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Abstract 
  The biogenesis of ribosomes is a fundamental process that occurs in all living 
cells. In mammalian cells, it is a highly complex process consisting of the 
coordinated synthesis and assembly of four ribosomal RNAs (rRNAs) with about 80 
ribosomal proteins (RPs). More than 150 non-ribosomal proteins are involved in the 
processing of rRNAs. The main focus of this project is to use adult rat ventricular 
cardiomyocytes (ARVCs) as a model to address how mTOR complex 1 (mTORC1) 
and other signalling pathways regulate the synthesis of rRNAs. 
  A new technique has been developed to monitor the synthesis of new rRNAs 
using 4-thiouridine (4-SU) and I have applied it in both HeLa cells and heart muscle 
cells to study the control of ribosome synthesis. HeLa cells were treated with 
different mTOR inhibitors to identify effects on the transcription and/or decay of 
rRNA. We analysed both the synthesis rate and the decay rate of new RNAs made by 
Pol I and Pol III using real-time RT-PCR. Interestingly, rapamycin not only blocked 
the synthesis of 18S, 28S and 5S rRNA, but also induced the decay of newly 
synthesized rRNAs. This demonstrates that mTORC1 regulates Pol I and Pol III 
transcription, as well as the decay of rRNA. 
In cardiomyocytes, hypertrophic agents such as phenylephrine (PE) strongly 
activate protein synthesis and lead to heart cell growth. The boost of protein 
synthesis drives the increase of cell size and leads to hypertrophy. Cardiac 
hypertrophy (CH) is a major risk factor for heart failure. Therefore, it is important to 
understand the mechanisms that how hypertrophic agents which cause the 
overgrowth of heart muscle increase ribosome production. Although it is known that 
inhibiting mTORC1 largely blocks the rapid activation of protein synthesis by PE, 
here it did not affect the synthesis of new 18S rRNAs. However, inhibitors of the 
MEK/Erk pathway and p90
RSK each block the new rRNA synthesis. These data 
reveal that, in contrast to many other types of cell, ribosome biogenesis is controlled 
by MEK/ERK/p90
RSK signalling, not mTORC1, in cardiomyocytes. 
Taken together, the data presented here may provide cues for potential 
valuable therapy of cardiac left ventricular hypertrophy. 
 IV 
 
 
 
 
   V 
 
List of Contents 
Abstract                    III 
List of Contents                   V 
List of Figures and Tables                          XI 
Abbreviations                           XV 
Acknowledgements                        XVII 
Declaration of authorship                       XIX 
 
Chapter 1: Introduction                1 
1.1 Ribosome Biogenesis  and cell growth            3 
1.1.1 Overview of ribosome biogenesis in mammalian cells       3 
1.1.1.1 RNA polymerase I and rDNA transcription        6 
1.1.1.2 Ribosomal proteins and 5’-TOP mRNA translation      10 
1.1.1.3 5S rRNA synthesis by Pol III           11 
1.1.1.4 Pre-rRNA processing and ribosome assembly       12 
1.1.2 mTOR and regulation of cell growth            15 
1.1.2.1 The mTOR complex              15 
1.1.2.2 Regulation of mTORC1             19 
1.1.2.3 Regulation of mTORC2            19 
1.1.2.4 mTORC1 downstream targets and cell growth      20 
1.1.2.5 mTOR and mRNA translation          23 
1.1.2.6 mTORC1 and ribosome biogenesis          26 
1.2 Cardiomyocytes and regulation of cardiac hypertrophy      30 VI 
 
1.2.1 Overview of cardiomyocytes and cardiac hypertrophy       30 
1.2.2 Cardiac hypertrophy                31 
1.2.3 Regulation of cardiac growth              32 
1.2.3.1 G protein- coupled receptor (GPCR) signalling in cardiomyocytes  32 
1.2.3.2 Ras signalling in cardiac growth          34 
1.2.3.3 ERK signalling in cardiac hypertrophy        36 
1.2.3.4 p90RSK signalling in cardiac hypertrophy        38 
1.2.3.5 mTOR signalling in cardiac hypertrophy        41 
1.3 4-Thiouridine labelling method             44 
1.4 Aims of the study                  46 
 
Chapter 2: Materials and Methods             47 
2.1 Chemicals and reagents               49 
2.2 Adult rat ventricular cardiomyocytes (ARVC)        49 
2.2.1 Isolation of left ventricular cardiomyocytes from adult Sprague-Dawley 
rats                      49 
  2.2.2 Culture of ARVC              53 
  2.2.3 Cell treatment and protein extraction          54 
2.3 Human cervical carcinoma (HeLa) and T-Rex
TM- 293 (Invitrogen) cell lines 
                      55 
2.3.1 HeLa and T-Rex
TM 293 cell culture          55 
  2.3.2 Transfection of HeLa and T-Rex
TM 293 cells        56 
  2.3.3 Induction of BOP1Δ or BOP1ΔTOS in T-Rex
TM- 293 cell    56 VII 
 
  2.3.4 Cell treatment and protein extraction          57 
 2.4 4-Thiouridine labelling methods            58 
2.4.1 RNA preparation              58 
  2.4.2 Biotinylation of 4-SU labelled RNA          59 
  2.4.3 Isolation of 4-SU labelled RNA from total RNA      59 
2.5 Uridine uptake assay                60 
  2.5.1 Nucleoside Transport in HeLa cells          60 
  2.5.2 Uridine uptake assay in ARVC           62 
2.6 Real Time-quantitative PCR (RT-qPCR) amplification analysis    63 
2.7 Protein Chemistry and biochemistry            66 
2.7.1 Determination of protein concentrations        66 
2.7.2 SDS-PAGE and Western Blotting          66 
2.8 Immunofluorescence microscopy            67  
2.9 Quantitative Chromatin Immunoprecipitation (qChIP) in ARVC    69  
 
Chapter 3: Development of a novel method to study rRNA synthesis in 
mammalian cells                  71 
3.1 Introduction                  73 
3.2 4-SU labelling method development in HeLa cells        73 
3.2.1   4-thiouridine labelling alone does not affect mTORC1 or ERK 
signalling pathways in HeLa cells              73 
3.2.2  4-thiouridine can be incorporated into newly synthesized rRNAs in 
HeLa cells                76  VIII 
 
3.2.3  4-thiouridine labelling of rRNAs increases linearly with time in HeLa 
cells                  78 
3.3 Establishing the 4-thiouridine labelling assay in adult rat ventricular 
cardiomyocytes (ARVC)                78    
3.3.1  4-thiouridine labelling alone does not affect mTORC1 or MEK/ERK 
signalling pathways in ARVC with PE stimulation      78 
3.3.2  4-SU can be incorporated into newly synthesized rRNAs in ARVC  82 
3.3.3  Phenylephrine activates new rRNA synthesis in ARVC    82  
3.4 Discussion                  84 
 
Chapter 4: mTORC1 regulates the transcription and decay of rRNA in 
mammalian cells                  87 
4.1 Introduction                  89  
4.2 mTORC1 signalling pathway is a key regulator of rRNA synthesis   90 
4.2.1    The signalling inhibitor, rapamycin, interferes with the uptake of the 
uridine uptake into HeLa cells              90 
4.2.2  The synthesis of rRNAs is rapamycin-sensitive in HeLa cells  92 
4.2.3  Rapamycin induces the decay of new rRNA molecues    94 
4.2.4  Over-expression of S6K1 does not rescue inhibition of rRNA 
synthesis by rapamycin or PP242          96 
4.2.5  Inhibiting mTORC1 does not induce disruption of the nucleolus    101 
4.3 Effects of inducible expression of BOP1Δ on ribosomal RNA processing  104 
4.3.1  Transfection of BOP1Δ mutant in HEK293 cells              104 
4.3.2  Inducible expression of BOP1Δ enhances p21 transcription           106 
4.4 Discussion and future aims                      108 
 
 IX 
 
Chapter 5: The Control of rRNA synthesis in ARVCs                113 
5.1 Introduction                          115 
5.2 Rapamycin does not prevent PE-induced rRNA synthesis              116 
5.2.1 Rapamycin interferes with the uptake of the uridine uptake into the 
heart muscle cells                          116 
5.2.2  Rapamycin does not block PE-induced rRNA synthesis            119 
5.2.3  PP242 does not block the PE-induced new rRNA synthesis 
completely                          121 
5.3 PE enhances rRNA synthesis via MEK signalling                124 
5.3.1 The MEK inhibitor, AZD6244, does block PE-induced rRNA synthesis
                              124 
5.3.2 Another MEK inhibitor, PD184352, also blocks new 18S and 5S 
synthesis                            127 
5.4 RSKs and rRNA synthesis in Cardiomyocytes                130 
5.4.1 BI-D1870 blocks the PE-induced rRNA synthesis              130 
5.4.2 BI-D1870 affects Pol I complex binding to the rRNA gene in ARVC  
          136 
5.5 Discussion                          139 
 
Chapter 6: Concluding Remarks                      141 
 
References                            151 
Appendix                            177 
 X 
 
 
 
   XI 
 
List of Figures and Tables 
 
Figure 1.1: Ribosome biogenesis in mammalian cells.        5 
Figure 1.2: Structure of rDNA in eukaryotic cells.        7 
Figure 1.3: Mammalian rRNA synthesis: the Pol I and Pol lll transcription.  7 
Figure 1.4: Signalling pathways in regulation of rRNA transcription.    9 
Figure 1.5: Schematic diagram of pre-rRNA processing pathways in eukaryotic 
cells.                      13 
Figure 1.6: mTOR signalling.              16 
Figure 1.7: The four stages of mRNA translation.          24 
Figure 1.8: eIF4F formation and translation initiation.        25 
Figure 1.9: mTORC1 and rRNA synthesis in mammalian cells.     29 
Figure 1.10: G protein- coupled receptor (GPCR) signalling pathways.  33 
Figure 1.11: Ras signalling pathway in cardiomyocytes.       35 
Figure 1.12: p90
RSKs signalling in cardiomyocytes.        39 
Figure 1.13: Control of the steady state level of rRNA.        43 
Figure 1.14: The pyrimidine salvage pathway of 4-SU labelling.     43 
Figure 1.15: The experimental approach of 4-SU labelling of rRNA in 
Mammalian    cells.                  45 
Figure 2.1: The Langendorff perfusion system used for the isolation of rat 
ventricular cardiomyocytes.               51 
Figure 3.1: 4-SU labelling alone does not affect the mTOR signalling in HeLa 
cells.                      75 
Figure 3.2: 4-SU labelling up to 1 hour does not affect the activation state of 
ERK or mTORC1 signalling in HeLa cells.          75 
Figure 3.3: 4-thiouridine can be incorporated into newly synthesized rRNAs in 
HeLa cells.                    77 
Figure 3.4: 4-thiouridine labelling of rRNAs increases linearly in HeLa cells.  79 XII 
 
Figure 3.5: 4-SU labelling alone does not affect mTORC1 or MEK/ERK 
signalling pathways in ARVC with PE stimulation.        81 
Figure 3.6: 4-thiouridine is incorporated only into newly synthesized rRNA in 
cardiomyocytes.                  83 
Figure 3.7: PE enhances new rRNA synthesis in ARVC.       85 
Figure 3.8: PE induces the growth of cardiomyocytes.        85 
Figure 4.1: Rapamycin interferes with the uptake of the uridine uptake into 
HeLa cells                    91 
Figure 4.2: Rapamycin inhibits the accumulation of new rRNA.    93 
Figure 4.3: The synthesis of rRNAs is rapamycin-sensitive.      95 
Figure 4.4: Inhibition of mTORC1 by rapamycin promotes decay of newly 
synthesized rRNA.                   97 
Figure 4.5: Over-expression S6K1 does not rescue inhibition of rRNA synthesis 
by rapamycin or PP242.                99 
Figure 4.6: Rapamycin treatment induces a partial redistribution of B23 but 
not of BOP1 into the nucleoplasm.                      103 
Figure 4.7: The schematic diagram of BOP1Δ impairing 32S pre-rRNA 
processing pathways.                         105 
Figure 4.8: Transfection of BOP1Δ mutant in HEK293 cells.               107 
Figure 4.9: BOP1Δ mutant induces ribosomal stress gene (p21) synthesis.     109 
Figure 5.1: Effects of signalling rapamycin on the uptake of [
3H] uridine into 
ARVC.                             117 
Figure 5.2: Rapamycin does not inhibit the ability of phenylephrine to stimulate 
rRNA synthesis.                          120 
Figure 5.3: The mTOR inhibitor, PP242, partially inhibits PE-induced rRNA 
synthesis.                             122 
Figure 5.4: The MEK inhibitor, AZD6244, blocks the ability of PE to activate 
rRNA synthesis.                           125 
Figure 5.5: Another MEK inhibitor, PD184352, also blocks the ability of PE to 
activate rRNA synthesis.                        128 
Figure 5.6: The p90
RSK inhibitor, BI-D1870, inhibits PE-enhanced rRNA 
synthesis in ARVC.                          131 XIII 
 
Figure 5.7: BI-D1870 induces the decay of newly-synthesized rRNA in ARVC. 
                              135 
Figure 5.8: BI-D1870 inhibits the PE-induced recruitment of Pol I to the rRNA 
promoter.                            137 
Figure 6.1: A scheme showing the different signalling events involving 
regulating rRNA synthesis in HeLa cells and in ARVC.                145 
Figure 6.2: A scheme showing the hypothesis that how MEK/ERK/p90
RSK 
signalling regulating Pol I complex assembly in ARVC.                148 
 
   
TABLE 2.1: The stock of Ca2+-free buffer          50 
TABLE 2.2: List of Plasmids              57 
TABLE 2.3: List of Primer Efficiency            64 
TABLE 2.4: List of Primary Antibodies            68 
 
 
 
 
 
 
 
 
 
 
 XIV 
 
 
 
 
 
 
 
 
 
 
 
   XV 
 
Abbreviations 
4E-BP:    eIF4E-binding protein 
4-SU:    4- thiouridine 
5’TOP:  5’-terminal tract of oligopyrimidine 
αAR:    α-adrenergic receptor 
βAR:    β-adrenergic receptor 
α-MHC:  α-myosin heavy chain 
β-MHC:  β-myosin heavy chain 
AA:     Amino acid 
AC:    Adenylyl cyclase  
ACTB:    Actin beta 
ActD:    Actinomycin D 
ANF:    Atrial natriuretic factor 
Ang II:   Angiotensin II 
ARVC:   Adult rat ventricular cardiomyocyte  
ATP5B:  ATP synthase 
BNP:    B-type natriuretic peptide 
BSA:     Bovine serum albumin 
CH:    Cardiac hypertrophy 
DAG:    Diacylglycerol 
DMEM:   Dulbecco’s modified Eagle Medium 
DMSO:   Dimethyl sulphoxide 
eEF:    Eukaryotic elongation factor 
eIF:    Eukaryotic initiation factor 
ERK:    Extra-cellular signal regulated protein kinase 
ET-1:    Endothelin- 1 
ETS :    External transcribed spacer  
FCS:                Foetal calf serum 
IGS:    Intergenic spacer 
ITS:    Internal transcribed spacer   
GAP:               GTPase-activating protein 
GAPDH:         Glyceraldehyde-3-phosphate dehydrogenase 
GDP:               Guanosine diphosphate XVI 
 
GEF:    Guanine nucleotide exchange factor  
GqPCR:  Gq protein-coupled receptor 
GTP:    Guanosine triphosphate 
HEK:    Human embryonic kidney  
MAP:    Mitogen- activated protein 
MAPK:  Mitogen-activated protein kinase 
MEK:    MAPK/extracellular signal-regulated protein kinase kinase 
Mnk:    MAPK signal integrating kinase 
MPG- Strep:  Magnetic- porous- glass streptavidin 
mTORC:  Mammalian target of rapamycin complex 
PABP:   Poly(A)-bindng protein 
PE:    Phenylephrine  
PI3K:    Phosphatidylinositol 3-kinase 
PIP2:    Phosphatidylinositol bisphosphate 
PKB:    Protein kinase B 
PLC:    Phospholipase C 
Pol:    Polymerase 
rDNA:   Ribosomal DNA 
RP:    Ribosomal protein 
RPL13:  Ribosomal protein L13 
rRNA:   ribosomal RNA 
S6K:    70-kDa protein kinase that phosphorylates ribosomal protein S6 
SDS-PAGE:    Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SL-1:    Selectivity factor-1 
snoRNA:  small nucleolar RNA 
snoRNP:  small nucleolar ribonucleoprotein particle 
TFIIIB:  Pol III-specific transcription factor B  
TFIIIC:  Pol III-specific transcription factor C 
TIF:    Transcription Initiation Factor  
TSC:    Tuberous sclerosis complex  
UBF:    Upstream Binding Factor 
 
 XVII 
 
Acknowledgements 
 
  I would like firstly to thank my supervisors Professor Chris Proud and 
Professor Paul Townsend. Without their help and support, this study would not have 
been performed. I would also like to thank the British Heart Foundation for their 
funding of this project. 
  Many thanks to past and present members of both the Proud and the 
Townsend laboratories for being my role models and their advice. I especially would 
like to thank Dr. Valentina Iadevaia for much help and guidance. I have to say thank 
you to Dr. Xuemin Wang. I am very grateful for her daily encouragement. I would 
also thank Dr.Rui Liu for all his help.  
  Finally, I would like to thank my parents, Jia-yu Li and Xiumei Zhang for 
their supports and unconditional love. 
 
 
 
 
 
 
 
 
 
 
 XVIII 
 
 
   XIX 
 
Declaration of Authorship  
 
  
  
I, Ze Zhang 
  
declare that the thesis entitled 
  
 The Control of Ribosomal RNA Synthesis in Mammalian Cells 
  
and the work presented in the thesis are both my own, and have been generated by 
me as the result of my own original research.  I confirm that: 
  
  
§   this work was done wholly or mainly while in candidature for a research degree at 
this University; 
  
§   where any part of this thesis has previously been submitted for a degree or any 
other qualification at this University or any other institution, this has been clearly 
stated; 
  
§   where I have consulted the published work of others, this is always clearly 
attributed; 
  
§   where I have quoted from the work of others, the source is always given. With the 
exception of such quotations, this thesis is entirely my own work; 
  
§   I have acknowledged all main sources of help; 
  
§   where the thesis is based on work done by myself jointly with others, I have made 
clear exactly what was done by others and what I have contributed myself; 
  
§   parts of this work have been published as:  
  
 
 Iadevaia, V., Z. Zhang, E. Jan and C. G. Proud (2012). "mTOR signaling regulates 
the processing of pre-rRNA in human cells." Nucleic Acids Res 40(6): 2527-2539. 
 
  
  
  
  
  
Signed: ……………………………………………………………………….. 
  
Date:……………………………………………………………………………. 
 XX 
 
 1 
 
 
 
 
 
 
 
Chapter 1 
 
Introduction 
 
 
 
 
 
 
 
 
 2 
 
 
   3 
 
1.1  Ribosome Biogenesis  and cell growth 
1.1.1 Overview of ribosome biogenesis in mammalian cells 
Ribosome biogenesis is an important process during cell division and is 
evolutionarily conserved. The ribosome is a complex and highly regulated molecular 
machine which is responsible for protein synthesis. In mammalian cells, gene 
expression is tightly controlled in response to external conditions, particularly 
growth factors, hormonal signals or different types of stress (Mayer and Grummt 
2006; DeBerardinis et al. 2008). It is essential for cells to keep a stable proliferation 
rate and suitable cell size. In general, global protein synthesis is activated to drive 
cell growth under favourable conditions. There are two major mechanisms to 
accelerate rates of translation: (I) in the short term, increasing translation efficiency 
using existing ribosomes and translation facilities; (II) in the longer term, increasing 
translation capacity by up-regulating the synthesis of ribosome components 
(ribosomal RNAs and ribosomal proteins) and certain translation factors (Montanaro 
et al. 2008; Hannan et al. 2011). Therefore, ribosome biogenesis plays a key role in 
controlling cell growth, proliferation as well as cell division (Mayer et al. 2004; 
Mayer and Grummt 2006). It requires a high degree of coordination among different 
cell signalling events. 
In mammalian cells, cytoplasmic ribosomes are composed of four ribosomal 
RNAs (rRNAs) and about 79 ribosomal proteins (Rps). They consist of two subunits 
which have sedimentation coefficients of 40 x 10
-13 and 60 x 10
-13 according to their 
sedimentation rates through a sucrose gradient. As one Svedberg (S) unit is 10
-13, the 
two ribosomal subunits are named as 40S and 60S ribosomal subunits. Ribosome 
biogenesis involves the synthesis and processing of the ribosomal components, 
including the assembly of the four rRNAs with multiple Rps. All three types of RNA 
polymerases (Pol) I, II, III are involved. They produce, respectively, the large rRNAs 
(5.8S, 18S and 28S), the 5’-TOP mRNAs encoding ribosomal proteins, and the 5S 
rRNA (Fig. 1.1) (Goodfellow et al. 2006; Kopp et al. 2007). Correct synthesis of 
these components of the ribosome in exactly the right quantities requires close 
coordination between the synthesis and processing of the four rRNAs, and the 
transcription and translation of the ribosomal protein mRNAs. Ribosome biogenesis 
is one of the most energy-consuming processes in the cell, and it also needs a lot of 4 
 
amino acids plus ribonucleotides. In HeLa cells, about 7500 ribosomes are made per 
minute which requires transcription of almost 200 rRNA genes and the synthesis of 3 
x10
5 ribosomal proteins (Mayer and Grummt 2006). These processes need to be 
coordinated to ensure that appropriate amounts of rRNA and ribosomal proteins are 
available. Furthermore, the levels of ribosomes in a cell determine its maximal rate 
of protein synthesis, and therefore have a major influence on cell growth and 
proliferation. Activation of protein synthesis contributes to a range of disease e.g. by 
tissue overgrowth (Hannan et al. 2011). Moreover, deregulation of ribosome 
biogenesis may trigger the tumour suppressor protein p53 and induce apoptosis 
and/or cancer (Montanaro et al. 2008).  One major disorder of cell growth control is 
cardiac hypertrophy (CH) in adult hearts: under this condition, cardiac muscle cells 
grow in size (e.g., in response to overload) without increasing in cell number 
(Molkentin and Dorn 2001; Kacimi and Gerdes 2003; Shioi et al. 2003). This is 
initially a beneficial adaptive response but can ultimately impair the function of the 
heart, leading to cardiac failure. Indeed, CH is a major risk factor for heart failure. 
This will be discussed in more detail below (Section 1.2).  
 It is hence critical to understand how cells regulate ribosome production in 
response to various stimuli, i.e. insulin, growth factors. It was shown in the late 
1960s in bacteria that both 40S and 60S ribosomal subunits can be broken down into 
their RNA and protein components to conserve energy, then reassemble into 
functional ribosomes under proper conditions (Nomura et al. 1967). As a result, it is 
suggested that there is a dynamic equilibrium between ribosomal components and 
ribosome synthesis depending on growth factors and nutrient availability. However, 
the exact mechanism underlying the relationship between ribosome biogenesis and 
extra-cellular conditions in mammalian cells remains poorly understood (Mayer and 
Grummt 2006; Jastrzebski et al. 2007). It has been shown that signalling events such 
as mTORC1 signalling can regulate ribosome biogenesis by affecting ribosomal 
RNA (rRNA) synthesis or/and increasing translation of 5’-TOP mRNAs encoding 
for ribosomal proteins (Fig.1.1) (Hamilton et al. 2006; Mayer and Grummt 2006; 
Kubica and Blenis 2010; Michels 2011).  
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Figure 1.1: Ribosome biogenesis in mammalian cells. Ribosome synthesis 
requires all three RNA polymerases: Pol I for the synthesis of 47S pre-rRNA which 
will further be processed into mature 5.8S rRNA, 18S rRNA and 28S rRNA; Pol II 
for transcription of 5’-TOP ribosomal protein (RP) genes; and Pol III for 
transcription of 5S rRNA. Ribosome components are processed and ribosome 
subunits are assembled in the nucleolus, a specific region within the nucleus where 
rRNA transcription also occurs.  
                           
                               Adapted from Mayer and Grummt, 2006 
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1.1.1.1 RNA polymerase I and rDNA transcription  
The transcription of ribosomal RNA genes by RNA polymerase I (Pol I) is 
tightly coordinated with cell growth (Grandori et al. 2005). It has been shown that 
the rate-limiting step in ribosome biogenesis is the transcription of the ribosomal 47S 
by RNA polymerase I (Moss and Stefanovsky 1995; Hannan et al. 1998). As the 
level of three main rRNAs synthesis including 18S, 28S and 5.8S rRNA are 
dependent on Pol I transcription, therefore the rate of Pol I transcription determines 
the rate of ribosome biogenesis (Chedin et al. 2007). Since Pol I has a major impact 
on cell growth, it is important to elucidate how cells control Pol I transcription under 
different conditions. It is essential to understand the components and signalling 
events involved in regulating Pol I transcription in mammalian cells. The large, >1 
MDa, Pol I complex in human cells is a highly conserved multi-subunit enzyme set 
of proteins which direct rDNA transcription (Russell and Zomerdijk 2006). 
Eukaryotic ribosomal RNA genes (rDNA) are organized as tandem repeats (Fig.1.2). 
Each repeat is separated by an internal repetitive intergenic spacer (IGS). Each 
rDNA transcription unit contains sequence encoding for 18S, 5.8S and 28S rRNA; 
the external transcribed spacer (ETS) and the internal transcribed spacers (ITS) 
(Fig.1.2) (Mandal 1984). 
 In mammalian cells, transcription initiation by Pol I requires the formation 
of pre-initiation complex (PIC) with other transcription initiation factors, as Pol I 
alone has no ability to recognize or bind specifically to the promoter DNA sequence 
(Russell and Zomerdijk 2005). PIC assembly requires at least three basal factors: 
Transcription Initiation Factor IA (TIF-IA), Transcription Initiation Factor IB (TIF-
IB, also known as selectivity factor SL1) and Upstream Binding Factor (UBF) (Fig 
1.3A) (Hannan et al. 1998; Brandenburger et al. 2001; Brandenburger et al. 2003). In 
human and rat cells, both the TIF-IB/SL-1 and UBF transcription factors have been 
shown to recognize and bind to the rDNA promoter region, and are required for 
efficient transcription in vitro (Smith et al. 1990). In mammalian cells, TIF-IA 
interacts with both Pol I and DNA binding-protein, TIF-IB/SL-1, thus is required for 
recruiting Pol I to the rDNA promoter and assists PIC formation (Grummt 2010).  
 
 7 
 
 
 
 
Figure 1.2: Structure of rDNA in eukaryotic cells. Each rDNA transcription unit 
consists of the sequence encoding for 18S, 5.8S and 28S rRNAs, the external 
transcribed spacer (ETS) and internal transcribed spacers (ITS). The transcription 
unit is separated by an internal repetitive intergenic spacer (IGS). 
 
 
 
 
 
 
A) 
 
 
 
B) 
 
 
 
 
Figure 1.3: Mammalian rRNA synthesis. A) The RNA polymerase I 
transcription. Pol I transcription initiation requires three basal factors: TIF-IA, TIF-
IB/SL1 and UBF. Together with Pol I, these factors form pre-initiation complex. 
Recruitment of PIC to the rDNA promoter region promotes rRNA gene transcription. 
B) The RNA polymerase III transcription. Pol III transcription requires two 
transcription factors: TFIIIB and TFIIIC. The DNA-binding protein, TFIIIC, 
recognizes 5S rRNA gene promoter sequence and binds to TFIIIB. TFIIIB then 
recruits Pol III to the promoter and initiates transcription.  8 
 
Significantly, all three basal factors can be regulated by different signalling 
pathways including mTORC1 and MEK/ERK/p90
RSKs to influence PIC formation 
and/or Pol I activity (Fig.1.4) (Mahajan 1994; Moss and Stefanovsky 1995; Zhao et 
al. 2003). Early studies showed that rRNA synthesis in mammalian cells is 
rapamycin-sensitive (Mahajan 1994; Moss and Stefanovsky 1995), implying that 
mTORC1 plays an important role in the regulation of Pol I transcription. mTORC1-
dependent regulation of Pol I transcription will be further discussed in Section 
1.1.2.6. 
In cancer cells, extracellular signal-regulated kinase (ERK) is hyper-activated 
during carcinogenesis and it up-regulates Pol I transcription to increase rRNA 
synthesis (Drygin et al. 2010). Studies have shown that ERK signalling activates 
rRNA synthesis by targeting the transcription factors TIF-IA and UBF, and thus 
positively regulates ribosome biogenesis and cell growth (Russell and Zomerdijk 
2005; Russell and Zomerdijk 2006). ERK enhances Pol I activity by phosphorylating 
UBF at both Thr117 and Thr201, such phosphorylations increase the interaction of 
UBF with DNA and are important for Pol I transcription elongation (Stefanovsky et 
al. 2001; Stefanovsky et al. 2006; Stefanovsky et al. 2006). In non-proliferating 
neonatal cardiomyocytes, increased UBF expression alone promotes rRNA synthesis, 
and is essential for the initiation of cardiac hypertrophy (heart cell growth) induced 
by hypertrophic agonists i.e. PE (Hannan et al. 1996; Brandenburger et al. 2001; 
Brandenburger et al. 2003). Glennon and Kaddoura also showed that ERK signalling 
is necessary for PE-induced cardiomyocyte hypertrophy in culture (Glennon et al. 
1996). This observation, together with the finding that UBF is phosphorylated by 
ERK (Stefanovsky et al. 2006), indicates that increased rRNA synthesis during 
hypertrophic growth is possible regulated via ERK pathway. 
Besides rapamycin, activation of TIF-IA and ribosomal gene transcription is 
sensitive to the MEK inhibitor, PD184352, indicating that TIF-IA is also targeted by 
MEK/ERK pathway in vivo (Zhao et al. 2003). ERK is essential for hypertrophic 
response to PE in heart cells (Sugden and Clerk 1998). ERK is rapidly activated in 
response to hypertrophic stimuli, PE (Fig.1.4) (Wang and Proud 2002). Moreover, 
ERK and p90
RSKs, which are activated by ERK, phosphorylate TIF-IA at two serine 
residues (Ser633 and Ser649) at the C- terminal region (Zhao et al. 2003). Given the 
importance of TIF-IA phosphorylation for Pol I transcription (Zhao et al. 2003),  9 
 
 
   
 
Figure 1.4: Signalling pathways in regulation of rRNA transcription. The 
diagram shows the chain of events of by which growth stimulus activates 
MEK/ERK/ p90
RSKs signalling pathway and also activates mTORC1. In 
cardiomyocytes, hypertrophic agonists such as PE activate the Ras/Raf/MEK/ERK/ 
p90
RSK pathway. ERK can activate Pol I/ Pol III transcription, although the role of 
p90
RSK remains unclear. mTORC1 also promotes Pol I/Pol III activation. However, it 
is not known whether Pol I/Pol III transcription are directly regulated by mTORC1 
or through other links, i.e., the downstream S6 kinase. 
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ERK might up-regulates Pol I transcription in response to hypertrophic stimuli via 
phosphorylation of TIF-IA. It is possible that some effects of ERK are mediated 
through the p90
RSK, the downstream substrate of ERK (Blenis et al. 1991; Roux et al. 
2003; Zhao et al. 2003). However, Ser649 in C-terminal region of TIF-1A is not a 
consensus phosphorylation site for the N- terminal domain of p90
RSK. Hence, the 
role of p90
RSK in regulating Pol I activity, at least in cardiomyocytes, remains 
unclear and may require the regulation of other components of the Pol I machinery.  
Thus, the MEK/ERK/p90
RSKs pathway targets two Pol I transcription factors, 
TIF-IA and UBF, leading to up-regulation of rDNA transcription. The role of the 
ERK pathway in cardiac hypertrophy is discussed in Section 1.2.3.3. 
 
1.1.1.2 Ribosomal proteins and 5’-TOP mRNA translation 
In mammalian cells, ribosomes contain 79 different ribosomal proteins, all of 
which are encoded by 5’-terminal oligopyrimidine (TOP) mRNAs. 5’-TOP mRNAs 
contain an oligopyrimidine tract at their 5' end and are transcribed by Pol II. Besides 
the cytoplasmic ribosomal proteins, they also encode other components of the 
translational machinery such as elongation factors (Meyuhas 2000; Iadevaia et al. 
2008). As up-regulation of 5’-TOP mRNA translation and thus ribosome biogenesis 
elevates the capacity of protein synthesis, control of 5’-TOP mRNA translation is 
important in cell growth, which requires increased protein synthesis in response to 
nutrients and growth factors.  
The 5’-TOP sequence regulates RP expression at the level of translation. In 
serum-starved condition, the 5’-TOP impairs the translation of these mRNAs, while 
under serum stimulation, these transcripts are recruited into polysomes and translated 
efficiently (Warner 1999). Although it has been known for more than 15 years that 
mTORC1 controls the translation of the 5’-TOP mRNAs, it is not known how 
mTORC1 does this (Hamilton et al. 2006). Rapamycin inhibits the 5’-TOP mRNAs 
translation, while expressing a rapamycin- resistant S6K1 mutant reportedly 
suppresses such inhibitory effect of rapamycin (Jefferies et al. 1997). The results 
imply that S6K1 activity and maybe S6 phosphorylation play a role in mediating the 
block of 5'TOP mRNA translation by rapamycin.  11 
 
Nevertheless, recent studies have questioned the role of S6 phosphorylation 
by S6K1 in the control of 5’-TOP mRNA translation. It has reported that the control 
of 5'-TOP mRNA translation is fully dependent on PI3-kinase, but requires neither 
S6K1 nor S6 phosphorylation in response to amino acids (which also promotes TOP 
mRNAs) (Tang et al. 2001). This agrees with another study showing that with 
depletion of both S6K1 and S6K2 in cells, 5’-TOP mRNA translation is still 
enhanced in a rapamycin-dependent manner upon stimulation (Pende et al. 2004). 
Moreover, in differentiating mouse embryonic lymphoid cells, 5’-TOP mRNA 
translation was repressed without changes in S6 phosphorylation (Barth-Baus et al. 
2002). These data demonstrate that regulation of mTOR-dependent 5’-TOP mRNA 
translation does not require S6K1 or S6 phosphorylation.  
It remains elusive how mTORC1 controls the transcription factors that make 
rRNA or whether RP mRNA transcription is regulated in mammalian cells. The 
regulation of general mRNA translation is discussed in detail in Section 1.1.2.5. 
 
1.1.1.3 5S rRNA synthesis by Pol III 
In mammalian cells, RNA polymerase III is responsible for the synthesis of 
5S rRNA and tRNAs which are essential for ribosomal biogenesis and global protein 
synthesis. It is important to maintain high rate of Pol III transcription to sustain cell 
growth. Indeed, in cancer cells, 5S rRNA and tRNA synthesis occur at highly 
elevated rates (White 2005). Hence, like Pol I transcription, Pol III transcription is 
tightly regulated. 
Pol III mediated transcription requires two Pol III-specific transcription 
factors: TFIIIB and TFIIIC (Fig.1.3B) (White 2005). TFIIIC is a large DNA-binding 
protein which directly recognizes and binds to the DNA promoter sequence 
(Geiduschek and Kassavetis 2001; Schramm and Hernandez 2002). Once TFIIIC is 
bound to DNA, it recruits TFIIIB to the promoter region; TFIIIB then recruits Pol III 
and positions it at the transcription start site (Geiduschek and Kassavetis 2001; 
Kassavetis et al. 2001). Unlike the three rRNAs synthesised by Pol I, 5S rRNA does 
not require further processing. 12 
 
5S rRNA synthesis is regulated by different signalling pathways through Pol 
III transcription factors (Fig.1.4). mTORC1 signalling has been shown to control 5S 
rRNA synthesis by directly phosphorylating MAF1, a repressor of Pol I transcription 
(White 2005; Michels et al. 2010). This will also be discussed in Section 1.1.2.6. 
ERK has also been shown to up-regulate Pol III production by directly 
phosphorylating the essential factor TFIIIB, which stimulating it recruiting Pol III 
and TFIIIC as a consequence (Felton-Edkins et al. 2003). Phosphorylation of TFIIIB 
involves ERK directly binding to Brf1, the subunit of TFIIIB; and mutation of an 
ERK docking domain or phosphoacceptor site in Brf1 inhibits serum-induced Pol III 
transcription (Felton-Edkins et al. 2003).  
In non-proliferating cells, primary neonatal cardiomyocytes, ERK has also 
been shown to increase Pol III production of tRNA and 5S rRNA during 
hypertrophic growth (Goodfellow et al. 2006). ERK directly activates Pol III 
transcription factor TFIIIB and mediates the essential TFIIIB subunit Brf1 
expression during hypertrophy, as a result, the synthesis of tRNA and 5S rRNA were 
enhanced (Goodfellow et al. 2006). This observation shows a role of ERK signalling 
pathway in controlling rRNA synthesis during hypertrophy growth in heart cells. 
 Taken together, these data demonstrate that ERK is directly involved in 5S 
rRNA regulation. 
 
1.1.1.4 Pre-rRNA processing and ribosome assembly  
It was first established in 1970 that the nucleolus is the site of ribosome 
assembly(Smetana et al. 1970). In eukaryotic cells, ribosome biogenesis takes place 
in the nucleolus, which is a dynamic sub-nuclear body within the nucleus (Olson and 
Dundr 2005). The mammalian 47S rRNA precursor is transcribed here, then 
processed, and assembled with 5S RNA synthesized by Pol III and 79 different 
ribosomal proteins to generate the mature 40S and 60S ribosomal subunits (Fig.1.1) 
(Hannan and Rothblum 1995; Hannan et al. 1998). Because the nucleolus is the 
location where ribosomes are made, its overall structure is largely determined by its 
ability to assemble ribosomes (the rate of ribosome biogenesis)  
 13 
 
 
 
 
 
Figure 1.5: Schematic diagram of pre-rRNA processing pathways in eukaryotic 
cells. The 47S pre-rRNA contains 5’ and 3’ external transcribed region (ETS) and 
two non-coding internal transcribed spacers (ITS), as well as the mature 18S, 5.8S 
and 28S rRNA. Following pathway A or B, the pre-rRNAs are modified and the 
mature rRNAs are generated. 
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(Smetana et al. 1970; Olson and Dundr 2005). In fact, nucleolar hypertrophy 
(enlarged nucleoli) has long been recognized as a key feature of cancer cells 
(Smetana et al. 1970; Ploton 1994). Indeed, its overall structure is tightly linked to 
the regulation of Pol I and Pol III, since the size and the structure of the nucleolus 
reflects the level of rRNA synthesis (Altmann and Leblond 1982; Moss and 
Stefanovsky 1995). For example, inhibition of Pol I rDNA transcription by 
actinomycin D causes rapid disruption of nucleolar organization in HeLa cells 
(Olson and Dundr 2005). 
  Eukaryotic ribosome assembly starts with the synthesis of 47S pre-rRNA by 
Pol I. rDNA transcription has been discussed above in Section 1.1.1.1. The long 
rRNA precursor undergoes complex processing pathways to generate mature 18S, 
5.8S and 28S rRNA soon after the initiation of Pol I transcription (Fig.1.5) (Kopp et 
al. 2007). Soon after synthesis, 47S precursor rRNA is processed into 45S pre-rRNA. 
45S pre-rRNA contains the sequences for mature 18S, 5.8S and 28S rRNA, 5’ and 3’ 
external transcribed spacers (ETS), as well as two internal transcribed spacers (ITS) 
(Granneman and Baserga 2004). The 18S rRNA is then assembled into the small 40S 
subunit, whereas the 5.8S and 28S rRNA together with 5S rRNA synthesized by Pol 
III will form the 60S subunit.  
Pre-rRNA processing and  assembly of mature rRNAs into ribosomal 
subunits requires at least 170 proteins including endo- and exoribonucleases, ATP-
dependent RNA helicase, chaperones and assembly factors, as well as about 170 
small nucleolar ribonucleoprotein particles (snoRNPs) (Gaspin et al. 2000; Ofengand 
2002). snoRNPs are RNP complexes containing small nucleolar RNAs (snoRNAs). 
By base-pairing with pre-rRNAs, snoRNAs, like the U3 snoRNA, are responsible for 
correctly positioning the modifying enzymes on the pre-rRNA (Granneman and 
Baserga 2004). In yeast, the primary 35S pre-rRNA transcript forms a large RNP 
complex (90S pre-ribosome) with non-ribosomal proteins and ribosomal 
proteins(Udem and Warner 1972; Trapman et al. 1975). In HeLa cells, the formation 
of large complexes (90S pre-ribosome) with similar structure can also be observed 
(Warner and Soeiro 1967). However, the component and function of these 
complexes in mammalian cells remain largely unclear. Once the large complex, 90S 
pre-ribosome, is formed, it is rapidly separated into 43S and 66S particles 
(precursors to the 40S and 60S ribosomes subunits), and the synthesis of 40S and 
60S ribosomal subunits remains largely independently of each other(Nissan et al. 15 
 
2002; Fromont-Racine et al. 2003). The 43S particles are exported to the cytoplasm 
where they are subsequently matured to 40S ribosome subunits, while 66S pre-
ribosomes require several modification steps in the nucleus before export to the 
cytoplasm (Fromont-Racine et al. 2003).  
Over 350 different proteins with over 200 species of snoRNAs have been 
found in mammalian nucleoli, and over 150 of these proteins seems to be related to 
ribosome biogenesis (Olson and Dundr 2005). Because ribosome assembly is such a 
dynamic process which requires so many factors, it still remains challenging to 
determine how pre-ribosomal particles are assembled and to identify complexes 
which are specific for every maturation step. 
 
 
1.1.2 mTOR and regulation of cell growth 
1.1.2.1 The mTOR complex 
The mammalian target of rapamycin (mTOR) is the mammalian homologue 
of the yeast TOR protein, and is the member of the Ser/Thr PI3K-related kinase 
family. mTOR is a large multi-domain protein (289 kDa). mTOR complex exists as 
two distinct forms: mTORC1 (mTOR complex 1) and mTORC2 (Fig.1.6A). 
mTORC1 consists of the evolutionarily conserved mTOR, Raptor (regulatory 
associated protein of mTOR) (Kim et al. 2002), mLST8 [also known as GβL (Gβ-like 
protein)] (Kim et al. 2003), deptor [for DEP (dishevelled, egl-10, pleckstrin) domain-
containing mTOR interacting protein] (Peterson et al. 2009) and PRAS40 (for Pro-
rich Akt substrate of 40 kDa) (Fonseca et al. 2007; Sancak et al. 2007; Wang et al. 
2007). mTORC1 is known to be a central regulator involving in global protein 
synthesis, cell growth, proliferation and ribosome biogenesis (Schmelzle and Hall 
2000; Hannan et al. 2003; Fingar et al. 2004; Wullschleger et al. 2006).  
On the other hand, mTORC2 comprises mTOR, Rictor (rapamycin-
insensitive companion of mTOR) (Sarbassov et al. 2004), SIN1 (mammalian stress 
activated protein kinase interacting protein 1) (Jacinto et al. 2006), mLST8 and 
Protor (protein observed with Rictor) (Pearce et al. 2007). In both yeast and 
mammals, TORC2 has been shown to be involved in actin cytoskeleton 
reorganization and cell survival (Loewith et al. 2002; Jacinto et al. 2004; Sarbassov 
et al. 2004).  16 
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Figure 1.6: mTOR signalling. A) Composition of mTORC1 and mTORC2.  
mTOR forms two types of multi-protein complex: mTORC1 and mTORC2. Short 
term rapamycin treatment only impairs mTORC1 functions, while long term 
treatment of rapamycin can interferes with mTORC2 activity. B) mTORC1 
signalling. Insulin and growth factors activate the PI3K/PKB signalling pathway. 
PKB phosphorylates TSC2 and inhibits its activity. The GAP domain of TSC2 then 
stops promote hydrolysis of GTP on Rheb, and the activated Rheb· GTP stimulates 
mTORC1 signalling. Growth factors can also activate mTORC1 via ERK and /or 
p90
RSKs signalling. Both ERK and p90
RSKs are able to phosphorylate TSC2, and lead 
to activation of Rheb. 
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Rapamycin was first discovered as an anti-fungal agent isolated from the soil 
bacterium Streptomyces hygroscopicus from Easter Island, and was used clinically as 
an anti-cancer drug (Vezina et al. 1975; Baldo et al. 2008). Rapamycin acts as an 
allosteric inhibitor of mTOR rather than as an ATP-competitive catalytic inhibitor 
(Guertin and Sabatini 2009). Rapamycin suppresses mTOR activity by binding to a 
small immunophilin FKBP12 (FK-506 binding protein of 12kDa). The rapamycin-
FKBP12 complex then specifically binds to the FRB (FKBP12/rapamycin binding) 
domain of mTOR, and inhibits mTOR catalytic activity (Brown et al. 1995). 
Accordingly, rapamycin-FKBP12 complex only interacts with mTORC1 (Fingar and 
Blenis 2004; Jacinto et al. 2004; Sarbassov et al. 2004). mTORC1 is rapidly 
dissociated and inhibited (Oshiro et al. 2004; Yip et al. 2010). However, some 
functions of mTORC1 are insensitive to rapamycin (Fingar and Blenis 2004). Unlike 
mTORC1, mTORC2 is resistant to rapamycin in short-term treatment. Nevertheless, 
due to the binding of rapamycin-FKBP12 to newly synthesized free mTOR to 
prevent mTORC2 formation,  mTORC2 assembly can be inhibited after prolonged 
treatment with rapamycin in certain cell types (Sarbassov et al. 2006). As there is so 
far no specific inhibitor of mTORC2, the understanding of mTORC1 is much more 
advanced than mTORC2. 
Recently, several inhibitors of the kinase activity of mTOR have been 
developed to study the cellular rule of mTOR. One of them, PP242, blocks both 
mTORC1 and mTORC2, and prevents primary cell proliferation (Feldman et al. 
2009). Furthermore, PP242 is a more effective mTORC1 inhibitor than rapamycin, 
as it inhibits cap-dependent translation under conditions in which rapamycin has no 
effect (Feldman et al. 2009). Therefore, PP242 impairs the functions of mTORC2 
and mTORC1, including rapamycin-insensitive functions of mTORC1.  
AZD8055 is another small-molecule mTOR kinase inhibitor which is 
developed by AstraZeneca (Marshall et al. 2011). AZD8055 has greater effects than 
rapamycin on the inhibition of cell proliferation and induction of autophagy in 
cancer cell lines (Marshall et al. 2011). In general, AZD8055 is a more effective 
inhibitor of mTOR than rapamycin. The development of mTOR kinase inhibitors 
provides a valuable tool to investigate the cellular roles of mTOR both in vitro and in 
vivo, but they do not distinguish between mTORC1 and mTORC2. 19 
 
1.1.2.2 Regulation of mTORC1  
  Insulin, growth factors and other signals activate upstream signalling 
components such as PI3K (phosphatidylinositol 3-phosphate kinase)/PKB (protein 
kinase B, also known as Akt) or ERK/P90
RSK that lead to activation of mTORC1 
signalling (Fig.1.6B). Tuberous sclerosis complex 1 and 2 (TSC1 and TSC2), also 
known as hamartin and tuberin respectively, are important upstream regulators of 
mTOR (Manning et al. 2002; McManus and Alessi 2002). In vivo, the tumour 
suppressor protein TSC2 exists in a heterodimeric complex with TSC1, and this 
TSC1/TSC2 complex inhibits downstream signalling events. PKB phosphorylates 
TSC2 on Ser939 and Thr1462, which in turn inactivates TSC2 and disrupts the 
TSC1/TSC2 complex. TSC1/2 targets the small G-protein Rheb (Ras homolog 
enriched in brain) (Manning and Cantley 2003). As a result, the GTPase-activator 
protein (GAP) domain of TSC2 stops hydrolysis of GTP on Rheb, and Rheb· GTP 
activates mTORC1 (Garami et al. 2003). Studies in Drosophila have shown that co-
overexpression of Tsc1 and Tsc2 (Drosophila homolog of TSC1 and TSC2) leads to 
a decrease in cell size, cell number, and organ size, implying that TSC1 and TSC2 
are the negative regulators of cell size (Potter et al. 2001). 
  Growth factors and α1-adrenergic agonists, i.e. phenylephrine (PE) (in heart 
muscle cells) also activate mTORC1 but via the MEK/ERK pathway. ERK1/2 
phosphorylate TSC2 at Ser540 and Ser664 (Ma et al. 2005) and therefore activates 
mTORC1. The suppression of TSC1/TSC2 may also depend on the phosphorylation 
of TSC2 by p90
RSKs at Ser939, Thr1462 and Ser1798 (Roux and Blenis 2004). 
Moreover, both ERK and p90
RSKs phosphorylate Raptor on sites which are reported 
to promote the activation of mTORC1 (Carriere et al. 2008; Carriere et al. 2011).  
The activated mTORC1 then phosphorylates and in turn regulates its 
downstream substrates, i.e. S6K1 and 4E-BP1, as well as other factors, i.e. eEF2.  
 
1.1.2.3 Regulation of mTORC2 
mTORC2 is distinguished from mTORC1 by several features including 
molecular composition and cellular roles. In particular, rapamycin only efficiently 20 
 
inhibits the function of mTORC1 while mTORC2 remains largely insensitive in the 
short term (Loewith et al. 2002; Fingar and Blenis 2004; Sarbassov et al. 2004).  
So far, the mechanism by which mTORC2 is regulated is less clear. Recently, 
it has been shown that mTORC2 can be acutely activated by growth factors and 
nutrients in a PI3K-dependent manner (Gan et al. 2011). Like small G-protein Rheb, 
another small G protein Rhes (Ras homolog enriched in striatum) has been shown to 
bind and activate both mTORC1 and mTORC2 in its GTP bound state 
(Subramaniam et al. 2012). Furthermore, a recent study showed that mTORC2 is 
activated upon association with the ribosomes, and the binding between mTORC2 
and ribosome was enhanced by insulin- induced PI3K signalling (Zinzalla et al. 
2011). Using siRNA (small interfering RNA) to knockdown proteins which are 
involved in ribosome maturation and formation inhibits mTORC2 stimulation, 
indicating that ribosomes directly bind to and activate mTORC2 (Zinzalla et al. 
2011). Finally, TSC1/2 which suppresses mTORC1 associates with mTORC2 and 
plays an essential role in mTORC2 activation (Huang et al. 2008), implying 
mTORC1 and mTORC2 can be regulated differentially by the same upstream 
components.  
Mammalian mTORC2 is required for phosphorylation of protein kinase B 
(PKB, also known as Akt) at Ser473, PKC-α and SGK at all hydrophobic motif (HM) 
and turn motif (TM) sites for proper folding and stabilization nascent polypeptide 
(Sarbassov et al. 2005; Jacinto et al. 2006; Facchinetti et al. 2008; Julien et al. 2010; 
Oh et al. 2010). These results might suggest that mTORC2 links protein production 
with quality control. However, so far, there is very little or no evidence provided that 
mTORC2 involved in regulation of ribosome biogenesis and cell proliferation 
(Facchinetti et al. 2008; Oh et al. 2010). Therefore, this study will focus on the role 
of mTORC1 in regulating rRNA synthesis. 
 
1.1.2.4 mTORC1 downstream targets and cell growth 
The S6 kinases 
  There are two ribosomal protein S6 kinases (S6K1 and S6K2) encoded by 
two distinct genes in mammalian cells (Shima et al. 1998). Both S6Ks are stimulated 21 
 
by insulin and growth factors, and such stimulation is blocked by rapamycin, 
indicating they are downstream targets of mTORC1(Chung et al. 1992). Activation 
of S6Ks is regulated by sequential phosphorylation at multiple sites in a stepwise 
order (Alessi et al. 1997; Pullen et al. 1998; Weng et al. 1998; Magnuson et al. 2012). 
Rapamycin prevents phosphorylation of many sites including those are directly 
phosphorylated by mTOR in vitro (Weng et al. 1998; Wang and Proud 2006). 
Ribosomal protein S6 is a downstream target of both S6K1 and S6K2 (mainly S6K2). 
S6K1 and S6K2 phosphorylate S6 in its C-terminus at multiple sites including 
Ser235, Ser236, Ser240 and Ser244 (Banerjee et al. 1990). S6 can also be 
phosphorylated by p90
RSKs at Ser235/Ser236 in an mTOR-independent manner 
(Pende et al. 2004; Roux et al. 2007). 
  At one time, it was believed that S6Ks were critical for translation of mRNAs 
which contain a terminal oligopyrimidine (TOP) sequence in their 5’UTR (Meyuhas 
2000). The relationship between S6Ks and regulation of 5’-TOP mRNA translation 
has been discussed previously in Section 1.1.1.2. 
S6K signalling has long been known to influence cell size (Montagne et al. 
1999; Thomas 2002; Ruvinsky and Meyuhas 2006). In Drosophila, the size of cells 
from the adult animals lacking the S6K gene is smaller compared to wild-type cells, 
while the cell numbers from two types of animals are reportedly very similar 
(Montagne et al. 1999).  Indeed, deletion of S6Ks results in smaller adult animals, i.e. 
mice, fruit-flies (Shima et al. 1998; Montagne et al. 1999). Furthermore, over-
expression S6K1 resulted in increased cell size (Fingar et al. 2002). Up-regulation of 
5’-TOP mRNA translation will increase ribosomal protein and elongation factor 
synthesis, and this probably favours cell growth.  It is thus possible that S6K controls 
cell size via promoting 5’-TOP mRNA translation. However, the model that S6K up-
regulates 5’-TOP mRNA translation has been largely discredited due to the 
observations that 5’-TOP mRNA translation proceeds normally in S6K-deficient 
animals (Pende et al. 2004; Hamilton et al. 2006). 
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4E-BPs 
  The eIF4E binding proteins (4E-BPs) negatively regulate translation by 
binding to eIF4E and preventing it from binding to eIF4G and other initiation factors 
to form translation initiation complexes (Haghighat et al. 1995). 4E-BPs exist as 
three isoforms: 4E-BP1, 4E-BP2 and 4E-BP3 (Poulin et al. 1998). eIF4E binds to the 
5’-cap structure of mRNA. Upon translation initiation, it recruits other initiation 
factors, i.e. eIF4G, to form translation initiation complexes (Fig.1.8). 4E-BPs binds 
to eIF4E and prevents it binding to other translation initiation factors, therefore, 4E-
BPs block cap-dependent translation (Haghighat et al. 1995). Phosphorylation of 4E-
BPs by mTORC1 prevents 4E-BPs binding to eIF4E, and eIF4E is released and free 
to bind to other initiation factors (Fig.1.8). As a result, the repressed translation by 
4E-BPs is initiated (Mamane et al. 2006). mRNA translation initiation will be 
discussed in detail below in Section 1.1.2.5. 
Expression of a phosphorylation site-defective 4E-BP1 mutant which 
constitutively binds to eIF4E leads to a decrease in cell size (Fingar et al. 2002). 
Recent evidence has shown that 4E-BP1/2 double knockout mice are increased in 
body weight due to, at least in part, an increase in fat accumulation, but without a 
significant increase in cell number (Le Bacquer et al. 2007). It suggests that 4E-BPs 
only regulate cell growth but not cell proliferation. Contradictorily, Dowling and his 
colleagues argue that mTORC1 mediates cell proliferation, but not cell growth 
through the 4E-BPs (Dowling et al. 2010).  
 
 eEF2 Kinases 
eEF2 (eukaryotic translation elongation factor 2), a monomer of about 100 
kDa, facilitates mRNA translation at elongation stage which will be discussed below 
in Section 1.1.2.5. The phosphorylation of eEF2 is catalysed by the specific 
Ca
2+/Calmodulin-dependent enzyme eEF2 kinase (Nairn et al. 1985; Ryazanov et al. 
1988). eEF2K is an unusual protein kinase which is not a member of the main 
Ser/Thr α-kinase superfamily (Ryazanov et al. 1997). eEF2 is the only known 
substrate for eEF2K, and phosphorylation of eEF2 at Thr56 prevents it binding to the 23 
 
ribosomes and therefore, in effect inactivates it and inhibits translation (Browne and 
Proud 2002).   
In Chinese hamster ovary (CHO) cells, dephosphorylation of eEF2 has been 
shown to accelerate translation elongation in response to insulin in a rapamycin-
sensitive manner (Redpath et al. 1996), implying the involvement of mTORC1. 
mTOR phosphorylates eEF2K at several sites (Wang and Proud 2006). S6K1 
(regulated via mTOR) phosphorylates eEF2K at Ser366 and inhibits its activity 
(Wang et al. 2001). This site is also phosphorylated by p90
RSKs which lie 
downstream of the ERK signalling. Regulation of eEF2 by stimuli that activate ERK 
is insensitive to rapamycin, but blocked by inhibitors of MEK/ERK signalling, 
consistent with the involvement of p90
RSK1. Phosphorylation of eEF2K at Ser78 is 
induced by insulin and controlled by mTOR (Browne and Proud 2004). 
Phosphorylation at this site interrupts the binding of calmodulin to eEF2K, and thus 
inhibits its activity. mTORC1 also regulates the phosphorylation at Ser359 (Knebel 
et al. 2001). These data confirm the role of mTORC1 in the control of eEF2 
phosphorylation and of translation elongation.  
 
1.1.2.5 mTOR and mRNA translation 
  The process of mRNA translation is divided into four main stages: initiation, 
elongation, termination and ribosome recycling (Fig.1.7) (Proud 2007). In eukaryotic 
cells, most mRNAs are translated in a cap-dependent manner. The cap structure 
which contains a 7-methylguanosine triphosphate is present at the 5’terminus of all 
cellular eukaryotic mRNAs (Gingras et al. 1999). The role of S6K in controlling 
translation of 5’TOP mRNAs, which encode ribosomal proteins and translational 
components, is discussed above (see Section 1.1.2.3 S6Ks).  
It is often stated that translation initiation is the rate-limiting stage of protein 
synthesis. Initiation requires a set of eukaryotic initiation factors (eIFs). During 
initiation, eIF4E interacts with the large scaffolding protein eIF4G and recruits it to 
the 5’cap structure of mRNA (Fig.1.8). Binding of eIF4E to eIF4G is regulated by 
4E-BP1 as discussed above (see Section1.1.2.4 4E-BPs). With eIF4A (an ATP-
dependent helicase), eIF4E and eIF4G form eIF4F complex. eIF4G also binds to 
PABP [the Poly(A)-bindng protein],  and results in circularizing the mRNA. eIF4G  24 
 
    
 
 
 
 
 
 
 
 
Figure 1.7: The four stages of mRNA translation. Initiation: the 40S ribosomal 
subunit binds to the 5’-cap structure (m
7GTP) of mRNA, and the Met-tRNAi 
attaches to the start codon (AUG). Joining of 60S ribosomal subunit forms the 80S 
ribosome. Elongation: the 80S ribosome moves along the mRNA and recruits 
aminoacyl-tRNAs to produce a polypeptide. Termination: the stop codon 
(UAA,UAG or UAA) is recognized and promotes the dissociation of the ribosomal 
subunits. The newly made polypeptide is released.  
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Figure 1.8: eIF4F formation and translation initiation. 4E-BP1 binds to eIF4E 
and prevents its interaction with eIF4G to form a functional translational initiation 
complex, and thus translation is inhibited. Phosphorylation of 4E-BP1 by mTOR 
promotes dissociation eIF4E from 4E-BP1. Free eIF4E binds the 5’cap structure of 
the mRNA and interacts with the scaffold protein eIF4G and eIF4A to form eIF4F. 
Binding of PABP [poly(A)-binding protein] to eIF4G circularises the mRNA. eIF4G 
then recruits the 40S small ribosomal subunits. The 40S subunit with a set of 
proteins scan along 5’ region to locate the AUG start codon.  
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recruits the 40S small ribosomal subunit to the mRNA through eIF3 which binds to 
the 40S subunit, which can initiate scanning along the 5’ region of the mRNA to 
locate the start codon with the aid of a set of initiation factors (Fig.1.7).  
Eukaryotic translation elongation is controlled by two main elongation 
factors (eEFs): eEF1α and eEF2 (Proud 2004). eEF1α brings the aminoacyl-tRNA to 
the free ribosomal A site, while eEF2 regulates the translocation of mRNA from 
ribosomal A site into P site (Proud 2009). Phosphorylation of eEF2 by eEF2 kinase 
inhibits its activity as discussed above (see Section 1.1.2.4 eEF2).    
Translation termination is triggered when the ribosome encounters the stop 
codon (UGA, UAG or UAA). Recognition of this codon results in the release of 
newly synthesized polypeptide chain and of the ribosomal subunits, which are then 
recycled to participate in initiation again.  
 
 
1.1.2.6 mTORC1 and ribosome biogenesis 
mTORC1 is a key regulator of cell growth (Schmelzle and Hall 2000; Kubica 
and Blenis 2010). In Drosophila, studies have shown that inhibition of dTORC1 by 
rapamycin leads to a reduction in cell size (Montagne et al. 1999). Similar result was 
also observed in mammalian cells that treatment of rapamycin blocks mTORC1 and 
results in much smaller cells (Schmelzle and Hall 2000). However, the exact 
mechanisms by which mTORC1 affects growth-related cellular processes and 
regulates ribosome biogenesis are unclear (Hamilton et al. 2006; Mayer and Grummt 
2006; Jastrzebski et al. 2007). It is possible that mTORC1 signalling up-regulates 
rRNA synthesis or/and increases ribosomal protein synthesis (Fig.1.1) (Hamilton et 
al. 2006; Mayer and Grummt 2006; Kubica and Blenis 2010; Michels 2011).  
mTORC1 and mRNA translation have been discussed above (see Section 1.1.2.5). 
The link bewteen mTORC1 and regulation of all four rRNA synthesis by Pol I and 
Pol III will be discussed here. 
Early studies using mouse ascites nucleoli derived from cells starved for 
amino acids have stated that deprivation of essential amino acids (especially leucine) 
leads to a rapid (Half-maximal inactivation occurring within 30 min) decrease in Pol 
I transcription (Grummt et al. 1976). In addition, removing amino acids from CHO 
cells causes a marked increase in the amount of 4E-BP1 associated with eIF4E and 27 
 
loss of eIF4F complexes, indicating that amino acids (especially leucine) are 
required for activation of translation initiation via modulation of mTORC1 activity 
(Wang et al. 1998; Proud 2002). Together with the observation that rapamycin 
inhibits rDNA transcription; these data imply that rRNA synthesis is regulated by 
mTORC1 (Mahajan 1994).  
In yeast, Tor1 is translocated into the nucleus in response to nutrient supply, 
and is associated with 35S rDNA promoter chromatin to regulate the transcription of 
RP genes and 35S rRNA synthesis (Powers and Walter 1999; Li et al. 2006). In 
mammalian cells, evidence supports the role of mTORC1 in regulating rRNA 
synthesis (Hannan et al. 2003; Kantidakis et al. 2010; Shor et al. 2010; Tsang et al. 
2010).   
In both NIH3T3 cells which undergo cell cycle normally and non-
proliferating cardiac muscle cells, the rapid repression of Pol I transcription by 
rapamycin shows that the mTORC1 signalling pathway is a key regulator of rDNA 
transcription (Hannan et al. 2003). In yeast, rapamycin treatment causes a decrease 
in the amount of Rrn3p (yeast homolog of TIF-IA)-polymerase I complex and 
inhibits rDNA transcription, suggesting the Tor pathway regulates yeast RNA Pol I 
transcription via the transcription initiation factor Rrn3P (Claypool et al. 2004). In 
mammalian cells, rapamycin treatment represses TIF-1A activity by decreasing its 
phosphorylation at Ser44 and promoting its phosphorylation at Ser199, whereas 
phosphorylation of S44 is required for TIF-IA activity and phosphorylation at 
Ser199 inactivates it (Mayer et al. 2004). Furthermore, rapamycin disrupts assembly 
of Pol I transcription initiation complex and leads to the translocation of TIF-1A 
from the nucleolus to the cytoplasm (Mayer et al. 2004). Indeed, these data together 
imply that TOR regulates rDNA transcription via the transcription factor TIF-IA in 
both yeast and mammalian cells.    
Moreover, UBF, another basal factor essential for Pol I transcription,  is also 
regulated by the mTORC1 signalling pathway in a S6K-dependent manner 
(Jastrzebski et al. 2007). Studies have suggested that UBF is regulated by mTOR via 
the activation of S6K1 in NIH3T3 cells (Hannan et al. 2003). Over-expression of a 
dominant-negative S6K1 mutant which dephosphorylates UBF in its C-terminal 
region prevents UBF binding to other transcription initiation factors (e.g. SL1), and 
thus represses Pol I transcription. Moreover, expression of a constitutively-active 28 
 
S6K1 mutant rescued the rapamycin-induced dephosphorylation of UBF and 
inhibition of rDNA transcription (Hannan et al. 2003). Thus, mTOR plays a critical 
role in the regulation of Pol I activity via a mechanism that requires S6K1 activation 
and phosphorylation of UBF. However, it is hard to determine whether S6K1 is 
directly regulating UBF phosphorylation as such work was carried on in nuclear 
extracts (Kubica and Blenis 2010).  
Finally, TIF-IB/SL-1 is also regulated by mTORC1. In HEK293 cells, mTOR 
as well as PI3K and MAPK pathways mediate rRNA synthesis by promoting TIF-
IB/SL-1 binding to the rDNA promoter, therefore enhancing pre-initiation complex 
formation and Pol I transcription (James and Zomerdijk 2004). 
Less is known about the role of TOR signalling in the regulation of Pol III 
transcription, compared to the regulation of Pol I transcription. In yeast, rapamycin 
treatment inhibited transcription initiation by Pol III and led to repression of 5S 
rRNA and tRNA synthesis, demonstrating that Tor signalling controls transcription 
by Pol III (Zaragoza et al. 1998). It is not entirely clear how mTORC1 regulates Pol 
III catalysed transcription in mammalian cells. Recent data have shown that mTOR 
directly interacts with TFIIIC, the transcription factor that binds to Pol III promoters, 
to accelerate tRNA and 5S rRNA production (Kantidakis et al. 2010). Further 
experiments confirm that mTORC1 directly phosphorylates MAF1 at Ser75, a key 
repressor of Pol III transcription, and relieves the repression of Pol III transcription 
caused by MAF1 (Goodfellow et al. 2008; Kantidakis et al. 2010; Michels et al. 
2010). The data suggest that mTOR directly interacts with TFIIIC and MAF1 in 
nuclei and regulates Pol III transcription. However, the exact mechanism is still not 
very clear. 
Taken together, mTORC1 pathway is tightly linked with cell growth by 
regulating protein synthesis (Schmelzle and Hall 2000; Proud 2004; Kubica and 
Blenis 2010). Importantly, to increase translation capacity, mTORC1 also regulates 
ribosome biogenesis including all four rRNAs (18S, 28S, 5.8S and 5S) and RP 
synthesis to balance nutrient availability and energy consumption (Fig. 1.9) (Mayer 
and Grummt 2006; Reiter et al. 2011). 
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Figure 1.9: mTORC1 and rRNA synthesis in mammalian cells. In mammalian 
cells, the mTOR complex 1 signalling pathway controls cell growth in a rapamycin-
sensitive manner. Protein synthesis requires new ribosomal components. rRNA 
synthesis by Pol I is regulated by mTORC1. Evidence also shows that mTORC1 
regulates Pol III catalysed rRNA synthesis. Nevertheless, the exact mechanisms 
remain unclear.  
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1.2 Cardiomyocytes and regulation of cardiac hypertrophy 
1.2.1 Overview of cardiomyocytes and cardiac hypertrophy 
The heart is composed of approximately 30% cardiomyocytes and about 70% 
cardiac fibroblasts (Zak 1974). Cardiomyocytes are considered as terminally 
differentiated, non-dividing cells. Specifically, they do not enter S phase even when 
stimulated by
 growth factors. Other types of cells, i.e. fibroblasts, endothelial cells 
and smooth muscle cells, in the heart retain their mitotic ability. These cells were 
thought to be permanent withdrawal
 from the cell cycle, however, a recent paper 
suggests otherwise. It shows that the genesis of cardiomyocytes does occur at a low 
rate by the division of pre-existing cardiomyocytes during normal ageing, and its rate 
increases after myocardial injury (Senyo et al. 2013).  
Cardiac hypertrophy (CH) is a condition in which the increase of volume of 
heart muscle is due to the enlargement of cardiomyocytes. In heart muscle cells, in 
response to high demand, adaptive hypertrophic growth involves increases in protein 
content, greater cell size, altered myofibrillar organization, and changes in gene 
expression (McDermott et al. 1989; Hannan et al. 1995; Hannan and Rothblum 1995; 
Proud 2004). The initial adaptive response can lead to heart failure if the hypertrophy 
is sustained (Clerk and Sugden 1999; Wang and Proud 2002; Kacimi and Gerdes 
2003). Sustained increases in the rates of protein synthesis are required during 
cardiac hypertrophy (Morgan et al. 1987). The overgrowth of heart muscle cells is a 
key feature of hypertrophy. Enlargement of cells in the longer term requires faster 
protein synthesis which is dependent on an increase of ribosomal capacity. Indeed, 
increased translational efficiency of existing ribosomes alone is insufficient to 
account for the hypertrophic growth of cardiomyocytes and synthesis of new 
functional ribosomes must occur (Morgan et al. 1985; Morgan et al. 1987; 
McDermott et al. 1989; Brandenburger et al. 2001).  
Therefore, synthesis of new ribosomes is probably a pre-requisite for the 
hypertrophic agonists mediated hypertrophic growth of cardiomyocytes. Thus, it is 
important to determine the link between control of ribosome biogenesis and CH.  
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1.2.2 Cardiac hypertrophy 
  One of the difficulties in studying cardiac hypertrophy is that there are no 
well-established continuous cell lines can be used. Cardiomyocytes isolated from the 
ventricles of adult animals, especially rats, have been widely used to investigate 
protein turnover and intracellular signalling. However, it is often difficult to obtain 
good yield of adult cardiomyocytes from heart perfusion and to maintain adult 
cardiomyocytes in cell culture for more than a short time. Nevertheless, adult 
cardiomyocytes are the most physiologically relevant cell type to use for studying 
the regulation of heart cell growth on CH. The majority of studies have utilized 
primary cultures of neonatal rat ventricular myocytes to address the regulation of 
hypertrophic growth, as they are easier to isolate and can be maintained in culture for 
longer time. As little cell division occurs in neonatal cardiomyocytes, the growth is 
primarily due to increased cell volume/mass.  
  In the short term, in response to work overload or increased pressure, the 
heart muscle cells undergo hypertrophic growth to adapt the high demand (Morgan 
and Baker 1991). In the longer term, this beneficial hypertrophic growth may cause 
maladaptive decompensated hypertrophy and lead to heart failure (Sugden and Clerk 
1998). To distinguish hypertrophic growth from normal growth, there are changes in 
pattern of gene expression and increased rRNA synthesis. 
 Studies from both in vivo and in vitro model systems have provided an 
overall picture of cardiac gene regulation during hypertrophic growth.  It has been 
suggested that the activation of immediate early gene expression is one of the first 
changes (Chien et al. 1991). Upon exposure to hypertrophic stimulation, immediate 
early genes that encode transcription factors, including c-jun and c-fos, are rapidly 
induced (Iwaki et al. 1990). In the longer term, hypertrophy involves induction of 
foetal isoforms of various genes including atrial natriuretic factor (ANF), B-type 
natriuretic peptide (BNP), skeletal muscle α-actin and β-myosin heavy chain (β-
MHC) (Calderone et al. 1995). These changes in gene expression are useful in 
experiments as indicators of hypertrophy.  
In addition to transcriptional regulation, increased accumulation of protein 
must be achieved. Besides the rapid changes in gene expression, hypertrophic stimuli 
increase the overall protein synthesis (Sugden and Fuller 1991; Hannan et al. 2003). 32 
 
Importantly, in the longer term, increased rRNA and ribosome biogenesis play a key 
role in cardiomyocyte hypertrophy (Morgan et al. 1985; Chua et al. 1987; 
McDermott et al. 1989; Hannan et al. 1995). Indeed, increased synthesis of 
ribosomes must occur to drive hypertrophic growth (Morgan et al. 1987; Hannan and 
Rothblum 1995). However, the mechanisms underlying the regulation of rRNA 
synthesis in cardiac growth are poorly understood. The main aim of this study is to 
investigate the links between the signalling events and the regulation of rRNA 
synthesis in cultured adult cardiomyocytes. 
 
1.2.3 Regulation of cardiac growth 
1.2.3.1 G protein- coupled receptor (GPCR) signalling in 
cardiomyocytes 
  A hypertrophic agonist is defined as a stimulus which can increase myocytes 
hypertrophy by increasing protein synthesis and induce a pattern of gene expression. 
Endothelin-1 (ET-1) and α1-adrenergic agonists, i.e. phenylephrine (PE), are the 
prime hypertrophic agents identified (Sugden and Clerk 1998). ET-1 and α1-
adrenergic agonists act through G protein coupled receptors (GPCRs) in the heart 
(Fedida et al. 1993; Sugden and Bogoyevitch 1996).  
  Heptahelical transmembrane G protein coupled receptors transduce 
stimulatory signals. All G proteins consist of an α subunit (Gα) and βγ dimers (Gβγ). 
Binding of agonists such as ET-1 and PE catalyses GDP to GTP exchange on the α 
subunit and then dissociates α subunit from βγ dimers. Three examples of functional 
classes of GPCRs which couple with three different signalling components in 
cardiovascular system are (Fig.1.10): 1) Gαs which couples to β-adrenergic receptors 
(β-AR); 2) Gαi which couples to the cholinergic receptors; and 3) Gαq which 
couples to α-adrenergic receptors (α-AR) and endothelin (ET) receptors (Koch et al. 
2000). After the dissociation of Gα from Gβγ, these two subunits then mediate the 
downstream signalling events (Fig.1.10). The Gαs· GTP subunit activates adenylyl 
cyclase (AC) which further catalyses the formation of cAMP (Xiao 2001), while 
both Gαi· GTP subunit and Gαq· GTP subunits can stimulate phospholipase Cβ 
(PLCβ) (Simon et al. 1991). On the other hand, Gβγ subunits stimulate PLCβ and  33 
 
 
 
 
 
Figure 1.10: G protein- coupled receptor (GPCR) signalling pathways. Binding 
of receptor to G proteins causes exchange of GTP for GDP on the α- subunit and 
dissociation of Gα·GTP subunit from Gβγ, and thus stimulate the downstream 
signalling events. ET, endothelin receptors; AT, angiotensin receptors; AR, 
adrenergic receptors; MusAcR, muscarinic acetylcholine receptors; PLCβ, 
phospholipase Cβ; AC, adenylyl cyclase; IP3, inositol 3-phosphate; DG, 
diacylglycerol.  
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enhance MAP kinase and Ras signalling in the heart (Crespo et al. 1994; Pumiglia et 
al. 1995). 
  The activation of PLCβ then stimulate the hydrolysis of phosphatidylinositol 
4,5- bisphosphate [PIP2]  to diacylglycerol (DG) and inositol 1,4,5- trisphosphate 
(IP3) (Exton 1996). DG plays a key role in hypertrophic responses by activating PKC, 
whereas IP3 appears to play a role in regulating intracellular Ca
2+ movement 
(Berridge 1993; Nishizuka 1995).  
 
1.2.3.2 Ras signalling in cardiac growth 
  Ras belongs to the small G protein family which regulates a wide variety of 
cellular processes. In its inactive state, Ras is bound to GDP and is converted to its 
active GTP-liganded state by guanine nucleotide exchange factors (GEFs) such as 
Sos (Fig.1.11A). Hydrolysis of the bound GTP to GDP which is facilitated by 
GTPase-activating proteins (GAPs) converts Ras to its inactive state. The 
mechanisms by which GPCR agonists activate Ras are not fully understood. 
Ras· GTP (the active form of Ras) activates several proteins including Raf (which 
phosphorylates and activates MEK1/2, which in turn phosphorylates and activates 
Erk1/2), PI3K and the Ral GDP-dissociation stimulator (Ral· GDS) (Fig.1.1B). 
  The Gq/G11 linked agonists angiotensin II (Ang II), endothelin-1 (ET-1) and 
phenylephrine (PE) rapidly activate Ras (the proportion of Ras· GTP increases) in 
cardiomyocytes (Chiloeches et al. 1999). Each of these agonists elicits hypertrophic 
responses (Molkentin and Dorn 2001). These agonists stimulate PKC through GPCR 
and PLC (Sugden and Clerk 1998). Stimulation of Ras by Ang II, ET-1 and PE 
increases Ras· GTP levels and this is reduced by inhibiton of PKC (Chiloeches et al. 
1999). Such observations suggest that the activation of Ras by GqPCR is PKC-
dependent. It is not entirely clear how GqPCR mediates the activation of Ras. It is 
likely that the signalling from Gβγ subunits through tyrosine kinases is also involved 
in the activation of Ras (Sugden and Clerk 2000). 
  The importance of Ras signalling in cardiac hypertrophy has been studied 
both in vitro and in vivo. Transfection or microinjection of an activated GTPase-  35 
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Figure 1.11: Ras signalling pathway in cardiomyocytes. A) After stimulation, 
inactive Ras is converted to its active GTP-liganded state by GEFs such as Sos. The 
GTPase activity of Ras hydrolyzes the bound GTP and converts Ras to an inactive 
state. B) Ras is activated through GPCRs. Activated Ras· GTP activates several 
effector proteins including Raf which lies upstream of the Erk cascade and the Ral 
GDP- dissociation stimulator (Ral· GDS). 36 
 
deficient Ras mutant (V12Ras) into cultured cardiomyocytes increased both cell size 
and ANF (one of immediate early genes responding to hypertrophic stimuli) 
expression (Thorburn 1994; Thorburn et al. 1994). Transgenic mice that over-
express V12Ras in mouse heart show cardiac hypertrophy and diastolic dysfunction 
(Hunter et al. 1995). These data show that over-expression of active Ras may cause 
changes in gene expression and promote hypertrophic responses. Furthermore, Ras 
has also been shown to play a role in the activation of protein synthesis by PE. In 
cultured adult rat cardiomyocytes, inhibition of Ras signalling using a recombinant 
adenovirus expressing the dominant-negative Ras mutant (N17Ras) prohibited the 
PE- induced protein and mRNA production (Abdellatif et al. 1998). Also, using the 
dominant-negative mutant N17Ras or farnesyl transferase (FT Inh III), the widely 
used Ras inhibitor, PE-induced protein synthesis was inhibited in ARVC (Wang and 
Proud 2002). Taken together, the data indicate that Ras activation is associated with 
cardiac hypertrophy. 
 
1.2.3.3 ERK signalling in cardiac hypertrophy 
  The ERK cascade is the best characterized of the MAPK pathways (Robinson 
and Cobb 1997). MAPK pathways are evolutionarily conserved and are essential 
signalling pathways involved in the regulation of cell proliferation, growth and 
differentiation (Seger and Krebs 1995). This set of serine/threonine protein kinases 
involves a module of three protein kinases, Raf, mitogen-activated protein kinase 
kinase (MEK) and extracellular signal-regulated kinase (ERK) (Roux and Blenis 
2004). ERK exists in two isoforms in mammalian cells, ERK1 and ERK2, also 
known as p44 and p42 MAP kinase. In the heart, all three levels of the ERK cascade 
kinases are strongly activated by Gq/G11 protein coupled receptor agonists (Sugden 
and Clerk 1998). Ras· GTP, the active form of Ras, binds to and activates Raf, which 
in turn phosphorylates and activates MEK1/2, leading to ERK1/2 phosphorylation 
and activation (Fig.1.11B). Once activated, ERK1/2 phosphorylate its downstream 
effectors including the 90 kDa ribosomal S6 kinases (p90
RSKs). 
  An inhibitor of MEK, PD184352 (also called CI-1040), has been widely used 
to target inhibit the MEK-ERK pathway (Allen et al. 2003). The principal effect of 
PD184352 is to inhibit activation of MEK1 (in particular) and MEK1 by Raf and 37 
 
thus inhibit activation of ERKs by agonists. This compound suppressed cell 
proliferation and potently induced apoptosis in malignant schwannoma cell lines 
(Mattingly et al. 2006). However, previous studies have shown that PD184352 
causes phosphorylation and activation of AMP-activated protein kinase (AMPK) in 
HEK293 cells (Dokladda et al. 2005; Moore et al. 2009). AMPK negatively 
regulates mTORC1 and Pol I rRNA synthesis under glucose restriction (Hoppe et al. 
2009). 
More recently, another compound, AZD6244, has become commercially 
available. AZD6244 (Selumetinib, ARRY-142886) is an ATP non-competitive 
MEK1/2 inhibitor. In primary hepatocellular carcinoma cells, AZD6244 inhibits the 
growth of primary HCC cells through inhibition of ERK1/2 and p90RSK 
phosphorylation, while it has little effects on the p38, c-Jun-NH2-kinase, 
phosphatidylinositol 3-kinase, or MEK5/ERK5 pathways (Huynh et al. 2007). 
Moreover, AZD6244 does not activate AMPK, thus, it is a more suitable compound 
to use in this study. These compounds are useful in studying the role of the ERK 
signalling in hypertrophic growth. 
ERK signalling was first shown to be involved in the hypertrophic response 
as hypertrophic agonists (PMA, ET-1 and norepinephrine) stimulate ERKs in 
cultured cardiomyocytes (Bogoyevitch et al. 1994; Lazou et al. 1998). Transfection 
of cells with constitutively-active MEK enhanced ANF expression by PE, while a 
dominant-negative MEK mutant inhibited ANF transcription (Gillespie-Brown et al. 
1995). Depletion of ERK1 and ERK2 using antisense oligonucleotides weakened the 
stimulation of the hypertrophic gene expression by PE in cultured myocytes 
(Glennon et al. 1996). Furthermore, in cultured adult rat cardiomyocytes, stimulation 
of GqPCR by PE caused the phosphorylation of eIF4E-binding protein 1 (4E-BP1), 
leading to its dissociation from eIF4E and allowing the formation of eIF4F 
complexes, and thus protein synthesis was enhanced (Wang and Proud 2002; Proud 
2004; Wang et al. 2008).  The treatment with PD184352, a specific inhibitor of 
MEK/ERK signalling pathway, blocked such effect of PE on 4E-BP1 and prevented 
PE-induced protein synthesis (Wang and Proud 2002).  A major end-point of this 
study was that ERK signalling is required to activate protein synthesis by PE in adult 
rat cardiomyocytes, and the data agree with Xiao et al.’s observation that the 
MEK/ERK pathway mediates α1-adrenergic agonists stimulates hypertrophic effects 38 
 
(increased protein synthesis) (Xiao et al. 2001). The studies demonstrate that 
MEK/ERK pathway is critical for activation of protein synthesis by PE through 
mTORC1 (Wang et al. 2001; Wang et al. 2003; Huang et al. 2009). Taken together, 
these data support the hypothesis that ERK signalling plays a critical role in the 
development of cardiac hypertrophy.  
However, whether the ERK pathway regulates cardiac hypertrophy is still an 
area of ongoing debate (Molkentin and Dorn 2001). A study has provided the 
contradictory data that transfection of constitutively activated MEK inhibits the 
stimulation of ANF expression by PE (Thorburn et al. 1995). Another one even 
suggests that activation of ERK is required for the anti-hypertrophic action of ANF 
(Silberbach et al. 1999). The discrepancies between data for the role of ERK 
signalling in hypertrophic responses may be caused by using different techniques or 
adult vs. neonatal cardiomyocytes in the studies. Most studies using neonatal 
cardiomyocytes, however, show that there are indeed different signalling 
connections between adult and neonatal myocytes. For example, many studies have 
reported strong activation of the JNKs by many hypertrophic stimuli in neonatal 
cells (Frey and Olson 2003), nevertheless, no JNK activation by PE or ET-1 can be 
observed in adult rat cardiomyocytes (Wang et al. 2001). 
More recent studies have used transgenic mice to address this issue. 
Expression of an activated form of MEK1 in the mouse heart stimulates ERK1/2 
specifically and induces a physiologic hypertrophic response (Bueno et al. 2000). 
This study using transgenic mice supports the role of ERK signalling as a 
hypertrophic mediator in vivo. The overall conclusion from these data is that the 
ERK signalling participates in hypertrophy; however, other pathways may also be 
involved. 
 
1.2.3.4 p90
RSK signalling in cardiac hypertrophy 
The p90 ribosomal S6 kinases (p90
RSKs) are Ser/Thr kinases and are activated 
by hypertrophic agonists in myocytes (Sadoshima et al. 1995; Zhao et al. 1996; 
Wang and Proud 2002). In mammalian cells, p90
RSKs have been shown to play 
important roles in regulating cell survival, growth and proliferation  39 
 
A) 
 
B) 
 
Figure 1.12: p90
RSKs signalling in cardiomyocytes. A) Schematic diagram of 
p90
RSKs structure. 90 kDa ribosomal S6 kinases (p90
RSKs) contain two functional 
domains, the N-terminal kinase domain (NTKD) and the C-terminal kinase domain 
(CTKD). The end of C-terminal of p90
RSKs contains an ERK1/2 docking domain and 
ERK activates p90
RSKs by phosphorylating at Thr573 in the CTKD. The structure is 
highly conserved in all four p90
RSKs isoforms. B) Ras is activated through GPCRs 
and the binding of Ras· GTP to Raf brings them to the plasma memberane to be 
activated. Subsequently, MEK1/2 is activated and then activated MEK1/2 
phosphorylate ERK1/2. p90
RSKs are directly phosphorylated and activated by 
ERK1/2. A fraction of activated p90
RSKs translocate to the nucleus, and can 
phosphorylate substrates eg. GATA4, TIF1A. 40 
 
(Cuello et al. 2011). The p90
RSKs family has four isoforms, and all four isoforms are 
characterized by the presence of two functional kinase domains, an N-terminal 
kinase domain (NTKD) and a C- terminal kinase domain (CTKD) (Fig 1.12A) 
(Anjum and Blenis 2008). Unlike p90
RSK1 which is strongly expressed in kidney and 
pancreas, p90
RSK2 and p90
RSK3 are highly expressed in heart muscle (Li et al. 2012).  
In un-stimulated cells, p90
RSKs are generally localised in the cytoplasm. In 
response to growth factors and other stimuli, ERK1/2 dock at the ERK-docking 
motif and phosphorylates all four p90
RSKs at Ser573 in the CTKD and at Ser363 
(Fig.1.12A) (Dalby et al. 1998). The activated CTKD of p90
RSKs then 
autophosphorylates at Ser380 to create a docking site for 3’-phosphoinositide-
dependent kinase-1 (PDK1) (Roux et al. 2003). After binding, PDK1 phosphorylates 
at Ser221 in the NTKD, leading the activation of p90
RSKs and substrates 
subsequently. ERK activates p90
RSKs at the plasma membrane and a fraction of the 
activated p90
RSKs translocates into the nucleus (Roux et al. 2003). The activated 
p90
RSKs accumulate in the nucleus and phosphorylate nuclear- localised 
transcriptional factors (e.g. CREB, NFγB), therefore directly influence specific genes 
expression (Chen et al. 1992; Markou et al. 2009).  
SL0101 is the first identified selective inhibitor of p90
RSKs, and it inhibits 
p90
RSKs activity by binding to its N-terminal kinase domain (Smith et al. 2005). BI-
D1870 is a more recently developed specific inhibitor of p90
RSKs. This small cell-
permeant molecule acts on the N-terminal kinase domain and inhibits all four 
isoforms of p90
RSKs (Fig.1.12A), while it does not significantly block 10 other AGC 
kinases and over 40 other protein kinases at 100X concentrations (Sapkota et al. 
2007). As this potent selective p90
RSKs inhibitor, BI-D1870, has become 
commercially available, researchers have used this compound to study the 
physiological roles of p90
RSKs in cardiac hypertrophy. One thing to note is that the 
treatment of BI-D1870 has been reported to activate ERK1/2 (Sapkota et al. 2007; 
Fonseca et al. 2011). This effect could be due to an inhibitory feedback loop 
involving p90
RSKs which normally limits ERK activation. 
In cardiomyocytes, several studies have focused on the role of p90
RSKs in the 
phosphorylation of Na+/H+ exchanger 1 (NHE1) in the plasma membrane and in the 
regulation of cardiac myofilament phosphorylation (Moor and Fliegel 1999; Cuello 41 
 
et al. 2011). Nevertheless, the importance of p90
RSKs in regulating cardiomyocytes 
hypertrophy in response to Gq protein- coupled receptor stimuli is unclear 
(Fig.1.12B). Recently,  a study has shown that p90
RSK2  activates GATA4, a DNA-
binding transcription factor, through phosphorylation at Ser261, in neonatal rat 
myocytes in response to PE (Li et al. 2012). As GATA4 mediates cardiac-specific 
gene (i.e. ANF, BNP) expression, inhibition of p90
RSKs using SL0101 abolished 
GATA4 phosphorylation and repressed PE-induced ANF and BNP expression (Li et 
al. 2012).  This is consistent with another study which points out that among 213 
mRNAs upregulated in response to Gq protein-coupled receptor agonists, ET-1 and 
α1-adrenergic receptor agonists, 51% required p90
RSKs (Amirak et al. 2012). These 
data indicate that p90
RSKs play a significant role in regulating cardiomyocyte gene 
expression in response to hypertrophic stimuli. Moreover, in neonatal 
cardiomyocytes, BI-D1870, a potent p90
RSKs inhibitor, inhibited ET-1-induced 
surface area increasing (Amirak et al. 2012). These data agree with the observations 
that depletion of p90
RSK3 expression using siRNA reduced PE-induced cell growth 
by 34% and inhibited ANF expression completely in cultured neonatal cells (Li et al. 
2012). Furthermore, RSK3
-/- mice attenuated the concentric myocyte hypertrophy 
induced by pressure overload (Li et al. 2012). Thus, p90
RSKs are required for cardiac 
hypertrophy. Nevertheless, the downstream signalling events mediating this function 
are less defined. 
 
1.2.3.5 mTOR signalling in cardiac hypertrophy 
Phenylephrine (PE), an α1-adrenergic agonist that acts through Gq-protein-
coupled receptors (GPCR), activates multiple signalling pathway and induce protein 
synthesis in a mTOR-dependent manner (Wang et al. 2001; Wang and Proud 2002; 
Wang and Proud 2002; Kacimi and Gerdes 2003; Xiang and Kobilka 2003). 
Inhibiting mTORC1 by using rapamycin can prevent or reverse hypertrophy induced 
by PE (Shioi et al. 2003; McMullen et al. 2004). It suggests that mTORC1 is a key 
regulator in the overgrowth of heart muscle cells. 
S6Ks, the downstream targets of mTORC1, have been show to play a role in 
controlling cell size and regulating 5’-TOP mRNAs translation. In the hearts of mice, 42 
 
it has shown that S6 phosphorylation is significantly elevated in response to pressure 
overload in a rapamycin-sensitive manner (McMullen et al. 2004). This observation 
implies that activation of the S6Ks may play a positive role in controlling heart 
growth in hypertrophic response. Nevertheless, the same group showed that deletion 
of both S6K1 and SK2 did not prevent the development of cardiac hypertrophy in 
mice (McMullen et al. 2004). Although over-expression of S6K1 did induce a mild 
degree of hypertrophy, S6Ks alone are not sufficient for the development of cardiac 
hypertrophy.    
The other potential regulators of CH are the 4E-BPs which are also down-
stream of mTORC1. In heart cells, in response to PE and ET-1 which stimulate 
mTOR signalling, 4E-BP1 is phosphorylated and dissociated from eIF4E (Wang and 
Proud 2002).  In adult cardiomyocytes, such effects of PE and ET-1 on 4E-BP1 are 
inhibited by rapamycin as well as by PD184352 which inhibits MEK1/2, but not by 
wortmannin which inhibits PI3K (Wang and Proud 2002). This study indicates the 
connection between the MEK/ERK pathway and the regulation of mTOR in 
response to hypertrophic stimuli. Also, these data suggest that inhibition of PE-
induced protein synthesis by rapamycin may partially be mediated through the 
dephosphorylation of 4E-BP1.   
  In cardiomyocytes, PE, ET-1 and other agents cause dephosphorylation and 
activate eEF2 (Wang et al. 2000; Wang and Proud 2002). Such effects accelerate 
translation elongation and favour protein synthesis (including ribosomal protein 
synthesis). Evidence has been presented that there exists a specific form of eEF2K 
which does not acquire Ca
2+/Calmodulin-independent activity in response to the 
increased levels of cAMP in adult rat ventricular cardiomyocytes (McLeod et al. 
2001). PE and ET-1 lead to inactivation of eEF2K, and this effect requires signalling 
via mTORC1 and MEK (Wang and Proud 2002). Furthermore, S6K1 and p90
RSKs 
can phosphorylate eEF2K at Ser365 which is an mTOR-regulated phosphorylation 
site (Wang et al. 2001). These observations suggest that there is a connection 
between MEK/ERK/p90
RSKs signalling and mTOR in controlling translation 
elongation (and protein synthesis) in cardiomyocytes. 
  In this study, the role of mTORC1 in controlling hypertrophic stimuli (PE) 
induced rRNA synthesis in adult rat cardiomyocytes will be addressed. 43 
 
 
Figure 1.13: Control of the steady-state level of rRNA. The steady-state levels of 
rRNA depend both on the rate of transcription and the rate of RNA degradation. 45S 
pre-rRNA is transcribed in the nucleus by Pol I and is then modified and assembled 
with rRNA and ribosomal proteins to form ribosomal sub-units. At the same time, 
some of the newly synthesized 45S pre-rRNA may also be undergoing degradation 
in the nucleus 
.  
 
 
 
 
  
Figure 1.14: The pyrimidine salvage pathway of 4-SU labelling. 
4-thiouridine is directly added to the cells’ medium, and the compound is then 
incorporated into newly synthesized RNAs via the pyrimidine salvage pathway 
which converts it into 4-thioUTP. 
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1.3 4-Thiouridine labelling method 
To explore the effects of mTOR signalling and other signalling events on the 
synthesis of rRNAs, the rates of synthesis of rRNAs were measured. Currently, the 
main methods used to measure RNA synthesis involve using radio-labelled 
precursors such as [
14C] orotic acid. In addition to the dangers of using radioisotopes, 
this method is not very sensitive, and most importantly, it is hard, if not impossible, 
to distinguish between different RNAs using this method. Also, rRNAs are the most 
abundant RNA in cells, especially 18S rRNA. Therefore, changes which are 
proportional small comparing to total rRNAs might be unable to detect. Moreover, 
the changes in steady-state rRNA levels may be due to alterations in transcription 
rates and/or RNA stability rates (Fig.1.13).  
To overcome these limitations and to begin to understand this in more detail, 
a new non-radioactive chemical method was developed to specifically pulse-label 
rRNAs to monitor only newly synthesized rRNA level in vivo. This method takes 
advantage of the fact that 4-thiouridine (4-SU) can be incorporated into newly 
synthesized RNAs in cells in culture via the pyrimidine salvage pathway 
(Pfefferkorn and Pfefferkorn 1977; Cleary et al. 2005). 4-SU is directly added to the 
medium, and the compound enters nucleotide metabolism as 4-thioUTP (Fig. 1.14). 
After certain labelling times, total RNA is extracted. To determine the incorporation 
of thio-substituted uridine into nucleic acids, total extracted RNA is incubated with 
EZ-Link Biotin-HPDP (PIERCE) which reacts specifically with the thiol group. 
Accordingly, only newly synthesized RNA containing 4-thiouridine will be 
biotinylated by Biotin-HPDP. The biotinylated 4-SU labelled RNA can then be 
isolated from total RNA by using streptavidin-magnetic beads. The method purifies 
only newly-synthesized labelled RNA and therefore can be used to measure the level 
of any RNA (e.g., here 18S rRNA) using real-time (RT)-PCR after reverse 
transcription (Fig. 1.15).  
This new approach has several important advantages over earlier radioactive 
labelling methods. Besides avoiding the use of radioactivity, it easily quantifies 
specific any RNA components by using appropriate qPCR primers.  
 
 45 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: The experimental approach of 4-SU labelling of rRNA in mammalian    
cells. 4-thiouridine is directly added into the cells’ media and total RNAs are extracted 
after a suitable period of incubation. Newly-synthesized RNAs can be isolated from total 
RNAs and can be quantified using quantitative Real-Time PCR after reverse 
transcription.  
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1.4 Aims of the study 
This project concerns the control of the biogenesis of ribosomes in 
mammalian cells and focus on investigating the signalling events controlling the 
cellular rRNA synthesis in cardiomyocytes, especially the signalling events related 
to cardiac hypertrophy (CH).  
In this study, a novel labelling technique will be developed to monitor new 
rRNA synthesis in HeLa cells. This 4-SU labelling method will then be applied to 
study the synthesis and the decay of rRNA in primary adult rat ventricular 
cardiomyocytes.  
This study will concentrate on the regulation of the synthesis of rRNA, in 
particular, (i) the regulation of 18S and 5S rRNAs by hypertrophic agents; (ii) the 
role of mTORC1 and other signalling pathways in this and (iii) the specific 
signalling components involved in this.  
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2.1 Chemicals and reagents 
 
All chemicals for cardiomyocyte isolation were purchased from BDH-Merck 
(Poole, UK) or Sigma-Aldrich unless otherwise stated. Bovine serum albumin (BSA, 
fraction V) was from Boehringer Mannheim and Collagenase (type II) was from 
Worthington Biochemical, New Jersey. Nylon monofilament filter cloth (200 μM) 
was from Cadish Precision Meshes. Dialysis tubing of size 5 (MWCO: 12-14000 Da) 
was purchased from Medicell International. One ml pastettes were from Alpha 
Laboratories. Vacuum filter unit Stericup sterile PES membrane of 0.22 μm pore size 
was from Millipore. 
All chemicals and biochemicals for RNA isolation and chromatin 
immunoprecipitation assay were obtained from Sigma-Aldrich unless otherwise 
stated. pcDNA3.1-HA-S6K*1 vector was made by previous lab member Dr. Ann 
Burchell. pcDNA5FRT-BOP1 FL and pcDNA5FRT-BOP1Δ vectors were made by 
current lab member Dr. Rui Liu. Tissue culture reagents were provided by Invitrogen. 
Trizol was from Invitrogen and EZ-Link Biotin-HPDP was from Pierce. Magnetic 
Porous Glass (MPG) Streptavidin beads were purchased from PUREBiotech. 
Actinomycin-D, PP242 and rapamycin were supplied by Calbiochem. PD184352 
was from Toronto Research Chemicals, and AZD6244 was from Selleck Chemicals. 
BI-D1870 was obtained from the Division of Signal Transduction Therapy, College 
of Life Sciences, University of Dundee (UK). A769662 and SL0101 are from 
TOCRIS bioscience. L-[
35S]-methionine and [
3H]-uridine were purchased from 
PerkinElmer. Econofluor scintillation liquid was from Packard Instruments. Real 
Time-PCR primers and 2x SYGR qPCR mastermix were purchased from 
PrimerDesign. Bradford reagent was from Bio-Rad Laboratories. 3MM filter paper 
was from Whatman International. Nitrocellulose transfer membrane of 0.45μm pore 
size was from Bio-Rad.
13C6,
15N4 arginine-10 and 
13C6,
15N4 lysine-8 were purchased 
from Silantes GmbH. 
 
 
2.2 Adult rat ventricular cardiomyocytes (ARVC) 
2.2.1  Isolation  of  left  ventricular  cardiomyocytes  from  adult 
Sprague-Dawley rats 50 
 
Adult male Sprague-Dawley rats (250-300g, Biomedical Research Facility, 
University  of  Southampton)  were  used  as  the  resource  for  retrograde  perfusion. 
Adult  rat  ventricular  cardiomyocytes  (ARVC)  were  isolated  using  Langendorff 
perfusion system (Wang and Proud 2002). Figure 2.1 shows a schematic picture of 
the perfusion apparatus I use to isolate the heart cells. Collagenase was perfused 
through the aorta and coronary arteries of the heart. Consider the highly sensitive 
feature  of  the  cardiomyocytes,  the  quality  of  the  isolation  procedure  which 
minimizes stress and diminishes damage to the heart cells is essential for successful 
cell culture and directly determines the survival rate of cardiomyocytes in culture. 
Experiment reproducibility is also highly dependent on the quality of the isolation. 
Therefore, the successful cardiomyocytes isolation is the primary and crucial step of 
the project. 
All reagents used for ARVC isolation were from the highest grade and all 
solutions were prepared with Milli-Q Ultrapure H2O. The basic solution, the stock of 
Ca
2+-free buffer, is used to make up the five main solutions during the isolation (see 
Table 2.1). Given the delicate nature of the cardiomyocytes, it is important to note 
that the pH of the stock buffer must be adjusted to about 7.30 to 7.40 prior to use. 
 
TABLE 2.1: The stock of Ca
2+-free buffer 
Chemical  Conc.[mM]  1L 
NaCl  130  7.9g 
HEPES  5  1.19g 
D-Glucose  10  1.8g 
KCl  5.4  0.336g 
MgCl2· 6H2O  3.5  0.712g 
NaH2PO4  0.4  0.062g 
 
The five main solutions were prepared as follow:  
 
1)  750 μM Ca
2+ solution: 200 ml Ca
2+-free buffer + 150 μl 1 M CaCl2 
 
2)  100 μM EGTA solution: 100 ml Ca
2+-free buffer+ 100 μl 100 mM EGTA 
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Figure 2.1: The Langendorff perfusion system used for the isolation of rat 
ventricular cardiomyocytes. The whole system was pre-warmed and kept at 37° C. 
All buffers were oxygenated for 5min before the perfusion started. Different colour 
dots mark the tubing for oxygen, 37° C water circulation and buffer transportation. 
The blue arrows indicate the flow direction of Ca
2+/EGTA/Collagenase buffers.  
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3)  Enzyme solution: 50 ml Ca
2+-free buffer+ 50 mg collagenase (Type II)  
+4.5 μl 1M CaCl2 
 
4)  Wash solution: 90ml Ca
2+-free buffer+ 10 μl 1M CaCl2+ 10% BSA 
 
5)  Heparin Beaker Solution: 25ml Ca
2+-free buffer+ 18.5 μl 1M CaCl2 
+ 60 μl 5000 unit/ml Heparin 
 
BSA powder (fraction V, fatty acid free, Boehringer Mannheim, Germany) 
was dissolved in stock Ca
2+-free buffer containing 80 μM Ca
2+ to a concentration of 
100 mg/ml under constant stirring at 4˚C. The BSA solution was then dialyzed 
against stock Ca
2+-free buffer containing 80 μM Ca
2+ at 4˚C for 1 hour, and was 
further dialyzed against fresh stock Ca
2+-free buffer containing 80 μM Ca
2+ at 4˚C 
overnight. The dialysed BSA solution was aliquoted and stored at -20 ˚C.  
Before the perfusion, all solutions were pre-warmed to 37˚C and oxygenated 
for at least 5 min. The adult rat was sacrificed by cervical dislocation and the heart 
was quickly excised. It is very important to make sure the aorta with proper length 
was still intact otherwise is difficult or impossible to ligate the heart to the cannula. 
The heart was squeezed quickly and gently two to three times in Heparin Beaker 
Solution to wash out the residual blood and to prevent clotting in the coronary 
vessels. These are the main routes for the retrograde perfusion. Immediately, the 
heart was carefully tied to the tip of the cannula by surgical silk and the perfusion 
began.  
The heart was first perfused with the750μM Ca
2+solution for 2 min to wash 
away any remaining blood (this can be longer if the heart was not contracting well), 
then with the 100μM EGTA solution for 4 min to stop contraction and with Enzyme 
solution for 18 to 20 min to digest away the extracellular matrices. After 1.5 to 2 min 
after the heart was perfused with Enzyme solution, the fluid was collected and 
recirculated in the chamber for the perfusion and later digestion. The collected 
enzyme solution should be oxygenated during the 18 min circulation. 
The rate of perfusion was dependent on the weight of the rats and was 
determined using following calculation: 
  Heart weight (g) = Animal weight (g) x 0.4%  
(The heart weighs about 0.4% of the whole animal body in 250g rats) 53 
 
 
  Perfusion rate (ml/min) = Heart weight (g) x 9 ml/min 
(9 ml/min per gram of heart is optimal for retrograde perfusion from experience) 
 
For example, if the animal weights 250 g,  
Then, the perfusion rate = 250 g x 0.4 % x 9 ml/min = 9 ml/min 
 
After the entire perfusion, the heart was removed from the cannula and the 
aorta was dissected away. The ventricular tissue was cut into small pieces to increase 
exposure to collagenase, and was then placed in a 50ml flat bottom flask with 5ml 
recirculated Enzyme solution containing 1% (w/v) BSA, and was further digested by 
shaking at 37 ˚C for 5 min under oxygenated conditions to mechanically separate the 
myocytes. The remaining ventricular tissue was shaken in the same way repeated 
three more times. The myocytes were separated from the undigested tissue by 
filtered through a nylon cloth (200 μm) at end of shaking. The cardiomyocytes were 
washed using Wash Solution two to three times and allowed to sediment under 
gravity to remove damaged or dead myocytes, which do not attach to the culture dish.  
 
 
2.2.2 Culture of ARVC 
  Six-well flat bottom plates (Corning Life Science) of tissue culture grade 
were pro-coated with laminin (Sigma-Aldrich) which provides a layer of fibre 
network for the isolated cardiomyocytes to attach to. Laminin was diluted to a final 
concentration of 10 µg/ml with M199 medium (Sigma-Aldrich). The tissue culture 
plates were coated with adequate amount of M199-diluted laminin (650 µl per well 
for 6-well plates) for at least 30 min at room temperature. It is important to make 
sure that all surfaces were covered by laminin. The coating liquid was removed and 
the plates were rinsed once with phosphate buffered saline (PBS: 2 mM KH2PO4  pH 
7.4, 10  mM Na2HPO4, 4 mM KCl, 170 mM NaCl) . The coated plates were then 
supplied with modified M199 medium and were kept in a 37° C incubator with 5% 
CO2 for at least 30min before use. 
  After isolation, the heart cells were washed three times with Wash Solution 
to remove the damaged myocytes. The remaining cells were washed twice using 54 
 
Dulbecco’s modified Eagle’s medium (DMEM) with 1 g/l glucose and 1.0 mM 
EGTA. The myocytes were further washed twice by sedimentation under gravity 
using M199 washing medium with 1.0 mM EGTA. Finally, the cardiomyocytes were 
re-suspended in modified M199 culture medium (2 mM glutamine, 50 U/ml 
penicillin, 50 µg/ml streptomycin, 5 mM creatine, 2 mM carnitine, 5 mM taurine, 1.0 
mM EGTA) and were cultured on laminin-coated plates. 
  Cardiomyocytes were plated roughly at a density of 1.57 x 10
4 rod shape 
cells/cm
2, and were then allowed to adhere to the coated dishes for 2h. Non-attached 
cells were discarded by aspiration. Fresh modified M199 culture medium was 
replenished to the attached healthy cardiomyocytes and incubated overnight at 37° C 
for any further treatment. Normally, a successful cardiomyocyte perfusion will 
expect to produce 95% rod-shaped healthy living heart cells. The serum-free medium 
prevents non-myocytes dividing contamination. Generally, cardiomyocytes in 
culture exhibit normal morphology up to at least three days in culture.  
 
 
2.2.3 Cell treatment and protein extraction 
Cardiomyocytes were treated with signalling inhibitors and agonists after at 
least an overnight culture (16h). Different agents were diluted with the modified 
M199 culture medium before addition to the cell culture to ensure evenly distribution 
throughout the culture dish. The cells were then treated with or without PE (10 μM) 
for 1h (otherwise indicated), the agonist, to stimulate heart cell growth (Lazou et al. 
1994). The concentration and treatment time prior to PE addition vary with different 
agents. Actinomycin-D, which interferes with DNA replication, and blocks general 
transcription, was added to the cell culture ahead for 30min at 2 μg/ml (Sobell 1985). 
Rapamycin, which disrupts mTORC1 signalling, was used at 100nM for 30min 
(Wang and Proud 2002). PP242, which inhibits both mTORC1 and mTORC2, was 
added at 2.5 μM for 30min (Feldman et al. 2009). PD184352 (Squires et al. 2002) 
and AZD6244 (Yeh et al. 2007) both target MEK1/2 and inhibit MAP kinase 
pathway and were used at 5 μM for 45min. SL0101 which inhibit p90
RSKs was used 
at 50  μM for 30min. BI-D1870 which is a specific p90
RSKs inhibitor was diluted to 
10 μM and was added to the cell culture 1h prior to stimulation with or without PE 
(Sapkota et al. 2007). 55 
 
After treatment, the culture dishes were placed on ice immediately after the 
medium was removed by aspiration. The cells were washed twice with ice-cold PBS 
and were harvested with protein extraction buffer (50 mM Tris-HCl pH 7.5, 1 mM 
EGTA, 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF, 5 mM sodium pyrophosphate, 1% 
(v/v) Triton X-100, 1 mM DTT, 1 g/ml leupeptin, 1 g/ml pepstatin, 1 g/ml 
antipain, and 0.2 mM PMSF). After 30min, the cardiomyocytes were lysed 
mechanically by scraping. The liquid was carefully transferred to a 1.5 mL 
Eppendorf tube and the tube was centrifuged at 20,000xg for 10min at 4° C to spin 
down membrane debris, mitochondria and nuclei. The pellet was discarded and the 
supernatant was collected and transferred into a new Eppendorf tube. The sample 
was kept at -20° C for further analysis. 
 
 
2.3 Human cervical carcinoma (HeLa) and T-Rex
TM- 293 
(Invitrogen) cell lines 
2.3.1 HeLa and T-Rex
TM 293 cell culture 
T-Rex
TM293 cells, which are modified from Human embryonic kidney (HEK) 
293 cells were purchased from Invitrogen. This T-Rex
TMsystem stably expresses the 
Tet  repressor  that  repressing  transcription  of  the  gene  of  interest  and  is  able  to 
express the gene of interest under induction. For more information, please refer to 
the user manual (Invitrogen, R710-07).  
Both human cervical carcinoma HeLa and T-Rex
TM 293 cells were cultured 
on 10-cm diameter plates in Dulbecco’s modified Eagle medium (DMEM) 
containing 10% heat-inactivated foetal calf serum (FCS), 100 μg/ml streptomycin 
and 100 U/ml penicillin. The cells were cultured in a 5% CO2 incubator at 37º  C. 
The cells were passaged when they reached about 80% confluence. The cells were 
passaged as following: medium was discarded by aspiration and the cells were 
washed twice with sufficient pre-warmed sterile PBS. These washing steps should be 
gentle to prevent removal of adherent cells. One ml of 0.05% (w/v) trypsin/ EGTA 
was added to the 10-cm plates and the cell plates were kept in the 37º  C for 
approximately 3 min. Then the culture dishes were gently tapped on the side to 56 
 
encourage the detachment of the cells. The detached cells were diluted in fresh pre-
warmed DMEM and were plated in new tissue culture dishes.  
 
2.3.2 Transfection of HeLa and T-Rex
TM 293 cells 
  Lipofectamine™ 2000 Reagent (Invitrogen, 11668-019) was used to perform 
lipid- mediated transfection. The day before transfection, HeLa and/or T-Rex
TM 
293cells were trypsinized and counted. Cells were passaged and diluted in fresh 
growth medium at approximately ~50% confluence. On the day of transfection, cell 
density should be no more than 80% confluence. Plasmids of interested and GFP 
vector which serves as a control for transfection efficiency were diluted and 
transfected into the cells according to the product manual. Cells were then incubated 
at 37° C in a CO2 incubator for 18 to 24 h before further treatment. Transfection 
efficiency was judged by GFP expression and was up to 95% by using this reagent. 
 
 
2.3.3 Induction of BOP1Δ in T-Rex
TM- 293 cell 
  According to the product guidelines, the vectors containing the gene of 
interest were each transfected into T-Rex
TM- 293 cell lines which constitutively 
expresses the Tet repressor. Tet repressor binds to promoter of the gene of interest 
and represses transcription of such gene. To express the gene of interest, doxycycline 
is introduced into the system. Doxycycline binds to each Tet repressor with high 
affinity and prevents it binding to the promoter of the gene of interest. Therefore, 
upon doxycycline addition, transcription of the gene of interest is induced.  
In this project, the vectors used were pcDNA5FRT-BOP1 FL and 
pcDNA5FRT-BOP1Δ which lack the first 264 amino acids. After transfection, fresh 
medium was added to the culture dishes to allow the cells to recover for at least 24 h 
before induction. Medium was discarded by aspiration and fresh medium containing 
1 μg/ml doxycycline to induce BOP1 expression. The cells were incubated for 3 days 
at 37° C with 5% CO2 before further analysis. 
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Table 2.2: List of plasmids 
Name  Vector  Supplier  Site  Primer sequence  TAG 
pcDNA5F
RT-BOP1 
FL 
pcDNA
5FRT 
Invitrogen  SpeI 
ClaI 
GGACTAGTATGGCGGGTTC
GCGGGGTGC  
CCATCGATCTAGGTGAAGA
GGCGGACAG 
GST 
pcDNA5F
RT-BOP1
Δ 
pcDNA
5FRT 
Invitrogen  SpeI 
ClaI 
GGACTAGTATGGGCTGGAT
CCAGCCTC  
CCATCGATCTAGGTGAAGA
GGCGGA 
GST 
 
2.3.4 Cell treatment and protein extraction 
HeLa and HEK 293 cells were cultured to near confluence and treated with 
100 nM 4-TU. In some instances, cells were pre-treated with2 µg/ml Actinomycin-D 
(30 min) which blocks general transcription, or with 100 nM rapamycin which 
disrupts mTORC1 signalling for 1 h. The cells were harvested after 45 min or 90 
min. 
Upon serum starvation, cells were rinsed once with pre-warmed phosphate-
buffered saline (PBS), and were then incubated with DMEM without FCS for 16 
hours. After overnight serum starvation, HeLa cells were treated with phorbol 12-
myristate 13-acetate (PMA, 1M) for 25 min. Where indicated, cells were treated 
with 100 nM rapamycin, mTORC1 signalling inhibitor,1 h prior to stimulation. 4-SU 
(100 nM) was added to the media right after, and the cells were harvested after 5 min, 
10 min or 60 min.  
At the end of treatment, the cells were extracted in the same way as described 
in section 2.2.3. 
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2.4 4-Thiouridine labelling methods 
2.4.1 RNA preparation 
The procedure for labelling newly synthesized RNA within cells using 
modified uridine was adapted from those described earlier (Woodford et al. 1988; 
Cleary et al. 2005) 
After treatment, cells were washed twice with ice-cold PBS. Total RNAs 
from HeLa, HEK293 cells and heart muscle cells were extracted by using Trizol 
(Invitrogen) following the manufacturer’s protocol. For each ml of Trizol, 200 l of 
chloroform was added and the lysate was mixed by vortex. The mixture was 
incubated at room temperature (RT) for two minutes, and then was centrifuged at 
20,000xg for 15 min. The top 400 l layer was gently transferred to a new Eppendorf 
tube. After adding 400l of isopropanol, the sample was after incubation at RT for 
10 min. Finally, total RNA was precipitated centrifuged at 20,000xg for 10 min. The 
pellet was rinsed once with 75% (v/v) ethanol and re-suspended in RNAase-free 
water. The samples were then stored at -80
◦ C prior to further analysis. 
 
 
2.4.2 Biotinylation of 4-SU labelled RNA 
To biotinylate 4-SU labelled RNA, total RNA was incubated with EZ-Link 
Biotin-HPDP (Pierce). Biotin-HPDP was suspended in dimethylformamide at a 
concentration of 1mg/ml. One l of this reagent was used per 1 g of RNA extracted 
from the labelling reaction. Biotinylation of 4-SU labelled RNA was performed with 
10 mM Tris-HCl (pH 7.5) and 1 mM EDTA in a final volume which was 5 times 
more than the volume of biotin-HPDP in the reaction. 
Example reaction: 
 
RNA (total):        10 µg 
Biotin-HPDP (last):   10 µl 
1M Tris-HCl (pH 7.4):      0.5 µl 
0.5M EDTA:                      0.1 µl 59 
 
      RNAase-free water:           up to final volume of 50 µl  
RNA was incubated with biotin-HPDP at RT for 2 h in dark. To precipitate, 
isopropanol was added and the sample was centrifuged at 20,000xg for 20 min.  
 
Following above example: 
5 M NaCl:                5 µl 
Isopropanol:            50 µl  
 
The pellet was rinsed with 75% (v/v) ethanol and re-suspended in RNAase-
free water. The sample was stored at -80
◦ C until required.  
 
 
2.4.3 Isolation of 4-SU labelled RNA from total RNA 
To purify 4-SU labelled RNA, Magnetic Porous Glass (MPG) streptavidin 
beads (PUREBiotech MSTR0510) were used to capture the biotinylated RNA. One 
l of MPG Streptavidin Beads was used per g of total RNA. The beads were 
incubated with carrier yeast tRNA (1 g tRNA per 5 l beads) for 20 min at ambient 
temperature to prevent non-specific binding and washed 3 times in 500 l MPG 
Buffer (1M NaCl, 10 mM EDTA, 100 mM Tris-HCl pH 7.5 ) before adding RNA. 
MPG beads were collected in a magnetic stand and re-suspended in MPG Buffer to 
the original volume of beads. The volume of biotinylated RNA sample was adjusted 
with RNAase-free water to the same volume of the beads. Biotinylated RNA was 
then added to the beads and incubated at RT for 20 min with rotation. The beads 
were collected on the magnetic stand for more than one minute and followed by 
washing three times in 500 l MPG Buffer, the first two times at ambient 
temperature and the last one at 65
◦ C. Two more washes were performed at ambient 
temperature to make sure all the non-4SU labelled RNA was washed away. Bound 
RNA which was labelled by 4-SU was eluted by suspending the MPG beads in 
freshly diluted 5% β-mercaptoethanol volume equal to original beads. The mixture 
was incubated at room temperature for 15 min with rotation. The beads were 
collected on the magnetic stand for more than one minute and the liquid was saved. 
Two g of glycogen (Roche #10 901 393 001) were added as carrier and RNA was 
precipitated using isopropanol and NaCl. The pellet was rinsed with 75% (v/v) 60 
 
ethanol and re-suspended in RNAase-free water. The re-suspended RNA sample was 
then placed in magnetic stand for more than one minute to allow them to settle. Any 
excess beads from earlier steps were collected. The supernatant was transferred to a 
new Eppendorf tube. This sample contains purified 4-SU labelled RNA. 
 
 
2.5 Uridine uptake assay 
2.5.1 Nucleoside Transport in HeLa cells 
  Uridine transport was monitored in cultured HeLa cells in medium either 
containing or lacking Na
+-ions, using a method based on those used earlier studies 
(Huang et al. 2003; Baldwin et al. 2004; Kato et al. 2006). 
  The main solutions were prepared as follow: 
I.  Transport Buffer : 
a.  137 mM NaCl,    
b.  5.4 mM KCl,  
c.  1.8 mM CaCl2,  
d.  1.2 mM MgSO4, 
e.  10 mM HEPES pH7.4 
 
II.   Labelling Buffer: 
a.  137 mM Choline chloride,  
b.  5.4 mM KCl,  
c.  1.8 mM CaCl2,  
d.  1.2 mM MgSO4,  
e.  10 mM HEPES-KOH pH7.4,  
f.  1 µM uridine,  
g.  1 µCi/nmol[
3H]-uridine (1:20 hot versus cold uridine) 
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III.  Washing Buffer : 
a.  137 mM Choline chloride,  
b.  5.4 mM KCl,  
c.  1.8 mM CaCl2,  
d.  1.2 mM MgSO4,  
e.  10 mM HEPES-KOH pH7.4,  
f.  1 mM uridine,  
g.  1 µM S-(4-nitrobenzyl)-6-thioinosine (NBMPR) 
h.  1 µM dipyrimidine 
 
IV.  Lysis Buffer: 
a.  0.5% Triton X-100 
b.  100 mM NaOH 
 
 
HeLa cells were culture in DMEM containing 10% FCS medium to near 
confluence and were treated with 5 nM or 100 nM rapamycin for 30 min at 37° C in a 
CO2 incubator. After removing the medium by aspiration, the cells were washed 
twice with ice-cool PBS. Cells were then incubated on ice in ice-cold transport 
buffer with or without rapamycin for 15 min. Transport buffer was discarded by 
aspiration. HeLa cells were incubated in labelling buffer for 20 s at ambient 
temperature. Labelling was stopped by removing the labelling buffer and washing 
the cells with ice-cold washing buffer three times. A sufficient amount of washing 
buffer should be used to cover the bottom of tissue culture plates and to make sure 
washing away residues of [
3H]-uridine. Cells were then lysed in ice-cold lysis buffer. 
Protein concentration was determined by BCA protein assay kit (Thermo Scientific, 
#23250). Ten µl lysate were diluted in 200 µl BCA to determine protein 
concentration. Quantification of radioactivity was measured using MicroBeta 
Workstation software by MicroBeta Trilux Liquid Scintillation Counter 
(PerkinElmer). Counts were normalized to protein concentrations for accurate 
measurements of [
3H]-uridine. 
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2.5.2 Uridine uptake assay in ARVC 
  Due to the sensitivity of cardiomyocytes, the method to measure uridine 
uptake in adult rat ventricular cardiomyocytes need to be modified based on the 
method described in section 2.5.1. 
  ARVC transport and washing buffers were prepared as indicated below, 
while labelling and lysis buffers were prepared as described in section 2.5.1. To 
improve the labelling efficiency, labelling time of uridine uptake was extended to 1 
min and concentrations of nucleotide receptors inhibitors were increased to 100 µM. 
To avoid stressing cardiomyocytes, both ARVC transport buffer and labelling buffer 
were pre-warmed to 37° C. 
I.  ARVC Transport Buffer : 
a.  137  mM NaCl,    
b.  5.4  mM KCl,  
c.  1.8  mM CaCl2,  
d.  1.2  mM MgSO4, 
e.  10  mM HEPES-KOH pH7.4 
f.  100 µM S-(4-nitrobenzyl)-6-thioinosine (NBMPR) 
g.  100 µM dipyrimidine 
 
II.  ARVC Washing Buffer : 
a.  137  mM Choline chloride,  
b.  5.4  mM KCl,  
c.  1.8  mM CaCl2,  
d.  1.2  mM MgSO4,  
e.  10  mM HEPES-KOH pH7.4,  
f.  1 mM uridine,  
g.  100 µM S-(4-nitrobenzyl)-6-thioinosine (NBMPR) 
h.  100 µM dipyrimidine 
 
Cardiomyocytes were cultured in modified M199 medium with or without 
specific signalling inhibitor for 16 h. Different inhibitors and concentrations used 
were indicated as below: rapamycin at 100 nM, AZD6244 at 5 μM and BI-D1870 at 63 
 
10 μM. After removing the medium by aspiration, the culture dishes were gently 
washed twice with pre-warmed 1X PBS. The cells were then incubated in pre-
warmed ARVC transport buffer containing 100 µM nucleotide receptors inhibitors 
with or without signalling inhibitors for 30 min at 37° C in a CO2 incubator. At the 
end of the nucleotide starvation period, ARVC transport buffer was discarded by 
aspiration. Cardiomyocytes were incubated in labelling buffer for 1 min at 37° C in a 
CO2 incubator. Labelling buffer was quickly removed to stop uridine labelling and 
the cells were washed three times with ice-cold ARVC washing buffer. Cells were 
then lysed in ice-cold Lysis buffer. Protein concentrations and [
3H]-uridine 
radioactivity quantifications were measured as described in section 2.5.1. 
 
2.6 Real Time-quantitative PCR (RT-qPCR) amplification analysis 
Total purified 4-SU labelled RNA was treated with RNAase-free DNAase 
(optional) and then subjected to reverse transcription with an Oligo(dT)15 Primer and 
random primers (Invitrogen 48190-011). 
Before beginning the real experiments, the primer efficiency test was 
perfumed (Table 2.3). This is to ensure that the primers will work appropriately and 
also help us to determine how much cDNA to use in the experiment. It is important 
to use an appropriate amount of cDNA to ensure that the quantitation is performed 
while the amplification reaction is in the linear phase. Otherwise, the final yield of 
the product will be saturated and will not reflect the real quantity of the target gene. 
The ideal primer efficiency would have a value of 2.00 which implies that the 
amount of target gene doubles every cycle. The primer efficiency was determined by 
setting up reactions using a series of concentrations of cDNA (typically 6 for my 
purpose). For each gene interested, qPCR reagents were mixed as below: 
Example protocol for RT-qPCR: 
For each 20 µl real-time PCR reaction: 
Diluted cDNA:      3 µl (20ng) 
Primer mix (of target gene):    1 µl (300nM) 64 
 
TABLE2.3: List of Primer Efficiency 
 
A) 
Primer
（Human） 
Efficiency 
18S  1.955 
28S  1.966 
5S  2.242 
ACTB  1.946 
GAPDH  1.961 
UBF  1.922 
p21  2.267 
p27  1.733 
 
B) 
Primer
（Rat） 
Efficiency 
18S  1.939 
5S  2.014 
ACTB  1.932 
GAPDH  1.894 
ATP5B  1.917 
RPL13  1.912 
UBC  1.979 
 
C) 
Primer
（Mouse） 
Efficiency 
18S  1.800 
5S  1.925 
GAPDH  1.831 65 
 
PrimerDesign 2x qPCR Mastermix:  10 µl 
RNAase/DNAase free water:    6 µl 
Final volume:        20 µl 
PCR amplification conditions using SYBRgreen were set as follows: 
  1 cycle   10 min   95° C    Enzyme activation 
  45 cycles  15 s    95° C    Denaturation 
      60 s    60° C    Data collecting   
Note: A Melting Curve after each PCR run was added to prove the primers 
specificity.  
A threshold fluorescence level is determined to subtract the background. Ct 
value, also called cycle threshold, is the cycle point when the sample fluorescence 
level reaches the threshold level. The amount of DNA ideally doubles every cycle 
and relative quantities of DNA can thus be calculated. For example, whose Ct is 2 
cycles earlier than another's has 2
2 = 4 times more templates. However, not all sets of 
primers work with 100% efficiency. The precise difference in starting template can  
be calculated using the exact primer efficiency. In previous example, if efficiency 
was 1.98, then the sample would have (1.98)
2=3.9204 times more templates. 
Subsequently, PCR using specific primers (PrimerDesign) were used to 
amplify 18S and other house-keeping genes according to product protocol. The 
comparative Ct method was employed to quantify the results. The relative amount of 
a target gene is calculated as the 2
–ΔΔCt, where  
  ΔΔCt = ΔCt,sample -ΔCt, control 
Here, ΔCt,sample is the Ct value for any sample normalized to the internal control and 
ΔCt, control is the Ct value for the calibrator also normalized to the internal control 
(Appendix A). 
  The specific primers used  were: 
Rattus 5S:  sense-GGCCATACCACCCTGAACGC- 
  anti-sense-CAGCACCCGGTATTCCCAGG- 
  Accession number:*000013 
Homo 5S:    sense-GGCCATACCACCCTGAACGC- 66 
 
anti-sense-CAGCACCCGGTATTCCCAGG- 
Accession number: NR_023363 
Homo P21:  sense-TCCAGCGACCTTCCTCATC- 
  anti-sense-GCCTCTACTGCCACCATCT- 
  Accession number: NM_000389 
Rattus norvegicus reference gene assay kit (PrimerDesign HK-SY-ra-600) were used 
to amply 18S and 28S rRNAs in ARVC. 
Homo sapiens reference gene assay kit (PrimerDesign HY-SY-hu-600) were used to 
amply 18S,28S rRNAs and Actin mRNA in HeLa and HEK293 cells.  
  
 
2.7 Protein Chemistry and biochemistry 
2.7.1 Determination of protein concentrations  
The Bio-Rad Protein Assay Kit (Bio-Rad Laboratories Ltd. UK) was used to 
determine cell lysate concentration using the Bradford assay (Bradford 1976). To 
make 1 x Bradford reagent, 5 x protein dye concentrate was 5 times diluted with 
distilled H2O. One l of cell extract was mixed with 1 ml 1 x Bradford reagent in a 
plastic cuvette. The cuvette was inverted several times to mix the content, and then 
the absorbance at 595 nm of the sample was measured. The concentration of the cell 
lysate was estimated by comparing the absorbance rate with a linear standard curve 
from serially diluted BSA. 
 
2.7.2 Sodium dodecyl sulphate-PAGE and Western Blotting 
SDS-PAGE gels consist of resolving gel and stacking gel. The gels generally 
consist of 40% acrylamide, 2% bisacrylamide, 10% (w/v) SDS, and a Tris-HCl 
buffer with specific pH (pH 8.8 for the resolving gel and pH 6.8 Tris-HCl buffer for 
the stacking part). Ammonium persulphate and TEMED are added when the gel is 
ready to be polymerized. They were polymerized in a gel caster (Bio-Rad Mini 
Protean® III gel apparatus). SDS, an anionic detergent, in the running buffer (384 
mM glycine, 50 mM Tri-HCl and 0.1% (w/v) SDS) at 200 V denatures secondary 67 
 
and non–disulphide–linked tertiary structures, and applies a negative charge to each 
protein in proportion to its mass (Laemmli, 1970). The samples were heated at 95
◦ C 
for 5 min with 5 x SDS sample buffer (0.5M Tris-HCl pH 6.8, 10% (w/v) SDS, 20% 
(v/v) glycerol, 0.12% bromophenol blue and 2 mM β-mercaptoethanol) to denature 
the secondary structures, break S-S bonds and to help SDS to bind. 
Total extracts were resolved by SDS-PAGE, and the proteins were electro-
transferred to nitrocellulose membranes in transfer buffer (192 mM glycine, 25 mM 
Tris and 0.02% (w/v) SDS with 15% (v/v) methanol) at 100V for 1 hour at 4
◦ C. 
After the transfer, nitrocellulose membranes were blocked from non-specific binding 
by incubating with 5% (w/v) skim milk powder in PBST (PBS with 0.02% Tween-
20) for 1 h at room temperature. The blocked membranes were then probed with 
primary antibodies diluted in 0.02% PBST containing 1% BSA at 4
◦ C overnight (or 
at room temperature for 2 h). Primary antibodies used in this project are list in Table 
2.4. The probed membrane can be retained for reuse whenever possible. The next 
morning, primary antibodies were removed and the membranes were washed 3 times 
with 0.02% PBST for 15 min each to remove excess antibodies. The membranes 
were incubated with horseradish peroxidase IRDye™ 800 (excitation 778 nm, 
emission 806 nm) conjugated secondary antibodies of mouse, rabbit, or sheep (LI-
COR Biosciences) at room temperature for 1 hour. The incubation allows the 
secondary antibodies to react with the primary antibody on the membranes. 
Membranes were then washed with 0.02% PBST for 15 min three times to remove 
excess antibodies at room temperature. Finally, the Odyssey
® Infrared Imaging 
System (LI-COR®, Biosciences) was used to detect and to quantify signals. 
Membranes were imaged with the infrared imager in both 700 and 800 nm channels 
in a single scan with resolution at 169 μm. All immunoblots are representative of at 
least three independent experiments. 
 
 
2.8 Immunofluorescence microscope  
HeLa and primary mouse embryonic fibroblasts (MEF) cells were used in 
immunofluorescence experiments to detect nucleophosmin (B23) localization. HeLa 
cells were also used to study the distribution of block of proliferation (BOP1).  
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Table 2.4: List of Primary Antibodies 
Antibody  Species  Dilutions  Source 
Anti-phospho-Thr202/Tyr204 
p44/42 
MAPK (ERK1/2)  
Rabbit  1:1000  Cell Signalling 
Technology 
Anti-p44/42MAPK 
(ERK1/ERK2)  
 
Rabbit  1:1000  Cell Signalling 
Technology 
Anti-Phospho-p90RSK 
(Thr573) 
Rabbit  1:1000  Cell Signalling 
Technology 
Anti-RSK2  Rabbit  1:1000  Cell Signalling 
Technology 
Anti-RSK3  Rabbit  1:1000  Cell Signalling 
Technology 
Anti-phospho-Thr389 p70 
ribosome protein S6 kinase 
 
Rabbit  1:1000  Cell Signalling 
Technology 
Anti-phospho- 
Ser240/244 p70 ribosomal 
protein S6  
 
Rabbit  1:1000  Cell Signalling 
Technology 
Anti-phospho- 
Ser235/236 p70 ribosomal 
protein S6  
 
Rabbit  1:1000  Cell Signalling 
Technology 
Anti-phospho- 
Ser473 PKB/Akt 
 
Rabbit  1:1000  Cell Signalling 
Technology 
Anti-phospho- Thr172 AMPKα  Rabbit  1:1000  Cell Signalling 
Technology 
α-Tubulin  Mouse  1:500  Santa Cruz Biotechnology 
Anti-Glutathione-S-Transferase 
(GST) 
Rabbit  1:1000  Sigma 
Anti-HA  Rat  1:1000  Roche 
Anti-BRF1/2  Rabbit  1:1000  Cell Signalling 
Technology 
Anti-UBF  Rabbit  1:1000  Santa Cruz Biotechnology 
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Primary antibodies for B23 were purchased from Sigma and BOP1 were from 
BioVaria. Secondary antibodies were from Jackson ImmunoResearch. Cells were  
plated on coverslips and were cultured for two days at 37˚C with 5% CO2. Cells were 
incubated with 100 nM rapamycin or 2 µg/ml actinomycin D for 2 h when they 
reached about 80% confluence. Cells were washed twice with PBS, and were then 
fixed with 4% paraformaldehyde (Sigma, F8775) for 15 min at ambient temperature.  
The solution was aspirated, and the cells were permeabilized with 1.5ml ice-cold 
PBS/0.1% Triton X-100 for 10 min. Finally, cells were blocked in 1ml 1% (w/v) 
bovine serum albumin (BSA) in PBS for 1 h at ambient temperature. The cells were 
incubated with primary antibodies for 2 h at ambient temperature. Cells were washed 
twice with PBS. It is important to be gentle when washing the coverslips to avoiding 
washing out cells or breaking the thin glass covers. Cells were then incubated with 
50μl 1:200 secondary antibody (Rhodamine-conjugated AffiniPure Donkey Anti-
Mouse IgG) for 2 h in dark at room temperature. Cells were washed gently again 
with PBS after incubation. This step should be fast and trying to avoid direct light. 
TO-PRO®-3 (Invitrogen, T3605) 1:1000 were used to visualize nuclei after 
incubating for 15 min at room temperature in dark. Coverslips were mounted with 
50μl ProLong® Gold antifade (Invitrogen, P36930) overnight in dark at room 
temperature. Nail polish can be used on the edge to secure the coverslips. The glass 
slides were kept in dark at 4˚C and subsequently visualized using a fluorescence 
microscopy. 
Pictures were taken with an Olympus CKX41 inverted microscope for bright-
field and fluorescence imaging. The exposure times were kept constant for each 
fluorescence channel with each experiment repeats. Images were processed using 
version 2.0 of Leica LAS AF software from Leica. Selected sections are shown in the 
figure. 
 
 
2.9 Quantitative Chromatin Immunoprecipitation (qChIP) in ARVC 
  ARVC were isolated in the same way as described in section 2.2. 
Cardiomyocytes were cultured in modified M199 medium overnight at 37˚C with 5% 
CO2. The next morning, ARVC were pre-incubated in medium containing or lacking 
BI-D1870 for 1h and then10 µM PE was added for 24h where indicated.  70 
 
Chromatin immunoprecipitation (ChIP) was prepared as described previously 
with modifications (Poortinga et al. 2004; Mann et al. 2010). Cross-linking was 
achieved with fresh made 1% formaldehyde (F8775, Sigma) for 5 min at ambient 
temperature and the cells were sonicated eighteen times for 30 sec. The samples 
were then spun and the supernatants were collected. The amount of chromatin was 
measured using Nanodrop similar as measuring DNA concentration. All buffers 
were kept at 4˚C. 
One hundred µg of cross-linked chromatin from each treatment was used to 
investigate Pol I binding to the rRNA gene using ChIP assay. Five to ten μg 
chromatin (5 to 10% of total chromatin) was saved as input for further analysis. 
Antibodies used for IP were anti-Pol I (sc-46699, Santa Cruz Biotechnology) and 
anti-Pol II (sc-47701, Santa Cruz Biotechnology). Ten μg of antibody was used in 
each immunoprecipitation reaction. Primers used for qPCR analysis of ChIP 
reactions are β-actin (Primerdesign), ENH (sense: -AGGAGGCCGGGCAAGCA-, 
antisense: -CCTCCTTGTTAGAGACCGTCCTTAA-), UCE (sense: -
AGTTGTTCCTTTGAGGTCCGGT-, antisense: -
AGGAAAGTGACAGGCCACAGAG-) and CORE (sense:-
AGTTGTTCCTTTGAGGTCCGGT-, antisense:-
CAGCCTTAAATCGAAAGGGTCT-).  The relative level of DNA binding was 
analysed using primers specific for the indicated regions of the Pol I promoter by 
qRT-PCR reactions. Average values of precipitated DNA were normalized to inputs 
control. Data are shown as mean ±  SEM (n =3)  
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Chapter 3 
 
Development of a novel method to study rRNA 
synthesis in mammalian cells 
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3.1 Introduction 
Ribosome biogenesis, the production of ribosomes, is a highly complex 
process involving the synthesis and processing of four different ribosomal RNAs 
(rRNAs) and around eighty ribosomal proteins (Rps). Ribosome synthesis is critical 
for maintaining cells’ protein synthesis capacity. Hence, ribosome biogenesis is 
tightly regulated, especially during cell growth and proliferation. Indeed, 
deregulation of ribosome biogenesis may trigger the tumour suppressor protein p53 
and induce apoptosis and/or cancer (Montanaro et al. 2008). Furthermore, early 
studies indicated that ribosomal RNA synthesis (ribosome content) is increased by 
25% in hypertrophying rat heart (Morgan et al. 1985). Therefore, it is crucial to 
address how the synthesis of ribosomes is regulated during cell growth (hypertrophy). 
In particular, it is important to investigate how mTOR complex 1 (mTORC1), a 
positive regulator of protein synthesis and cell growth, and other signalling pathways, 
regulates the synthesis of rRNAs in mammalian cells (Wullschleger et al. 2006). 
To study rRNA synthesis in living cells, a novel method has been developed 
to monitor the rate of synthesis of new rRNA molecules. This non-radioactive 
method can label only newly synthesized rRNA with 4-thiouridine (4-SU). 
Compared with earlier methods using radioactive isotopes to label new rRNA, this 
new method allows one not only to purify, but also to quantify, labelled rRNA using 
quantitative real-time PCR (RT-qPCR) (Fig.1.15).  
 
3.2 4-SU labelling method development in HeLa cells  
3.2.1 4-thiouridine labelling alone does not affect mTORC1 or ERK 
signalling pathways in HeLa cells 
Considering the limited availability and highly sensitive nature of adult 
cardiomyocytes, HeLa and HEK293 cells were used to develop and to establish the 
4-SU labelling technique as a way to measure new rRNA synthesis.  
The 4-SU labelling method was first tested in HeLa cells to assess whether 4-
SU treatment affected mTORC1 or other signalling pathways. Ribosomal protein S6 
phosphorylation is catalyzed by p70 S6K which is downstream of mTORC1 74 
 
(Fig.1.6). S6 is normally phosphorylated in growing cells and the level of 
phosphorylation drops when external conditions are unfavourable or under stress 
conditions which inhibit the upstream mTORC1 pathway. Therefore, the level of S6 
at Ser 240/244 phosphorylation, which are specific S6K sites, commonly serves as a 
marker for mTORC1 activation.  
Previous experiments have shown that the optimal concentration for 4-SU 
labeling is 100 μM in HeLa cells (data not shown). Therefore, HeLa cells were 
treated with 4-SU at 100 μM up to 2hr. Noticeably, there is no significant difference 
of S6 phosphorylation level between samples with or without 4-SU treatment at all 
time points (Fig. 3.1). The data suggest that 4-SU labelling alone at 100 μM does not 
activate or inhibit mTORC1 pathway. Also, one hundred μM 4-SU treatment does 
not activate Erk1/2 kinases for up to 2hr (Fig. 3.1).  
The 4-SU labelling technique was further tested under conditions where the 
mTORC1 pathway was already activated by serum. HeLa cells were cultured 
overnight in medium devoid of serum, and serum was added back together with or 
without 4-SU (100 μM) accordingly. Serum caused a rapid activation of both Erk1 
and Erk2, the two isoforms of this MAP kinase, within 5 min (Fig. 3.2). In contrast, 
activation of S6 kinase by serum was much slower. Judged from the phosphorylation 
of S6, maximal activation of S6 was reached after 60 min (Fig.3.2). As expected, a 
high phosphorylation level of S6 was noted in cells cultured in medium containing 
serum (NT, Fig.3.2). The activation of either Erk1/2 kinase or S6 was not observed 
in the cells which were cultured without serum (starved, Fig. 3.2). Most importantly, 
the two profiles with or without 4-SU labelling are almost identical. The data 
confirm that 4-SU labelling alone up to 1 h does not affect activation of the ERK or 
mTORC1 signalling pathways by serum. These observations show that 4SU does not 
interfere with the signalling pathways that are reported to control rRNA synthesis. 
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Figure 3.1: 4-SU labelling alone does not affect the mTOR signalling in HeLa 
cells. HeLa cells were treated with or without 4-SU (100μΜ) for the times indicated. 
The cells were then lysed and total proteins were extracted as described in 
MATERIALS AND METHODS. Then same amounts of extracts were used for Western 
blot analysis. Activation of p70 ribosomal protein S6 was assessed using an antibody 
that specific recognizes S6 phosphorylated at Ser
240/244. Activation of ERK1/2 was 
assessed using an antibody specific for phospho-Thr
202/Tyr
204.  
 
 
 
 
 
 
Figure 3.2: 4-SU labelling up to 1 hour does not affect the activation states of 
ERK or mTORC1 signalling in HeLa cells. Apart from the non-treated (NT) 
control cells, HeLa cells were cultured overnight in medium devoid of serum. Serum 
was added back for the indicated times except for the starved control cells (starved). 
Distilled H2O or 4-SU (100 μM) was added to the cells for 5, 10 and 60 minutes 
accordingly. Protein extracts were prepared as described in MATERIALS AND 
METHODS. Activation of Erk1/2 and S6 were assessed using specific antibodies as 
described in Fig.3.1.   
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3.2.2   4-thiouridine can be incorporated into newly synthesized 
rRNAs in HeLa cells  
Actinomycin D is commonly used as an investigative tool in cell biology to 
inhibit general transcription. It is believed that actinomycin D binds DNA duplexes 
at its transcription initiation complex and blocks the transcription elongation by 
RNA polymerases (Sobell 1985). At high concentrations (2 μg/ml), it inhibits Pol I, 
Pol II and Pol III activities. However, at lower concentrations (20 ng/ml), it can only 
inhibit Pol I activity completely, but not the other two RNA polymerases (Puvion-
Dutilleul et al. 1992). It remains unclear that how exactly low concentration 
actinomycin D affects Pol I and Pol III differently. This special characteristic of 
actinomycin D was applied to verify whether 4-SU is incorporated only into newly 
synthesized rRNAs in HeLa cells. 
HeLa cells were pre-incubated with actinomycin D at 2 μg/ml or 20 ng/ml for 
30 min. Then the cells were treated with 4-SU at 100μM for 3 hr (Fig. 3.3A). After 
isolation and purification, the amounts of 4-SU labelled rRNAs were examined using 
Real-Time PCR (See APPENDIX A for sample calculation). It is clear that 4-SU is 
incorporated into 18S rRNA after 3 h treatment, and that 4-SU labelled RNAs can be 
isolated and measured using RT-PCR (Control lane, Fig.3.3B). As expected, 18S 
labelling was almost totally inhibited by low concentrations of actinomycin D 
(Fig.3.3B). The level of the purified 4-SU labelled 18S rRNA further declined to 0.1% 
of control levels with a  higher concentration of actinomycin D (Fig.3.3B).  
Similarly, label was also incorporated into 5S rRNA and this was blocked by 
actinomycin D (Fig.3.3C). Interestingly, low concentrations of actinomycin D 
greatly inhibits labelled 18S rRNA but not labelled 5S rRNA which is synthesized 
by Pol III (Fig.3.3B&C). Higher concentrations were needed to achieve strong 
inhibition of Pol III activity. This difference suggests that at lower concentration, 
actinomycin D inhibits Pol I and Pol III distinctively, which consistent with what is 
already known.  
Taken together, the sensitivity of the 4-SU labelling to actinomycin D 
indicates that 4-SU is incorporated into only newly synthesized rRNAs in HeLa cells.   
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A) 
             
B)  
 
 
C)  
 
Figure 3.3: 4-thiouridine can be incorporated into newly synthesized rRNAs in 
HeLa cells. HeLa cells were pre-cultured with actinomycin D for 30 min at different 
concentrations, as indicated (high: 2 μg/ml or low: 20 ng/ml), and then the cells were 
incubated with 4-SU 100 nM for 3 h. 4-SU-labeled RNAs were extracted and 
purified as described in the ‘Materials and Methods’ section. The amounts of cDNAs 
derived from specific RNAs were quantitated by RT–qPCR and are expressed as 
described in the ‘Materials and Methods’ section: (C) Data for 18S rRNA (also 
measures its precursors); (B) Data for 5S rRNA. 
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The data show that 4-SU-labeled new 18S and 5S rRNAs can be isolated 
under physiological conditions in HeLa cells.  
 
3.2.3   4-thiouridine labelling of rRNAs increases linearly with time 
in HeLa cells 
A time-course experiment was performed to determine the incorporation rate 
of 4-SU into the new RNAs, and especially to establish whether it was linear with 
time.  
The qPCR profile clearly shows that 4-SU labelling of 18S, 28S and 5S 
rRNAs increases linearly in HeLa cells (Fig. 3.4). The data confirm that 4-SU is 
incorporated into new 18S, 28S and 5S rRNAs and it increases with time. More 
importantly, after only 45min of incubation with 4-SU, there were already some 
labelled new rRNAs (Fig.3.4). Therefore, the incorporation of 4-SU into Pol I and 
Pol III rRNAs is quite rapid. 
 
3.3   Establishing the 4-thiouridine labelling assay in adult rat 
ventricular cardiomyocytes (ARVC) 
3.3.1   4-thiouridine labelling alone does not affect mTORC1 or 
MEK/ERK signalling pathways in ARVC with PE stimulation 
  Having established the 4-SU labelling method in HeLa cells, it is important 
to assess whether this non-radioactive method could also be used in adult rat 
ventricular cardiomyocytes to measure newly made rRNA.  
To test whether growing heart cells in medium containing 4-SU affected their 
response to PE, ARVC were pre-incubated in control medium or medium containing 
4-SU for 30 min and then 10 µM PE was added for varying times for up to 45 min. 
To investigate the activation of mTORC1 signalling pathway, the phosphorylation of 
ribosomal protein S6 was studied. The activation of S6 was observed 5 min after 
phenylephrine (PE) treatment and increased with time up to 45 min, indicating PE  79 
 
 
 
 
 
 
Figure 3.4:4-thiouridine labelling of rRNAs increases linearly in HeLa cells 
HeLa cells were treated with 4-TU 100uM for 45min, 90min, or 3h. 4-SU labelled 
rRNAs were extracted and purified as described in MATERIALS AND METHODS. The 
amounts of rRNAs were indicated by RT-qPCR. 
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activates mTORC1 pathway (Fig. 3.5). Importantly, such phosphorylation pattern of 
S6 by PE treatment was not affected by 4-SU. 
In adult cardiomyocytes, Erk1/2 are activated by α-adrenergic agonists such 
as PE,  and are implicated in the hypertrophic growth response (Sugden and Clerk 
1998). As expected, PE rapidly induced the phosphorylation of ERK and p90
RSK, 
which lies downstream of ERK (Fig.3.5). Activation of ERK1/2 was maximal within 
5 min after addition of PE, and it subsequently declined but was still seen up to 45 
min. p90
RSK activation is more sustained. Noticeably, ERK or p90 RSK activation 
was not affected by the addition of 4-SU.  
PI3K lies upstream of the mammalian target of rapamycin (mTOR), and 
plays an important role in controlling organ size in Drosophila (Alessi et al. 1997). 
Previous studies have suggested that the activation of PI3K, which phosphorylates 
and activates protein kinase B (PKB, also known as Akt), is required for protein 
synthesis in both the basal state and in response to insulin or hypertrophic 
stimulation in heart muscle cells (Schluter et al. 1998). However, more recent data 
suggest that signalling via Ras, MEK/Erk  as well as mTOR is required for activation 
of protein synthesis in response to certain hypertrophic agents (Proud 2004). In fact, 
our group already showed that PE activates ERK1/2 but not PKB in ARVC, and that 
ERK1/2 signalling is required for the activation of protein synthesis by PE (Wang et 
al. 2001). 
To address whether PE activated PI-3 kinase signalling in ARVC, the 
phosphorylation of PKB was studied. Western blots using an antibody that 
specifically recognizes phospho-Ser
473 of PKB showed no detectable 
phosphorylation at this site in ARVC treated with PE with/without 4-SU up to 45 
min (Fig.3.5). Cell lysate from KB cells treated with insulin for 10 min was used as 
positive control for PKB antibody. Here I showed that neither PE nor 4-SU activates 
PKB, and thus that the activation of Erk1/2 does not due to activation of PI3K-PKB 
pathway. 
Hence, 4-SU does not affect the response of ARVC to PE in term of the 
activation of the mTORC1 or MEK/ERK signalling pathways. 
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Figure 3.5: 4-SU labelling alone does not affect mTORC1 or MEK/ERK 
signalling pathways in ARVC with PE stimulation. ARVC were pre-incubated in 
medium containing or lacking 4SU for 30min and then10 µ M PE was added for the 
indicated times (minutes). After lysis, equal amounts of lysate (by protein) were 
analysed by SDS-PAGE and immunoblot using the indicated antibodies. 
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3.3.2   4-thiouridine is incorporated into newly synthesized rRNA in 
cardiomyocytes 
To verify whether 4-thiouridine is incorporated only into newly synthesized 
rRNA in ARVC, actinomycin D was used to inhibit general transcription.  
To address whether actinomycin D affect ARVC response to PE, I incubated 
cardiomyocytes with PE 10M or insulin 10nM for 20 hours, and then incubated 
them with actinomycin D 2 μg/ml for 3h. At such concentration (2 μg/ml), 
actinomycin D inhibits all Pol I, Pol II and Pol III activities. Western blot analysis 
showed that S6K1 is activated by both PE and insulin, and such activation is not 
affected by actinomycin D treatment (Fig.3.6A). 
Next new rRNA synthesis was studied using actinomycin D. In neonatal 
cardiomyocytes, activation of Pol III 5S rRNA transcription has been shown to be a 
slow process (Goodfellow et al. 2006). Therefore, to assure both Pol I and Pol III 
rRNA synthesis is boosted by PE, ARVC were treated with 10M PE for 20h prior 
to 4-SU addition with or without actinomycin D. Without actinomycin D, the data 
clearly showed 4-SU is incorporated into new 18S, β-actin and 5S RNAs which are 
made by Pol I, Pol II and Pol III accordingly (Fig 3.6B). As expected, the amount of 
4-SU labelled RNA was enhanced by PE, which indicates that this hypertrophic 
agent activates all three polymerases. Importantly, the labelling of 18S, β-actin and 
5S RNA were completely blocked by 2 μg/ml actinomycin D treatment (Fig.3.6B).  
These data confirm that only newly-synthesized RNA is detected by 4-SU 
labelling method in adult rat ventricular cardiomyocytes. 
 
3.3.3   Phenylephrine activates new rRNA synthesis in ARVC  
  After confirming that only newly-synthesized RNA is labelled using the 4-
SU method, this method was then applied to study how rapidly the hypertrophic 
agent activates the synthesis of new RNA. 
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Figure 3.6: 4-thiouridine is incorporated only into newly synthesized rRNA in 
cardiomyocytes. Isolated ARVC were cultured overnight as described in the 
Methods. A) Cardiomyocytes were then treated with PE 10M or insulin 10nM for 
20 hours, and were cultured with actinomycin D 2 μg/ml for 3h. B) ARVC were 
treated with 10 µM PE and labelled with 4SU as indicated, actinomycin D being 
added where shown. Samples were processed for isolation of RNA and quantitation 
of new 4SU-labelled RNA by qPCR as described in the Methods. Data are 
normalised to total 18S rRNA with the levels in untreated cells being set as unity. 
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As discussed previously, the activation of rRNA transcription in 
cardiomyocytes is a slow process. Earlier data show that PE stimulates the synthesis 
of new 18S rRNA, β-actin mRNA and 5S rRNA by 24h (Fig.3.6B). It was of interest 
to test whether new rRNA can be detected at shorter time of PE treatment. Therefore, 
ARVC were incubated with PE for 9 or 21 h before the addition of 4-SU.  
By 12h PE treatment, it increased 18S rRNA labelling by about 25%; 
however, no significant increases in the labelling of 5S rRNA or β-actin were 
observed (Fig.3.7). By 24h PE treatment, much greater increases in labelling of all 
three new RNAs were observed. Noticeably, 18S rRNA is made from a common 
precursor which is also processed into 28S and 5.8S rRNA. The large increase in 
18S rRNA labelling also represents stimulation synthesis of 28S and 5.8S rRNA by 
PE. Hence, PE increase all transcripts involved in making ribosomes. Therefore, PE 
does substantially enhance rRNA synthesis/ribosome biogenesis in ARVC by 24h 
and 24h was chosen as the time-point for further experiments.  
To confirm that PE does increase ribosome biogenesis in ARVC by 24h, the 
effect of PE on cell size was studied. Earlier studies have shown that an accelerated 
rate of rRNA synthesis is the early event in cardiac hypertrophy (Chua et al. 1987; 
Morgan et al. 1987; McDermott et al. 1989). As expected, PE treatment for 24h 
induced the growth of ARVC (Fig.3.8).  
 
3.4 Discussion 
Cardiac hypertrophy (CH) is a potentially fatal disease condition by 
excessive growth of heart muscle cells (cardiomyocytes). A major process driving 
their growth is faster protein synthesis which requires increased cellular translational 
capacity, including ribosome number. mTORC1 plays a key role in CH: inhibiting it 
with rapamycin can prevent or even reverse hypertrophy (Hannan et al. 2003; Shioi 
et al. 2003; McMullen et al. 2004; Wang et al. 2008). mTORC1 also controls protein 
synthesis in adult rat ventricular cardiomyocytes (ARVC) (Wang et al. 2001; Wang 
and Proud 2002; Proud 2004). Increased ribosome levels are a key feature of CH  
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Figure 3.7: PE enhances new rRNA synthesis in ARVC. ARVC were treated with 
10 µM PE and labelled with 4SU as indicated. Samples were processed for isolation 
of RNA and quantitation of new 4SU-labelled RNA by qPCR as described in the 
Methods. Data are normalised to total 18S rRNA with the levels in untreated cells 
being set as unity. Data are presented as mean ± SEM ( n = 3). 
 
 
 
 
Figure 3.8 PE induces the growth of cardiomyocytes. Isolated ARVC were 
cultured overnight as described in the Methods. Cardiomyocytes were then treated 
with PE 10M or distilled H2O for 24h. Representative pictures of cells under 
control condition or after PE treatment. 
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(Morgan et al. 1985; Chua et al. 1987). Therefore, it is essential to investigate the 
regulation of the synthesis of rRNA in response to hypertrophic stimuli in ARVCs.  
 Here, a novel method has been developed to monitor only newly synthesised 
rRNAs in mammalian cells using labelling with 4-SU. The 4-SU labelling method 
was established and tested in HeLa and ARVC cells. My data show that 4-SU does 
not affect the mTORC1 or ERK pathway. Moreover, 4-SU is only incorporated into 
new rRNAs, as shown by the complete inhibition of labelling caused by high doses 
of actinomycin D, also low doses of actinomycin D for Pol I. Hence, the 4-SU 
method can be used to determine the synthesis rate of rRNAs upon different 
treatments in mammalian cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 87 
 
 
 
 
 
 
Chapter 4 
 
 mTORC1 regulates the transcription and decay of 
rRNA in mammalian cells 
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4.1 Introduction 
 
Ribosome biogenesis is essential for cells to sustain protein synthesis 
capacity and cell size, especially during cell growth and proliferation. This complex 
process is highly regulated in mammalian cells and requires a high degree of 
coordination among all three RNA polymerases, many additional proteins and small 
RNAs (Mayer and Grummt 2006). Three of the rRNAs, 28S, 18S and 5.8S, are 
transcribed as a single 47S precursor by RNA polymerase I (Pol I) in the nucleolus, 
which is then processed through multiple steps to generate the mature rRNAs 
(Fig.1.1&1.5). Ribosomal protein mRNAs are transcribed by Pol II, while Pol III is 
responsible for the transcription of 5S rRNA and tRNA.  Therefore, transcription of 
rRNAs and tRNA by Pol I and Pol III is essential to determine protein synthetic 
capacity and cell size. Indeed, in cancer cells, inactivation of tumor suppressors 
deregulates Pol I and Pol III , and has a great impact on the growth potential of 
tumors (White 2005).  
Signalling through the mammalian target of rapamycin complex 1, mTORC1, 
regulates many cellular processes involving in cell growth and cell division 
(Wullschleger et al. 2006).  Studies have shown that mTORC1 regulates ribosome 
biogenesis by promoting Pol I transcription and positively regulating the translation 
of ribosomal protein mRNAs (Mahajan 1994; Reiter et al. 2011). Studies in yeast 
shows TORC1 shuttles between the nucleus and the cytoplasm, and can directly bind 
to Pol I promoter, phosphorylate transcription factors, and thereby activate the 
transcription of rDNA (Powers and Walter 1999). However, it is not known whether 
mTORC1 behaves similarly in mammalian cells. It has been shown that mTORC1 
binds to the promoters of Pol I and Pol III transcribed genes in human cells in a 
rapamycin-sensitive manner (Tsang et al. 2010).  
Here, my data show that, in mammalian cells, rapamycin not only interferes 
the synthesis of rRNA, but also induces the decay of new rRNA, which demonstrates 
that mTORC1 is critical for controlling the expression of Pol I and Pol III dependent 
genes. I also show that 28S rRNA synthesis is affected by mutation of an rRNA 
processing factor, BOP1, which also interacts with mTORC1. The observations 
suggest that signalling through mTORC1 regulates ribosome biogenesis by 
controlling the transcription of rDNA and the processing of pre- rRNA. 
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4.2 mTORC1 signalling pathway is a key regulator of rRNA   
synthesis  
4.2.1 The signalling inhibitor, rapamycin, interferes with the uptake 
of the uridine uptake into HeLa cells  
As discussed previously, a non-radioactive labelling technique using 4-
thiouridine has been established to study synthesis of new rRNA molecules. This 
new approach has several advantages over earlier methods. The labelled RNA can be 
specifically purified and used to generate cDNA by reverse transcription. The cDNA 
can then be used as the template for quantitative real-time PCR (qRT-PCR) to 
measure any specific gene by using appropriate qPCR primers. However, as with any 
labelling approach applied in cells, one potential concern was that the signalling 
inhibitors may interfere with the uptake of the 4-SU into the cells, therefore, 
affecting the labelling of RNA indirectly. 
Rapamycin has long been shown to be a highly specific inhibitor of 
mTORC1 (Vezina et al. 1975), however at 100 nM, it also has been reported to 
interfere with nucleotides transport into human K562 cells (Huang et al. 2003). In 
order to minimize such effects, I tested a range of concentrations of rapamycin to 
inhibit mTORC1 signalling in HeLa cells. The phosphorylation of ribosomal protein 
S6 (RpS6) at Ser 240/244 was monitored as a readout of mTORC1 activation, as 
these residues are specific phosphorylated by the S6 kinases which are the 
downstream targets of mTORC1 (Fingar et al. 2002).  
At 1 nM, rapamycin partially inhibited RpS6 phosphorylation; however it 
requires at least 5 nM rapamycin to achieve maximal inhibition (Fig.4.1A). Even at 
5 nM, rapamycin inhibited the uptake of radio-labeled [
3H]uridine into HeLa cells by 
about 50%. Nevertheless, at higher concentrations, 100 nM rapamycin (the 
concentration often used to treat cells) inhibited it to a similar extent (Fig.4.1B). 
Therefore, 100 nM rapamycin was used for the following experiments. 
Since rapamycin does interfere with 4-SU uptake, this needs to be taken 
account into measuring new RNA synthesis using this labelling method.  
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B） 
      
     
Figure 4.1 Rapamycin interferes with the uptake of the uridine uptake into 
HeLa cells (A) HeLa cells maintained in medium containing serum were treated 
with or without rapamycin at the indicated concentrations for 90 min. Levels of 
phosphorylated and total RpS6 were analyzed by western blot; data are typical of 
three separate experiments. (B) Uridine uptake was measured after 20s incubation 
with [
3H]uridine in the absence or presence of 5 nM rapamycin (added 90 min prior 
to the uptake assay). The radioactivity was determined by scintillation counting, 
normalized to the total protein level for that sample and plotted as a percentage of 
the uptake into non-treated HeLa cells. Data are presented as mean ±  SEM (n = 3) 
with the control set as 1. 
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4.2.2 The synthesis of rRNA is rapamycin-sensitive in HeLa cells  
The role of specific signalling pathways in the regulation of rRNA synthesis 
was then studied using the 4-SU labelling method. The effects of rapamycin, a 
specific mTORC1 inhibitor, on the incorporation of 4-SU into newly synthesized 
rRNAs was initially examined. Such effects were tested at two different 
concentrations of rapamycin, 5 nM and 100 nM, the latter concentration being the 
one used previously to study mTORC1 signalling. It should be noted that these 
treatment times of rapamycin, up to 90 min, are too short to affect cell-cycle. Hence, 
the links between rRNA transcription and the cell cycle can be ignored. 
Consistent with earlier data (Fig.3.4) showing that 4-SU can incorporated into 
new RNAs in short time, here, the data show that 45 min is sufficient for 
incorporation 4-SU into new RNAs synthesized by Pol I, Pol II and Pol III (Fig.4.2 
& 4.3 control 45’ panels). The data also show that rapamycin inhibited the labelling 
of 18S rRNA at 45 min, implying that RNA polymerase I is positively regulated by 
mTORC1 (Fig.4.2A & 4.3A). Similar results were observed for 5S rRNA which is 
transcribed by Pol III and for the house-keeping gene, β-actin, which is transcribed 
by Pol II (Fig.4.2B & 4.3B, C). Moreover, the reduced labelling level at 45 min 
reflects, at least in part, the impaired uptake of 4-SU into the cells.  
Interestingly, treatment with rapamycin for longer times, up to 90min, caused a 
further decrease in newly-synthesized 18S and 5S rRNAs (Fig.4.2 & 4.3). Thus, the 
prolonged rapamycin treatment caused the amount of labelled new RNA to decrease 
significantly relative to earlier times. It should be noted that, although the reduced 
level of labeling at 45 min is probably mainly due to the interfered uptake of 4-SU 
into the cells, the further decrease in newly synthesized labelled rRNA at 90 min 
indicates rapamycin strongly inhibits new rRNA synthesis besides the uptake 
impairment. Similar data were obtained using rapamycin at 5 nM or 100 nM. This 
surprising effect could be due to the decay of new rRNA over time. Therefore, 
inhibition of mTORC1 not only blocks new rRNA synthesis, but also, unexpectedly, 
seems to induce the degradation of newly synthesized rRNA. Further pulse-chase 
experiment is required to test whether rapamycin also affects new rRNA stability. 
Prolonged inhibition of mTORC1 had the same effect on β-actin mRNA synthesis 
(Fig.4.3 C).  93 
 
A) 
 
 
 
B) 
 
Figure 4.2: Rapamycin inhibits the accumulation of new rRNA.  HeLa cells were 
pre-incubated with rapamycin (5 nM) for 15 min before the addition of 4-SU. Total 
RNA was extracted after 45 min or 90 min after addition of 4-SU and processed to 
measure levels of labelled rRNA species as described in the Materials and Methods. 
Purified labelled rRNA levels were compared to untreated control ones, data being 
normalized to the total level of 18 S rRNA. Data are presented as mean ±  SEM (n = 3). 
The times given below each column indicate the period of 4-SU labelling. Con45 is 
defined as control 45 min, and Rapa is rapamycin 45 min. Control is set to 1. 
 
 
 94 
 
The data imply that inhibition of mTORC1 may also cause decay of RNAs 
made by Pol I, Pol II and Pol III rRNAs. 4-SU labelling therefore provided the extra 
information to study the new rRNA decay that is not uncovered using traditional 
method. HeLa cells were also incubated with PP242, which inhibits both mTORC1 
and mTORC2, and a similar profile was observed (data not shown). The data 
confirm that mTORC1 signalling regulates the synthesis of 18S and 5S rRNAs. Also, 
it suggests that signalling through mTORC1 positively regulates ribosomal protein 
synthesis at transcriptional level. 
 
4.2.3 Rapamycin induces the decay of new rRNA molecules  
To determine more directly whether inhibiting mTORC1 induces the decay 
of new rRNAs, the 4-SU labelling method was applied to monitor the decay rate of 
new 18S and 5S over time. Another advantage of the 4-SU-labeling approach is that 
it can readily be configured as a pulse-chase experiment.  HeLa cells were pre-
treated with 4-SU 100 µM for 4 h to label sufficient amount of newly synthesized 
rRNA, and excess 4-TU was then removed by washing the cells with pre-warmed 
1xPBS. The incubation was continued with fresh medium lacking 4-SU. Total RNA 
was extracted at 45min and 90min with or without rapamycin 100 nmol/L treatment 
(Fig. 4.4 A). It should be noted that for pulse-chase experiments to study RNA 
stability, interference by rapamycin with nucleoside uptake is not an issue, as 
rapamycin is only added into the medium after removing 4-SU labelling. 
Using this method, no loss of new 18 S or 5S rRNA was observed after the 
end of the pulse in control cells (Fig. 4.4 A&B). On the other hand, rapamycin 
decreased the labelling of new 18S rRNA (Fig. 4.4 A). With longer rapamycin 
treatment, the amount of remaining labelled 18S fails to < 50%. Since 18S rRNA is 
derived from a single 47S precursor that also contains the 28S rRNA, it is likely that 
rapamycin might also induce decay of new 28S rRNA. Using the same approach, we 
did indeed observe that rapamycin caused the loss of newly made (4-SU-labeled) 
28S rRNA (Fig.4.4 C). Taken together, these data suggest that rapamycin might 
interfere with the downstream processing of new rRNA molecules resulting in their 
degradation.  95 
 
A) 
 
B) 
 
C) 
 
Figure 4.3: The synthesis of rRNAs is rapamycin-sensitive. HeLa cells were pre-
incubated with rapamycin 100 nM, for 15 min before the addition of 4-SU. Total 
RNA was extracted 45 min or 90 min after addition of 4-SU and processed to 
measure levels of labelled rRNA species as described in the ‘Materials and Methods’ 
section. Levels of purified labelled rRNA were compared with those in untreated 
controls that had been labelled for 45 min, data being normalized to the total level of 
18 S rRNA. Data are presented as mean ±  SEM (n = 3). The times given below each 
column indicate the period of 4-SU labelling. Con45 is defined as control 45 min, 
and Rapa is rapamycin 45 min.  96 
 
Interestingly, rapamycin also induced the decay of newly made 5S rRNA 
(Fig. 4.4 B). Since 5S rRNA does not require processing, such effect suggests that 
the inhibition by rapamycin might interrupt the overall process of ribosome assembly, 
therefore, impairing 5S rRNA stability. This may also explain the observation in 
Chapter 3 that low concentrations of actinomycin D partially repress the 
accumulation of new 4-SU-lablled 5S rRNA (Fig. 3.3C), even though at this 
concentration this compound has little direct inhibitory effect on Pol III (Puvion-
Dutilleul et al. 1992).  
The data clearly indicate that mTORC1 has a significant effect on Pol I and Pol 
III- mediated rRNA synthesis. A recent published research showed that mTORC1 
also regulates the processing of new rRNAs in vivo (Iadevaia et al. 2012). Hence, 
rapamycin impairs general ribosome assembly, and then induce the decay of existing 
rRNAs.  
 
4.2.4 Over-expression of S6K1 does not rescue inhibition of rRNA 
synthesis caused by rapamycin or PP242 
p70 S6 kinase 1 (S6K1), which lies downstream of mTORC1 and is known to 
regulate cell and organism size, phosphorylates ribosomal protein S6. In Drosophila, 
knocking out the ds6k gene results a severe body size reduction due to smaller cell 
size (Montagne et al. 1999). This may reflect a role for S6K1 in promoting ribosome 
biogenesis. It was once thought to regulate the translation of 5’-TOP (tract of 
pyrimidine) mRNAs which encode ribosomal proteins (Jefferies et al. 1997; Pende et 
al. 2004; Ruvinsky and Meyuhas 2006). This is not believed anymore; however, 
S6K1 is reported to positively regulate Pol I, and therefore rRNA synthesis (Hannan 
et al. 2003). Hence, activation of S6K1 is expected to up regulate ribosomal rRNA 
synthesis and increase the cell’s translational capacity.  
mTORC1 plays an essential role in the activation of S6K1. The 
immunosuppressant rapamycin inhibits mTORC1 and completely inhibits activation 
of S6K1 (Burnett et al. 1998). This effect could explain the ability of rapamycin to 
inhibit Pol I-mediated rRNA synthesis. It is therefore important to address whether  97 
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Figure 4.4: Inhibition of mTORC1 by rapamycin promotes decay of newly 
synthesized rRNA. HeLa cells were pre-incubated with 4-SU for 4 h. After washing 
with 1 ×  PBS to remove excess 4-SU and transfer to fresh medium, rapamycin 
(100 nM) was added. RNA was extracted and samples were processed as for Panels 
A and B in Figure 4.3. Data are presented and expressed as described in the 
‘Materials and Methods’ section, in this case being normalized to the 45 min control 
and given as mean ±  SEM (n = 3).  98 
 
expressing a rapamycin-resistant version of S6K1 can overcome the inhibition of 
rRNA synthesis that is caused by blocking mTORC1 signalling.  
For this, HeLa cells were transfected with either empty vector or constitutively 
active S6K1 (S6K1*-T389E-D3E) DNA using lipofectamine 2000 (Invitrogen). To 
test the S6K1* activity, the transfected HeLa cells were treated with PMA 1μM 
and/or rapamycin 100 nM for 45 min, and the phosphorylation of S6 was monitored 
as a read-out of intracellular S6K1 activity. As shown in Figure 4.4 A, PMA, a 
specific PKC activator, activates S6K1 which increases the phosphorylation of S6 at 
Ser240/244. Rapamycin treatment was able to inhibit this effect, showing it is 
mediated via mTORC1 and the S6Ks. In cells expressing S6K1*, the basal 
phosphorylation of S6 was increased and rapamycin failed to inhibit this, confirming 
that the levels of S6K1* expressed are enough to overcome the effect of rapamycin 
(Fig. 4.5 A).  
To assess whether over-expression S6K1 can rescue the inhibition of rRNA 
synthesis caused by mTORC1 inhibition, HeLa cells expressing S6K1* were treated 
with rapamycin or PP242. 4-SU was added to the media to label newly-synthesized 
rRNAs and the relative amounts of new rRNAs were measured using RT-qPCR. The 
level of new 18S rRNA was inhibited over 50% by rapamycin (Fig. 4.5 B). 
Noticeably, in S6K1*-transfected cells, the synthesis of new 18S rRNA was still 
inhibited by 57%. Similarly, 5S rRNA synthesis was greatly blocked by rapamycin, 
and overexpression of rapamycin-resistant S6K1* failed to rescue the inhibition (Fig. 
4.4 C).  
The data indicates that S6K1 alone is not sufficient to overcome the inhibition 
of rRNA synthesis caused by rapamycin or PP242. Thus, either S6K1 is not involved 
in the control of Pol I transcription or at least is not the only mTORC1-regulated 
component involved in this. 
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Figure 4.5: Over-expression of S6K1 does not rescue inhibition of rRNA 
synthesis by rapamycin or PP242. A) Lipofectamine 2000 (Invitrogen) was used to 
transfect empty vector or constitutively active S6K1* into HeLa cells. The cells were 
serum-starved overnight, and then were treated with PMA (1μM) for 45min and/or 
rapamycin (100nM). (B,C) HeLa cells transfected with empty vector or S6K1* were 
treated with rapamycin (100nM) or PP242 (1μM) for 2h. 4-SU was added to the 
medium 15 min later. Total RNAs were extracted and 4-SU labelled RNAs were 
purified. The levels of newly synthesized 18S rRNA and 5S rRNA were measured 
by RT-qPCR as described in ‘Materials and Methods’.  
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4.2.5 Inhibiting mTORC1 does not induce disruption of the 
nucleolus 
One possible explanation why blocking mTORC1 induces degradation of 
new rRNAs is that rapamycin blocks rRNA transcription and processing. In fact, my 
colleague, Dr. Valentina Iadevaia, has shown that mTORC1 regulate pre-rRNA 
processing in human cells (Iadevaia et al. 2012). The nucleolus is the site of rRNA 
transcription, rRNA processing and ribosome assembly. Blocking of RNA 
processing cause the disruption of nucleoli and leads to nuclear stress (Olson and 
Dundr 2005). Thus, rapamycin might interfere with rRNA processing by inducing 
nucleolus disruption. 
To further understand the influence of mTORC1 inhibition on nucleolar 
morphology and protein localisation, HeLa and mouse embryonic fibroblast (MEF) 
cells were used in immunofluorescence experiments to study the localization of 
nucleophosmin (B23) and BOP1 (block of proliferation 1). Nucleophosmin/B23 is a 
major nucleolar protein associated with nuclear matrix. It shuttles from nucleoli to 
nucleoplasm under nuclear stress caused by inhibition of ribosome biogenesis (Yun 
et al. 2003). Therefore, B23 serves as a good maker for nucleolar disruption by 
blocking rRNA synthesis. BOP1 is a nucleolar protein which is required for rRNA 
processing (Strezoska et al. 2000). TO-PRO3 (4-[3-(3-methyl-2(3H)-
benzothiazolylidene)-1-propenyl]-1-[3-(trimethylammonio) propyl]-, diiodide) was 
used to stain DNA and thus the nuclei; nucleoli are visible as darker areas within 
nuclei (yellow arrowheads, Fig. 4.6 A). 
HeLa cells were cultured in serum and treated with actinomycin D (2 μg/ml) 
or rapamycin (100 nM) for 2 h at 37˚C. At this concentration, actinomycin D only 
inhibits Pol I, and does not cause complete loss of nucleoli as they are still visible 
against the background nuclear staining. However, it did cause marked redistribution 
of BOP1 and B23 away from nucleoli, as they appeared spread across the 
nucleoplasm (Fig. 4.6 A). On the other hand, rapamycin treatment caused a certain 
amount of B23 to migrate from nucleoli to nucleoplasm, as nucleoli appeared 
slightly more diffuse than in control cells. However, compared to the strong 
disruption of nucleoli observed after actinomycin D treatment, the effect by  
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Figure 4.6: Rapamycin treatment induces a partial redistribution of B23 but 
not of BOP1 into the nucleoplasm. A) HeLa cells were treated for 2 h with 
rapamycin or actinomycin D. B) MEF cells were treated with actinomycin D 2 μg/ml 
or rapamycin 100nmol/L for 6 h.The cells were then fixed, permeabilized and 
analyzed by immunofluorescence with monoclonal anti-B23 (red) or anti-BOP1 
(green). Cell nuclei were visualized by TO-PRO3 staining. Yellow arrowheads 
indicate the darker intranuclear regions corresponding to nucleoli.  
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rapamycin is subtle (Fig. 4.6 A). Overall, it seems that unlike actinomycin D, 
rapamycin has, at most, only a modest effect on overall nucleolar integrity. 
Moreover, in another type of cells, MEFs, incubation with rapamycin (100 
nM) up to 6 h did not cause B23 protein re-localization (Fig. 4.6 B). However, the 
total amount of B23 in the nucleoplasm appeared to decrease greatly with 
actinomycin D and rapamycin treatment, which might suggest that blocking 
mTORC1 impairs B23 stability. The data show that inhibition of mTORC1 has very 
subtle or no effect on TO-PRO3 distribution as well (Fig.4.6 B).  
Taken together, the mechanism by which mTORC1 inhibition induces decay 
of new rRNA remains unclear, but is not due to a gross change in nucleolar 
morphology. 
 
4.3 Effects of inducible expression of BOP1Δ on ribosomal RNA 
processing 
4.3.1 Transfection of BOP1 Δ mutant in HEK293 cells 
Pol I generates a single 47S pre-rRNA, which is then processed in nucleolus 
through several steps to produce the mature 5.8S, 18S and 28S rRNAs (Fig. 4.7). 
Unlike Pol I, Pol III generates 5S rRNA which requires no processing. Pol I 
processing is better understood in yeast than in higher eukaryotes, and it has been 
shown that ERB1, the yeast homolog of mammalian BOP1, is an essential gene 
required for processing of the 25S and 5.8S ribosomal RNAs (Pestov et al. 2001). 
BOP1 (Block of Proliferation 1) is a key component of the PeBoW complex which is 
required for maturation of the 60S ribosomal subunit (Lapik et al. 2004). Studies 
have shown that BOP1 plays a novel role in ribosome biogenesis and cell 
proliferation in mammalian cells (Lapik et al. 2004; Holzel et al. 2005). In fact, 
expressing a truncated form of BOP1 (BOP1Δ) impairs the processing of the 32S 
pre-rRNA to form the mature 28S and 5.8S rRNAs without affecting 18S rRNA 
processing (Fig.4.7;(Strezoska et al. 2000)).  
My colleague, Dr. Valentina Iadevaia, has previously shown that rapamycin 
interferes with the processing of pre-rRNAs (Iadevaia et al. 2012). However, the  105 
 
 
 
 
Figure 4.7: The schematic diagram of BOP1Δ impairing 32S pre-rRNA 
processing pathways. Structure of the primary 47S rRNA transcript contains two 
internal transcriber spacers (ITS1 and ITS2) and two external transcribed spacers 
(5’ETS and 3’ ETS2). The 47S pre-rRNA is processed through intermediate 
precursors to mature 18S, 28S and 5.8S rRNAs. BOP1Δ is indicated as impairing the 
processing of the 32S pre-rRNA to form the mature 28S and 5.8S rRNAs without 
affecting 18S rRNA processing. 
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mechanism remains unclear that how mTORC1 involves into this process. To further 
investigate the link between mTORC1 and the processing of pre-rRNA, BOP1Δ 
need to be expressed in the cells first. A GST-tagged mutant form of BOP1 which 
lacks the first 264 amino acids (GST-BOP1Δ) was expressed in human embryonic 
kidney 293 (HEK293) cells (Fig. 4.8). 
As shown in Figure 4.8B, samples of lysate from control and transfected 
HEK293 cells were analyzed by western blot using an anti-BOP1 antibody. BOP1Δ, 
which lacks the first 264 amino acids, migrates faster than wild type BOP1 (Fig.4.8 
B). As GST-BOP1Δ is less stable than GST-BOP, some of GST-BOP1Δ degraded 
and migrated together with GST (Fig.4.8 B). 
After successfully expressing BOP1Δ in HEK293 cells, another colleague, Dr. 
Rui Liu, found that, in vivo and in vitro, mTORC1 can directly interact with BOP1 
which play an important role in the 32S rRNA processing (Fig. 4.7), and that the 
truncated version of BOP1 (BOP1Δ) can still interact with mTORC1 in vitro, but not 
in vivo, suggesting that mTORC1 may be involved in pre-rRNA processing by 
directly interacting with BOP1.  
 
 
4.3.2 Inducible expression of BOP1Δ enhances p21 transcription 
As reported for mouse cells (Strezoska et al. 2002), transiently expressing 
BOP1Δ interferes with processing of 32S pre-rRNA and induce a reversible, p53-
dependent cell cycle arrest. To overcome the limitations of transient transfection and 
to avoid the possibility that GST may affect BOP1 interaction with mTORC1, a 
stable cell line in which BOP1Δ can be expressed stably in an inducible manner was 
used instead. BOP1Δ protein will only be made in the cells under doxycycline 
induction. This cell line was generated by Dr. Rui Liu and Dr. Valentina Iadevaia.  
To investigate the link between BOP1Δ and rRNA processing, the novel 4-
SU labelling method was been employed to tag newly synthesised rRNA to study 
mature rRNA synthesis.  One thing to note is that expressing BOP1Δ did not affect 
uptake of uridine into the cells (data not shown).  As expected, a marked decrease 
(over 50%) in the accumulation of labelled 28S rRNA can be observed in cells  
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Figure 4.8: Transfection of BOP1 Δ mutant in HEK293 cells. A) Schematic 
diagram of BOP1 structure. BOP1Δ lacks the first 264 amino acids. B) HEK293 
cells were transfected with an empty vector or a vector encoding GST-BOP1 or 
GST-BOP1Δ where indicated. Samples of the lysates were analysed by SDS-
PAGE/western blot as described in ‘Materials and Methods’. 
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expressing BOP1Δ (Fig. 4.9 A). The data show that BOP1Δ does interfere with the 
processing of 32S pre-rRNA, while not affecting new 18S maturation (Fig.4.9 C)  
To examine the cellular response to interference with rRNA processing and 
thus ribosome biogenesis, p21/WAF1was studied. p21 is known to inhibit cell cycle 
at G1 stage. Induction of BOP1Δ greatly enhanced p21 transcription, (Fig. 4.9 B). 
This suggests that expressing BOP1Δ interferes with the production of mature 28S 
rRNA, and may induce ribosomal stress. The inducible expression of BOP1Δ has 
similar effects to the reported for transient expression of BOP1Δ in mouse cells 
(Strezoska et al. 2002). 
Taken together, these data confirm that expressing BOP1Δ interferes with 
rRNA processing, and induces p53. Since mTORC1 can directly bind to BOP1, 
mTORC1 may regulate Pol I processing in part by activating BOP1 to promote the 
production of new rRNA. 
 
4.4 Discussion and future aims 
The 4-SU labelling technique has been used here to monitor new rRNA 
synthesis in HeLa and HEK 293cells. The observation that rapamycin impairs 
uridine uptake suggests that mTORC1 signalling may promote the transport of 
nucleosides into mammalian cells. This effect would be consistent with a role of 
mTORC1 signalling in ribosome biogenesis, as nucleosides are essential precursors 
for RNA synthesis and thus ribosome production. In fact, PP242, another mTOR 
inhibitor, also impairs 4-SU uptake (data not shown). However, more work is 
required to verify whether this effect confirms a role for mTORC1 signalling or 
reflects an indirect effect of this compound. 
Furthermore, my data show that rapamycin treatment blocks the synthesis of 
new 18S and 5S rRNAs in HeLa cells. Rapamycin inhibited the labelling of newly 
synthesized 18S or 5S rRNA at 45 min and completely inhibited further 
incorporation up to 90 min of labelling. This is consistent with earlier studies in other 
cell-types (Mayer et al. 2004). However, unexpectedly, rapamycin also induced the 
decay of new rRNAs. Interestingly, this is not associated with a gross change in  
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Figure 4.9: BOP1Δ mutant induces ribosomal stress gene (p21) synthesis HEK 
293 cells were treated doxocyclin for 48h to induce BOP1Δ expression. Total RNA 
was extracted 4 h after addition of 4-SU and processed to measure levels of labelled 
RNA species as described in the ‘Materials and Methods’ section. Levels of purified 
labelled RNA were compared with those in un-stimulated samples, data being 
normalized to the total level of 18 S rRNA. A) Effect of BOP1Δ mutant on new 28S 
rRNA synthesis was analysis. Data are presented as mean ±  SEM (n = 3).  B) The 
transcription of p21 was measured by RT-qPCR. Data are presented as mean ±  SEM 
(n = 3). C) Effect of BOP1Δ on new 18S rRNA was analysed.  
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nucleolar morphology. One possible explanation is that rapamycin might impair the 
downstream rRNA processing, and the accumulation of unprocessed rRNA resulted 
in their degradation. My colleague, Dr. Valentina Iadevaia, has shown that 
rapamycin does indeed interfere with rRNA processing (Iadevaia et al. 2012). To 
investigate the mechanisms that link the mTORC1 pathway to the pre-rRNA 
processing, a truncated form of BOP1, a protein that is required for 32S pre-rRNA 
processing, was expressed in HEK293 cells. As expected, expression of BOP1Δ 
blocked new 28S rRNA synthesis. Thus, BOP1Δ interferes with the production of 
mature rRNAs, and thus with ribosome biogenesis. The expression of BOP1Δ also 
enhanced the transcription of p21, a gene activated by p53, which is in turn stabilized 
in response to ribosomal stress. These are consistent with a reported study in mouse 
cells that transient expression of BOP1Δ impairs multiple steps in 32S pre-rRNA 
processing and blocks cell cycle progression in a p53-dependent manner (Strezoska 
et al. 2002). Another colleague, Dr. Rui Liu, showed that BOP1 directly interacts 
with mTORC1 component raptor, and that its phosphorylation is regulated by 
mTORC1 signalling. Taken together, these finding suggest that upon ribosomal 
stress, mTORC1 impairs pre-rRNA processing via targeting/phosphorylating BOP1. 
Further work is required to investigate the underlying mechanism. 
As the 4-SU labelling method has been successfully applied in HeLa and 
HEK293 cells, this technique was next employed to study ribosomal rRNA synthesis 
in adult rat ventricular cardiomyocytes (ARVC). Increased ribosome levels are a key 
feature of cardiac hypertrophy (CH). Therefore, it is essential to investigate the 
signalling event that regulates the synthesis of rRNA in response to hypertrophic 
stimulation in ARVCs. It also remains important to characterize the significance of 
the mTORC1 pathway in regulating cardiac hypertrophy. Furthermore, the 4-SU 
labelling method can be also applied to study the degradation rate of new rRNAs in 
ARVCs. It is important to study how rapamycin affects rRNA decay, which may be 
linked to rRNA processing. The data will provide new information on the control of 
ribosomal rRNA turnover. 
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The Control of rRNA synthesis in ARVCs 
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5.1 Introduction 
  Adult heart muscle cells are considered as non-dividing cells as they 
withdraw from the cell cycle irreversibly soon after birth. In response to high 
demand, the growth of heart occurs through hypertrophy in which the volume of 
heart increases due to the enlargement of cardiomyocytes, rather than increase of the 
cell number. In adult cardiomyocytes, hypertrophic agents such as phenylephrine 
(PE) strongly activate protein synthesis and lead to heart cell growth (Hannan et al. 
2003).  
It was previously shown that hypertrophic agent PE elicits an acute activation 
of protein synthesis in ARVC, which is largely blocked by rapamycin (Wang and 
Proud 2002). This indicates a key role for signalling through mTORC1 in activating 
protein synthesis. The faster protein synthesis is dependent on an increase of 
ribosomal capacity (Morgan et al. 1985). Indeed, enlargement of cells requires 
increased ribosome biogenesis. Early studies demonstrated that increased synthesis 
of ribosomes, e.g., ribosomal RNAs, is an early event in hypertrophying rat heart 
(Morgan et al. 1985; Chua et al. 1987; Morgan et al. 1987). Cardiac hypertrophy 
(CH) is a major risk factor for heart failure. Therefore, it is important to understand 
the mechanisms that how hypertrophic agents which cause the overgrowth of heart 
muscle increase ribosome production. 
Production of ribosomes is a highly regulated process which involves the 
synthesis of four different ribosomal RNAs by three classes of nuclear RNA 
polymerases (Mayer and Grummt 2006). A single precursor is made in the nucleolus 
by RNA polymerase I (Pol I), and is further processed to generate the mature 5.8S, 
18S and 28S rRNAs. Unlike the three larger rRNAs, the 5S rRNA is made in the 
nucleoplasm by Pol III. Studies have demonstrated that mTORC1 plays an essential 
role in controlling ribosome biogenesis in many settings (Mayer and Grummt 2006; 
Kantidakis et al. 2010; Michels et al. 2010; Tsang et al. 2010).  
   After developing the 4-SU labelling method in HeLa cells, this technique has 
been applied successfully in primary adult rat cardiomyocytes to quantify the 
synthesis of new rRNAs (see Chapter 3). Previously, the data showed that PE 
stimulates the synthesis of new 18S and 5S rRNAs, implying that it activates Pol I 
and Pol III (Figure 3.7). Here, this new non-radioactive method is employed to 116 
 
further study the signalling events that underlie the activation of ribosomal RNAs by 
PE in ARVC. It has shown that PE-activated rRNA synthesis is blocked by 
inhibition of the MEK/ERK/p90
RSKs pathway. However, surprisingly, rapamycin 
fails to block the stimulation of rRNA synthesis induced by PE, indicating that 
mTORC1 does not mediate rRNA production activated by PE. In fact, p90 ribosomal 
S6 kinases (p90
RSKs), kinases that are activated by ERK, appear to mediate the 
activation of rRNA synthesis. Indeed, inhibition of p90
RSKs not only blocks the 
stimulation of rRNA synthesis by PE but also induces the decay of new rRNA. The 
association of Pol I with the rRNA promoter is also interrupted by BI-D1870, a 
specific p90
RSKs inhibitor. Unlike in HeLa and other cells, in ARVC 
MEK/ERK/p90
RSK signalling, but not mTORC1, appears to play a major role 
regulating rRNA synthesis. 
 
5.2 Rapamycin does not prevent PE-induced rRNA synthesis 
5.2.1 Rapamycin interferes with the uptake of the uridine uptake 
into the heart muscle cells  
After having established and applied the 4-SU labelling method in HeLa cells, 
this technique was used in primary adult rat cardiomyocytes to study the regulation 
of rRNA metabolism. 4-SU enters the cells and then can be incorporated into new 
RNA molecules. However, as discussed previously (Chapter 4.2.1), the signalling 
inhibitors may interfere with the uptake of the 4-SU into the cells. Therefore, they 
may affect RNA synthesis by impairing relevant signalling activation (Fig.5.1A). 
Hence it is important to check whether rapamycin affects uridine uptake in ARVC. 
I therefore studied the uptake of [
3H] uridine into ARVC. A time-course 
experiment was performed to determine the incorporation rate of uridine into the 
new RNAs in ARVC, and a linear rate of uptake was observed up to 90 s (Fig.5.1B). 
However, the net rate of uridine uptake is not maintained linearly at longer times, as 
the nucleoside transporters are equilibrative, rather than concentrative (Baldwin et al. 
2004). Thus, the uptake of uridine into ARVC has to be studied only over short times, 
and 60 s was chosen as the time point for further studies. Previous study in HeLa  117 
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Figure 5.1: Effects of signalling rapamycin on the uptake of [
3H] uridine into 
ARVC. (A) A scheme showing the equilibrative nucleoside transporters (ENTs) in 
ARVC and that rapamycin interferes with the uptake of the uridine. (B) ARVC were 
incubated in medium to which 1 µCi/nmol [
3H]uridine was added at t=0. Cells were 
incubated further for the indicated times (s) before harvesting and processing for 
measurement of [
3H]uridine uptake as described in the Methods.  (C) ARVC were 
treated with different concentrations of rapamycin 30 min prior to stimulation with 
10 µM PE for a further 30 min. Samples of lysate were processed by SDS-
PAGE/immunoblot using the indicated antibodies. (D) [
3H]uridine uptake was 
measured as for Panel A, but cells were treated with 10 µM PE and/or 100 nM 
rapamycin for 16h prior to performing the uptake assay. Data are shown as mean 
± SEM (n =3).   
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cells indicated that rapamycin (100 nM) inhibited the uptake of radio-labeled [
3H] 
uridine (Fig. 4.1B). Firstly, what concentration of rapamycin is required to inhibit 
mTORC1 signalling completely in ARVC was verified.  Phosphorylation of S6 at 
Ser240/244 was monitored as a marker for activation of mTORC1 pathway, since 
these sites are specially phosphorylated by S6 kinases which are activated by 
mTORC1 (McMullen et al. 2004). Figure 5.1C indicated that even at 5 nM or 10 nM, 
rapamycin strongly inhibited the phosphorylation of S6. However, it required 100 
nM to reach the maximal inhibition of mTORC1. Consequently, 100 nM was used as 
general concentration for all other experiments. 
Rapamycin at 100 nM did interfere with the uptake of uridine into ARVC 
(Fig.5.1D). Thus, this effect needs to be take account into when studying new rRNA 
synthesis using the 4-SU labelling method. Importantly, the hypertrophic agent PE 
alone did not affect uridine uptake (Fig.5.1D), implying that PE activates rRNA 
synthesis without interfering with nucleoside transport. 
 
5.2.2 Rapamycin does not block PE-induced rRNA synthesis   
In adult rat cardiomyocytes, the Gq-coupled agonist phenylephrine activates 
protein synthesis and leads to cardiac hypertrophy. Wang and Proud (2002) 
previously showed that PE activates multiple translational regulators to increase 
global protein synthesis in an mTORC1-dependent manner in ARVCs. Rapamycin 
treatment which blocks mTORC1 activity can prevent or even reverse cardiac 
hypertrophy induced by PE in vivo (McMullen and Izumo 2004). Therefore, it is 
clear that mTORC1 plays an important role in regulating the overgrowth of heart 
muscle cells, implying it may play a role in increasing ribosome biogenesis. To 
further address the mechanism whereby mTORC1 regulates rRNA synthesis in 
ARVC, I tested if rapamycin can also block rRNA synthesis induced by PE. 
My data confirm that PE activates both Pol I and Pol III-transcribed rRNA 
synthesis by about 2 fold after overnight incubation (Fig.5.2A&B). Rapamycin 
decreased the ‘basal’ rate of rRNA accumulation in un-stimulated cells, reflecting 
rapamycin impairing uridine uptake observed in Fig.5.1D. However, it did not  
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Figure 5.2: Rapamycin does not inhibit the ability of phenylephrine to stimulate 
rRNA synthesis. (A, B) ARVC were treated with PE in the presence of 100 nM 
rapamycin (added 30 min prior to the PE) for 24h and labelled with 100 µM 4-SU 
for the final 4 h. Samples were processed for isolation of rRNA and quantitation of 
new 4SU-labelled 18S (A) or 5S (B) rRNA by qPCR as described in the Methods. 
Data are shown as mean ± SEM (n = 3). Numbers above the dotted arrows indicate 
the fold increase in labelling caused by PE in each pair of samples. 
 
 
 
 121 
 
reduce the increase of new 18S rRNA or 5S rRNA synthesis induced by PE (Fig. 
5.2A&B). Indeed, PE enhanced 4-SU labeling even more strongly in the presence of 
rapamycin. 
This seems a surprising result as rapamycin does inhibit hypertrophic growth 
of ARVC (Shioi et al. 2003). It suggests that although mTORC1 plays an essential 
role in regulating ribosome biogenesis at the level of protein synthesis, it is not a 
major regulator of rRNA synthesis in ARCV in response to PE.  
 
5.2.3 PP242 does not block the PE-induced new rRNA synthesis 
completely 
Nevertheless, rapamycin does not affect functions of mTORC2 or some 
functions of mTORC1 (Jacinto et al. 2004; Wang et al. 2005; Feldman et al. 2009). It 
was therefore still possible that mTOR does play a role. Hence, another compound, 
PP242, which unlike rapamycin, directly blocks the kinase activity of mTOR and 
effectively inhibits both mTORC1 and mTORC2 was used (Feldman et al. 2009).  
As expected, PE induced phosphorylation of S6 at both Ser235/236 and 
Ser240/244, indicating PE activates mTOR pathway (Fig.5.3A). As mTOR is 
inhibited by PP242 , such activation was blocked, while ERK phosphorylation 
induced by PE was not affected (Fig.5.3A). Like rapamycin, PP242 also impaired 
uridine uptake. Compared to control conditions, PP242 inhibited the uptake of radio-
labelled [
3H] uridine by 40% (Fig.5.3B). Thus, this effect of PP242 also needs to be 
take account when measuring new rRNA synthesis using the 4-SU labelling method. 
PE increased both 18S and 5S rRNA synthesis, and PP242 blocked the basal 
4-SU labelling accumulation in control condition (Fig.5.3C&D). It is likely due to 
interfering with 4-SU uptake. With PE treatment, PP242 partially, but not 
completely, inhibited the stimulation of 18S and 5S rRNA synthesis (Fig.5.3C&D), 
In the presence of PP242, PE was still able to promote rRNA transcription, 
especially for new 5S rRNA synthesis, indicating that although PE-induced rRNA 
transcription is rapamycin-insensitive, mTORC2 may be involved in particular in the 
control of Pol I. A new inhibitor which specifically inhibits mTORC2 is required to 
confirm this hypothesis.  122 
 
A） 
                   
 
B） 
      
C)                                                                         D) 
 
 123 
 
Figure 5.3: The mTOR inhibitor, PP242, partially inhibits PE-induced rRNA 
synthesis. (A) ARVC were treated with 10 µM PE for 15min and, where indicated, 1 
µM PP242 (added 30min prior to PE). Samples of lysate were processed by SDS-
PAGE/immunoblot using the indicated antibodies. (B) [3H]uridine uptake was 
measured as for Fig.5.1A, but cells were treated with PE and/or PP242 for 16h. 
p<0.05 
ψ vs. control. Data are shown as mean ±  SEM (n = 3). (C, D) ARVC were 
treated with 10 µM PE for 24h in the presence of 1 µM PP242 (added 30min prior to 
PE) where indicated and labelled with 100 µM 4SU for 4 h as indicated. Samples 
were processed for isolation of RNA and quantitation of new 4SU-labelled rRNA by 
qPCR as described in the Methods. Data are shown as mean ±  SEM (n = 3).Numbers 
above the dotted arrows indicate the fold increase in labelling caused by PE in each 
pair of samples.  
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However, the lack of such a specific mTORC2 inhibitor prevents further study of 
this. As PE still enhances new 5S rRNA synthesis in the presence of PP242, 
signalling events independent of mTOR are required to mediate 5S rRNA synthesis 
in ARVC.  
The data imply that other signalling pathways, besides or in addition to 
mTOR signalling, are involved in the activation of ribosome synthesis at the level of 
rRNA transcription. Therefore, further investigation was required to identify the 
signalling pathways that control rRNA transcription in cardiomyocytes. 
 
5.3 PE enhances rRNA synthesis via MEK signalling 
5.3.1  The MEK inhibitor, AZD6244, does block PE-induced rRNA 
synthesis 
Surprisingly, blocking the mTORC1 pathway with rapamycin does not 
inhibit the activation of new 18S rRNAs synthesis in ARVC. Taking together the 
observation that S6K1/2 double knock-out mice still undergo cardiac hypertrophy 
(McMullen et al. 2004), the result which is consistent with my finding suggests that 
other signalling pathways are involved in the control of ribosome synthesis in ARVC. 
This important point requires further investigation. 
Previous studies have shown that PE activates the MEK/ERK signalling 
pathways in ARVC independently of PI-3 kinase, and MEK/ERK signalling is 
essential for activation of protein synthesis by PE (Wang et al. 2001; Wang and 
Proud 2002; Wang and Proud 2002). Thus, to investigate the role of MEK signalling 
in rRNA synthesis, a specific MEK inhibitor, AZD6244 was used. AZD6244 is a 
highly potent and selective inhibitor of MEK1/2 which inhibits ERK1/2 
phosphorylation both in vitro and in vivo tumour model (Yeh et al. 2007).   
PE rapidly induced the phosphorylation of ERK and phosphorylation of S6 at 
Ser240/244 sites which are specific targets for mTORC1-activated S6 kinases 
(Fig.5.4A), indicating PE activates ERK and mTORC1 pathway as expected. ERK 
activation by PE was completely inhibited by AZD6244 (Fig.5.4A). AZD6244 also 
largely blocked phosphorylation of S6 (Fig.5.4A), confirming the earlier finding that  125 
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Figure 5.4: The MEK inhibitor, AZD6244, blocks the ability of PE to activate 
rRNA synthesis. (A) ARVC were treated with 10 µM PE for the indicated times and, 
where indicated, 5µ M AZD6244 (added 45min ahead). Samples of lysate were 
processed by SDS-PAGE/immunoblot using the indicated antibodies. The right-hand 
lane for the p-AMPK blot shows samples from hepatoma cells treated with 300nM 
A-769662 for 1h and run in a non-adjacent lane on the same gel. (B) [3H] uridine 
uptake was measured as for Fig. 5.1A, but cells were treated with PE and/or 
AZD6244(added 45min prior to PE)  for 16h prior to performing the uptake assay. 
Data are shown as mean ±  SEM (n = 3). (C, D) ARVC were treated with 10 µM PE 
for 24h in the presence of 5 µ M AZD6244 (added 45min prior to the PE) where 
indicated and labelled with 100 µM 4SU for 4h. Samples were processed for 
isolation of RNA and quantitation of new 4SU-labelled rRNA by qPCR as described 
in the Methods. Data are shown as mean ± SEM (n = 3). 
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the activation of mTORC1 signalling by PE is mediated via the MEK/ERK pathway 
(Wang et al. 2001; Wang and Proud 2002; Wang and Proud 2002). However, 
previous studies have shown some MEK pathway inhibitors caused phosphorylation 
and activation of AMP-activated protein kinase (AMPK) in HEK293 cells (Dokladda 
et al. 2005), and AMPK negatively regulates mTORC1 and Pol I rRNA synthesis 
under glucose restriction (Hoppe et al. 2009). Thus, it was important to test whether 
AZD6244 activates AMPK in ARVC. Figure 5.4A proved that neither PE nor 
AZD6244 activated AMPK. It confirms that unlike other MEK pathway inhibitors, 
AZD6244 is a highly selective inhibitor of MEK1/2. 
Importantly, as discussed above (Section 5.2.1), it was necessary to test 
whether AZD6244 affected uridine uptake before subsequent experiments were 
performed. Figure 5.4B determined that AZD6244 did not affect the uptake of 
uridine into ARVC. Hence, unlike rapamycin, AZD6244 can be used to study the 
role of MEK signalling in new rRNA synthesis without considering decreased 
uptake of 4-SU.    
Differently from mTOR inhibitors, AZD6244 did not block basal 18S or 5S 
rRNA transcription, but it did completely block PE-stimulated accumulation of 18S 
and 5S rRNAs (Fig.5.4C&D). The data indicated that PE activates rRNA synthesis 
mainly via MEK/ERK signalling. More importantly, MEK signalling regulates the 
activation of Pol I by PE independently of mTORC1, at least rapamycin- sensitive 
functions of mTORC1.   
 
5.3.2  Another MEK inhibitor, PD184352, also blocks new 18S and 
5S synthesis  
To confirm my finding that PE activates Pol I via MEK/ERK signalling, 
another MEK inhibitor, PD184352, was used. PD184352 completely blocked the 
PE-induced activation of ERK, and also largely inhibited the activation of 
phosphorylation of S6 at Ser235/236 and Ser240/244 (Fig.5.5A). Consistent with 
earlier data obtained using AZD6244, PD184352 inhibited PE-induced activation of 
the ERK and mTORC1 signalling pathways, and it did not stimulate AMPK in 
ARVC (Fig.5.5A). 128 
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Figure 5.5: Another MEK inhibitor, PD184352, also blocks the ability of PE to 
activate rRNA synthesis. (A) ARVC were treated with 10 µM PE for 15min and, 
where indicated, 5µ M PD184352 (added 45min ahead). Samples of lysate were 
processed by SDS-PAGE/immunoblot using the indicated antibodies. The right-hand 
lane for the p-AMPK blot shows a sample from hepatoma cells treated with 300nM 
A-769662 for 1h and run in a non-adjacent lane on the same gel. (B, C) ARVC were 
treated with 10 µM PE for 24h in the presence of 5 µM PD184352 (added 45min 
prior to the PE) where indicated and labelled with 100 µM 4SU 4h. Samples were 
processed for isolation of RNA and quantitation of new 4SU-labelled rRNA by 
qPCR as described in the Methods.  
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Like AZD6244, PD184352 did not interfere with uptake of uridine into 
ARVC (data not shown). PD184352 had no significant effect on basal 18S or 5S 
rRNA transcription; however, it entirely blocked PE-induced new rRNA synthesis 
(Fig.5.5B&C). This confirms that PE activates Pol I and Pol III via MEK/ERK 
signalling. 
 
5.4 RSKs and rRNA synthesis in Cardiomyocytes 
5.4.1  BI-D1870 blocks the PE-induced rRNA synthesis 
To address the signalling components downstream of MEK/ERK controlling 
the activation of Pol I and Pol III by PE in ARVC, the compound BI-D1870 was 
used. This is a specific inhibitor of p90
RSKs (Sapkota et al. 2007), which inhibits all 
four p90
RSK isoforms. Earlier data suggest that both p90
RSK2 and p90
RSK3 are highly 
expressed in heart tissue (Anjum and Blenis 2008), and my data confirm that these 
two isoforms are present in ARVC (Fig.5.6A). Treatment with PE for 24 h did not 
change the levels of p90
RSK2 and p90
RSK3, while BI-D1870 decreased the levels of 
p90
RSK2, but not affect p90
RSK3 (Fig.5.6A).  
The p90
RSK isoforms are directly activated by ERK1/2 in response to growth 
factors and other stimuli (Roux et al. 2003; Anjum and Blenis 2008). Previous study 
showed that PE rapidly activates ERK independently of PI-3 kinase/PKB pathway in 
ARVC (Wang and Proud 2002). Consistent with earlier study, my data confirm that 
PE activates (phorsphorylates) ERK1/2, but not PKB (Fig.5.6B). Treatment with BI-
D1870 did not decrease the activation of ERK by PE; on the contrary, it actually 
enhanced it (Fig.5.6B). A previous study also observed the same effect of BI-D1870 
and demonstrated that BI-D1870 does effectively block p90
RSK activity in ARVC 
(Fonseca et al. 2011). According to earlier findings (Sapkota et al. 2007), this 
increase is likely caused by BI-D1870 blocking an inhibitory feedback loop.  
As key controls, it was verified that BI-D1870 did not interfere with the 
uptake of uridine into ARVC (Fig.5.6C), showing that BI-D1870 can be used to 
study the role of p90
RSK in rRNA synthesis without considering effects on nucleoside 
transporters. BI-D1870 had no significant effect on basal 4-SU labelling of 18S or  131 
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Figure 5.6: The p90
RSK inhibitor, BI-D1870, inhibits PE-enhanced rRNA 
synthesis in ARVC. (A) ARVC were treated with PE (10 M) and/or BI-D1870 (10 
M) for 24 h. Cells were lysed and equal amounts of protein were analysed by SDS-
PAGE and immunoblot using the indicated antibodies. (B)ARVC were treated with 
10 µM PE for 15 min with or without BI-D1870 at the indicated concentrations 
(added 60 min prior to PE stimulation). Samples of lysate were processed by SDS-
PAGE and immunoblot using the indicated antibodies. The right-hand lane for the p-
PKB blot shows a sample from insulin-treated KB cells as a positive control. Set I 
and set II are from two independent experiments. (C) [
3H] uridine uptake was 
measured as for Fig. 5.1A, but cells were treated with PE and/or BI-D1870 (added 
1h prior to PE) for 16h prior to performing the uptake assay. Data are shown as mean 
±  SEM (n = 3). (D,E) ARVC were treated with 10 µM PE for 24 h in the presence of 
10 µM BI-D1870 (added 1h prior to PE) where indicated and labelled with100 µM 
4SU for 4 h. Samples were processed for isolation of RNA and quantitation of new 
4SU-labelled rRNA by qPCR as described in the Methods. Data are shown as mean 
±  SEM (n = 3). (F,G) As D,E, but SL0101 (50µmol/L ) was used in place of BI-
D1870. Data are shown as mean ±  SEM (n = 3). 
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5S rRNA transcription; however, it did entirely block PE-induced new rRNA 
synthesis in ARVC (Fig.5.6D&E). To confirm these data, an additional p90
RSK 
inhibitor, SL0101 was also used (Smith et al. 2005). The in vitro data have shown 
that this compound is a much less potent inhibitor of p90RSKs (Bain et al. 2007). 
Therefore, SL0101 was employed at a higher concentration (50 μM) which is 
generally used in other studies. As shown in Fig. 5F&G, SL0101 strongly inhibited 
the activation of 18S and 5S rRNA synthesis caused by PE, but without affecting 
basal synthesis rates. Such observation indicates that SL0101 is very unlikely to 
affect uridine uptake, while the observed inhibition of the effect of PE supports the 
conclusion that p90
RSKs play a key role in mediating the activation of rRNA 
synthesis in response to PE. The incomplete inhibition likely reflects the lower 
potency of this inhibitor. Hence, BI-D1870 was employed for further investigations. 
Overall, the data indicates that PE activates Pol I and Pol III via p90
RSKs. A 
previous study has proposed that p90
RSKs regulate rRNA synthesis by targeting the 
RNA polymerase I-specific transcription initiation factor TIF-IA (Zhao et al. 2003). 
This study may explain the effect of BI-D1870 in inhibiting 18S rRNA synthesis by 
Pol I, however, it still remains unclear that how BI-D1870 inhibits the activity of Pol 
III.   
One possible explanation is that BI-D1870 also induces the decay of new 
rRNAs. It has shown previously that rapamycin interferes with ribosome biogenesis 
and induces the decay of rRNAs in HeLa cells (Chapter 4.2.4). As the assembly of 
functional ribosomes requires all four rRNAs, three of which (i.e.18S, 28S and 5.8S) 
are made by Pol I, it was possible that inhibition of the activation of Pol I indirectly 
affected the stability of new 5S rRNA. Since 5S rRNA cannot be incorporated into 
new ribosomes without the other three rRNAs, the decay of new 5S rRNA is induced. 
To test this possibility, 4-SU labelling method was applied as a pulse-chase protocol 
to study the stability of new rRNAs in ARVC (Fig.5.7A). The data clearly show that 
BI-D1870 causes the decay of new 18S and 5S rRNAs, and it has stronger effect 
with longer time (Fig.5.7A&B). The accelerated decay rate of new rRNA may 
explain the decreased new 5S rRNA accumulation by BI-D1870. 
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B) 
 
Figure 5.7: BI-D1870 induces the decay of newly-synthesized rRNA in ARVC. 
(A,B) ARVC were incubated in the presence of 10 µM PE for 20h and labelled with 
100 µM 4SU for a further 4h, as indicated. They were then transferred to medium 
lacking 4SU, with or without 10 µM BI-D1870 and incubated for a further 1 or 3h. 
Samples were processed for isolation of RNA and quantitation of new 4SU-labelled 
rRNA by qPCR as described in the Methods. Data are shown as mean ±  SEM (n =3) 
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5.4.2 BI-D1870 affects Pol I complex binding to the rRNA gene in 
ARVC  
Previous studies using neonatal rat cardiomyocytes have shown that upon 
hypertrophy, the cellular level of upstream binding factor (UBF), a component of PoI 
complex, was substantially increased (Brandenburger et al. 2001; Brandenburger et 
al. 2003).  Likewise, the expression of Brf, a component of Pol III-specific 
transcription factor, was also induced during hypertrophy (Goodfellow et al. 2006). 
However, even though PE activated both 18S rRNA and 5S rRNA, there was no 
significant change in the levels of UBF or Brf1 in ARVC by PE with/or BI-D1870 
after 24 h (Fig.5.8A). Hence, although induction of UBF and Brf1expression was 
necessary in neonatal rat cardiomyocytes, increased expression of these components 
by PE in ARVC cannot be observed. Nevertheless, PE might regulate UBF and Brf1 
in the long term or other components of the Pol I/III machinery may be involved in 
PE-induced rRNA synthesis. 
A previous study has suggested that p90
RSKs regulate the activity of Pol I by 
phosphorylating transcription initiation factor TIF-IA (Zhao et al. 2003). A  more 
recent study has shown that upon PE stimulation in cardiomyocytes, p90
RSK was 
activated, and significant nuclear accumulation of p90
RSK2 was observed (Li et al. 
2012). Taken together, I questioned whether BI-D1870 inhibits PE-activated p90
RSK, 
interfering p90
RSK nuclear localization, and then affecting the activation of one or 
more RNA polymerase I-specific transcription initiation factors. Thus, the assembly 
of Pol I complex would be disrupted, and subsequently new 18S rRNA synthesis 
would be inhibited. 
  To verify this theory, chromatin immunoprecipitation (ChIP) analysis was 
used to assess whether BI-D1870 impairs the association of Pol I complex with the 
rDNA promoter. Three different sets of primers, corresponding to different regions 
of the rDNA promoter, were used to study the association of Pol I with the promoter 
(Fig.5.8B). As a negative control, Pol II was immunoprecipitated and my data 
confirmed that Pol II did not cross-link to the CORE region of the Pol I promoter 
(Fig.5.8C top). PE greatly promoted the association of Pol I with the rDNA promoter 
for each of the three pairs of primers (Fig.5.8C bottom panel). More importantly, 
prior treatment with BI-D1870 completely repressed such enhancement (Fig.5.8C  137 
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Figure 5.8: BI-D1870 inhibits the PE-induced recruitment of Pol I to the rRNA 
promoter. (A) ARVC were treated with 10 µM PE for 24 h with or without BI-
D1870 at the indicated concentrations (added 60min prior to PE stimulation). 
Samples of lysate were processed by SDS-PAGE and immunoblot using the 
indicated antibodies. (B) A scheme showing the layout of the rat rDNA promoter and 
genes, with the non-transcribed, external and internal spacers indicated (NTS ETS 
and ITS), and relevant regions corresponding to the qPCR primers indicated (see 
also Methods). (C) Top: The inset shows an ethidium bromide-stained gel which 
represents the amount of CORE and GAPDH products amplified after 20 PCR 
cycles. ARVC were treated with 10µM PE for 24h. 100µg of cross-linked chromatin 
was immunoprecipitated with anti-Pol I antibody or anti-Pol II antibody. Bottom: 
ARVC were pre-incubated in medium containing or lacking BI-D1870 for 1h and 
then 10 µ M PE was added for 24h where indicated. The percent (%) total DNA 
value represents DNA enrichment with the anti-Pol I antibody followed by 
subtraction of the negative control anti- Pol II bound sample. qChIP analysis of Pol I 
binding at rDNA sequences was analysed by qPCR using primers specific for the 
indicated regions of the Pol I promoter, and the value was normalized to the input 
control. * p<0.05 Control vs. PE; Ψ p<0.05   PE vs. PE+BI-D1870. Data are shown 
as mean ±  SEM (n =3)  
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bottom panel). Therefore, signalling through p90
RSKs is essential for the PE-induced 
recruitment of Pol I to the 45S rDNA promoter.  
 
5.5 Discussion 
  This section of the study focused on investigating the role of signalling 
events in regulating the synthesis of rRNA upon PE stimulation in ARVC.  
The data show that the hypertrophic agent phenylephrine (PE) stimulates the 
synthesis of 18S rRNA (which is made by RNA polymerase I) and 5S rRNA (made 
by RNA polymerase III) in adult cardiomyocytes. As discussed in Chapter 4, rRNA 
synthesis is driven by rapamycin-sensitive signalling through mTORC1 in HeLa 
cells. Rapamycin inhibited both Pol I and Pol III rRNA transcriptions, and induced 
the new rRNAs decay in HeLa cells. In contrast, the activation of rRNA synthesis by 
PE was not inhibited by rapamycin, indicating that other pathways are involved. 
PP242, a potent inhibitor of both mTORC1 and mTORC2, only partially eliminated 
the stimulation by PE, indicating a role for other signalling pathway besides mTOR 
in the activation of rRNA synthesis. Both rapamycin and PP242 inhibited the basal 
rRNA accumulation, this likely reflecting their impairing the uptake of uridine into 
ARVCs. This could suggest mTOR regulates uridine uptake. 
PE stimulates MEK/ERK signalling in ARVC. Pharmacological inhibition of 
this pathway blocks the ability of PE to activate the synthesis of 18S and 5S rRNA. 
Furthermore, BI-D1870, the inhibitor of the p90
RSKs protein kinases which are 
activated by ERK, also blocks the ability of PE to promote rRNA synthesis. It also 
induces the decay of new 18S and 5S rRNAs. It was possible that inhibition of 18S 
synthesis induces the decay of new 18S and the block of Pol I activation indirectly 
affects 5S rRNA stability, probably because 5S rRNA cannot be incorporated into 
new ribosomes without other rRNAs produced by Pol I (Iadevaia et al. 2012). 
Moreover, BI-D1870 inhibits the association of RNA polymerase I with the rRNA 
promoter, revealing key roles for p90
RSKs in the biogenesis of rRNA in this setting.  
  These findings show that MEK/ERK/p90
RSK signalling, rather than 
signalling through mTORC1, drives rRNA synthesis in adult cardiomyocytes 
undergoing hypertrophy. Indeed, a recent study has shown that p90
RSK3 is required 140 
 
for cardiac hypertrophy in neonatal cardiomyocytes and is necessary in response to 
pressure overload in vivo (Li et al. 2012). Overall, p90
RSKs play a key role in the 
activation of rRNA synthesis by hypertrophic stimuli in rat heart cells. Future work 
is required to determine the underlying mechanisms that how p90
RSKs activate rRNA 
synthesis in ARVC. Our findings may provide cues for potential valuable therapy of 
cardiac left ventricular hypertrophy. 
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Concluding Remarks  
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The focus of this study was to investigate the signalling events controlling 
the ribosome biogenesis in cardiomyocytes, especially those related to cardiac 
hypertrophy (CH). CH is a potentially fatal disease caused by overgrowth of heart 
muscle cells, and increased ribosome synthesis is a key feature of CH (Morgan et al. 
1985; Chua et al. 1987; McDermott et al. 1989). Hence, it is important to understand 
the underlying signalling events that are involved in increased rRNA synthesis 
during hypertrophy in adult rat ventricular cardiomyocytes (ARVC). 
  The regulation of the synthesis of rRNA in HeLa and ARVC cells was 
studied; in particular, the role of mTOR and other signalling pathways involved in 
controlling ribosome biogenesis. A non-radioactive labelling method was applied to 
study new rRNA synthesis in both HeLa and ARVC cells. In this approach, only 
new RNA is labelled with 4- thiouridine (4-SU), and the labelled RNA can then be 
isolated from total RNA to quantify it using quantitative real-time PCR (RT-qPCR). 
The data show that 4-SU alone does not affect the mTORC1 or MEK/ERK pathways 
in either HeLa or ARVC cells; hence, this method can be used to study the signalling 
events involved in the control of the synthesis of new rRNA. However, mTORC1 
inhibitor rapamycin does interfere with uridine uptake (Fig 4.1); it needs to be taken 
account into when measuring new RNA synthesis using this labelling method. On 
the other hand, neither the MEK inhibitor, AZD6244, nor the p90
RSK inhibitor, BI-
D1870, affected uridine uptake, indicating they can be used without interference in 
nucleoside transport. Interestingly, such observation that rapamycin, but not 
AZD6244, inhibits nucleosides transport in ARVC would be consistent with a earlier 
study showing that rapamycin, but not the MAPK kinase inhibitors, resulted in a 
reduction of intracellular uptake of [
3H]uridine in K562 cells (Huang et al. 2003). 
The fact that rapamycin affects nucleoside uptake by interfering with nucleoside 
transporters indicates a link between mTORC1 signalling and ribosome production, 
as nucleosides are fundamental precursors for rRNA synthesis. Nevertheless, more 
work is required to verify whether this effect represents a role for mTORC1 or 
reflects an indirect effect of these compounds. Given that mTORC1 signalling 
positively regulates many anabolic processing, so a role in nucleoside uptake is not 
unexpected. 
  My study in HeLa cells showed that inhibiting mTORC1 by rapamycin not 
only interferes the synthesis of 18S rRNA, but also induces the degradation of new 144 
 
rRNAs (Fig.4.3&4.4). Since 18S rRNA is processed from a single precursor that also 
contains the 28S rRNA, it is likely that rapamycin also induces the decay of new 28S 
rRNA. In fact, rapamycin did cause the loss of 4-SU labelled newly made 28S rRNA 
(Fig.4.4C). In summary, rapamycin might interfere with the processing events that 
generate 18S and 28S rRNA, and as a result, promote their degradation. Indeed, my 
colleague, Dr. Valentina Iadevaia showed that mTORC1 positively regulates rRNA 
processing (Iadevaia et al. 2012). In addition, rapamycin also induces the decay of 
newly made 5S rRNA by Pol III which does not require processing (Fig 4.4B). This 
observation suggests that rapamycin inhibits the overall processing of ribosome 
assembly; therefore, impaired ribosome biogenesis influences 5S rRNA stability. 
Taken together, these data indicate that mTORC1 is essential for regulating rRNA 
processing and stability in HeLa cells (Fig.6.1).  
On the other hand, surprisingly, rapamycin did not block PE-induced rRNA 
synthesis in cardiomyocytes (Fig.5.2). Rather, inhibition of the MEK/ERK pathway 
blocked the ability of PE to activate the synthesis of 18S and 5S rRNA (i.e., Pol I 
and Pol III) (Fig.5.4&5.5). Moreover, inhibition of the p90
RSKs, protein kinases 
downstream of ERK, also completely blocked the ability of PE to promote rRNA 
synthesis (Fig.5.6). Furthermore, the p90
RSKs inhibitor BI-D1870 induces the decay 
of new rRNA (Fig.5.7). PE greatly enhanced the association of RNA polymerase I 
with the rRNA promoter and BI-D1870 largely blocked this effect (Fig.5.8). This 
observation confirms that signalling through p90
RSKs is required for PE-induced 
recruitment of Pol I to the 45S rRNA promoter. Indeed, it appears that the 
MEK/ERK/p90
RSK pathway, rather than mTORC1 signalling, drives rRNA synthesis 
in adult cardiomyocytes undergoing hypertrophy. The MEK/ERK pathway is already 
known to be important in CH; however, the role of the MEK/ERK/p90
RSK pathway 
in ribosome biogenesis has not been studied before. It is important to note that this 
study is independent of the known link in ARVC between the MEK/ERK signalling 
and the activation of mTORC1 pathway which is involved in the regulation of 
protein synthesis (Wang et al. 2001).  
My data suggest that mTORC1 signalling, and thus the S6Ks, are not 
involved in PE-activated rRNA transcription. This conclusion agrees with the 
observation that S6K-deficient mice still develop cardiac hypertrophy (McMullen et 
al. 2004), despite the common belief that S6K plays an important role in the  145 
 
 
 
 
      
Figure 6.1: A scheme showing the different signalling events involving 
regulating rRNA synthesis in HeLa cells and in ARVC. Upon stimulation, rRNA 
transcription was increased. In HeLa cells, mTORC1 plays an essential role in 
regulating Pol I and Pol III productions (i.e. 18S and 5S rRNAs). On the other hand, 
MEK/ERK/p90
RSK signalling, but not mTORC1, appears to regulate rRNA synthesis 
in ARVC in response to PE. 
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regulation of  cell growth and proliferation (Montagne et al. 1999; Thomas 2002; 
Ruvinsky and Meyuhas 2006). However, mTORC1 does play a key role in CH. 
Inhibiting mTORC1 with rapamycin can prevent or even reverse hypertrophy (Wang 
and Proud 2002; Hannan et al. 2003; Shioi et al. 2003). In the short term, PE 
activates protein synthesis by activating pre-existing components (i.e. translation 
factors). In the long term, PE increases rRNA and other components of the protein 
synthesis machinery. Studies have shown that, in the short term (typically 5-60 
minutes), rapamycin treatment partially blocks the activation of protein synthesis by 
PE in ARVC (Wang et al. 2001; Proud 2004). However, in the long term (hours-
days), rapamycin does not inhibit the synthesis of new 18S rRNAs (see Section 
5.2.2). This suggests that distinct upstream signalling pathways are involved in 
controlling these two processes (Fig.6.1).  
It still remains important to characterize the significance of the mTORC1 
pathway in regulating cardiac hypertrophy, as rapamycin suppressed load-induced 
hypertrophy in mice (Shioi et al. 2003). One possible explanation is that instead of 
regulating rRNA synthesis, mTORC1 regulates cell growth by controlling synthesis 
of ribosomal proteins (Rps). 5'-TOP mRNAs; containing an oligopyrimidine tract at 
their 5'-terminus (5'-TOP), many of which encode Rps. An early study showed that 
rapamycin suppresses 5'-TOP mRNA translation (Jefferies et al. 1997), indicating 
the production of Rps involves signalling through mTORC1. Future work is required 
to  identify  the  specific  signalling  components  involved  in  controlling  ribosomal 
protein synthesis in ARVCs and indeed in other cells. 
Previous studies on ribosome biogenesis have usually used neonatal 
cardiomyocytes, due to the difficulties of making and using adult cardiomyocytes. In 
this study, primary adult rat cardiomyocytes were used to study the regulation of 
ribosome biogenesis under cardiac hypertrophy which is a heart disease in adult 
animals. The signalling connections differ between adult and neonatal heart cells, for 
instance, the activation of c-Jun N-terminal kinases (JNKs) by a variety of pro-
hypertrophic stimuli have been reported in neonatal cardiomyocytes (Frey and Olson 
2003), while no activation by PE is observed in adult cells (Wang et al. 2001). 
Therefore, using adult cells may provide important information for understanding 
signalling networks underlying hypertrophy. 147 
 
  BI-D1870 completely blocks PE-induced 18S and 5S rRNA synthesis, but it 
actually enhances the activation of ERK by PE in ARVC (Fig. 5.6B). This 
observation implies that besides a role for ERK, p90
RSK plays a major role in 
controlling rRNA synthesis in ARVC. It agrees with  a recent study which reports 
that p90
RSK3 is required for developing cardiomyocyte hypertrophy in both neonatal 
myocytes and mice subjected to transverse aortic constriction (Li et al. 2012). Since 
the p90
RSK inhibitor BI-D1870 completely blocks the PE-induced accumulation of 
newly-made 18S and 5S rRNA in ARVC, how this compound regulates Pol I 
transcriptional machinery was addressed next. The ChIP analysis reported here 
indicates that BI-D1870 impairs the association of Pol I complex with the rDNA 
promoter (Fig.5.8C). In addition, a previous study has shown that PE quickly 
activates p90
RSK and significant accumulation of p90
RSK2 was observed after 15 min 
in the nuclei of neonatal rat ventricular myocytes (Wang and Proud 2002; Li et al. 
2012). Taken together, a possible model is deduced about the role of the 
MEK/ERK/p90RSK signalling in regulating Pol I-mediated  rRNA synthesis in 
ARVC. During PE-induced hypertrophic growth, p90
RSK enters the nucleus to 
promote Pol I rRNA synthesis by activating one or more Pol I transcription initiation 
factors (Fig.6.2A). Treatment of ARVC with BI-D1870 may inhibit the translocation 
of p90
RSK into the nucleus, and inactivated transcription initiation factors fail to 
assemble into functional Pol I complex (Fig. 6.2B). As a result, Pol I transcription is 
arrested and new 18S rRNA synthesis is inhibited. To verify this model, the links 
between the components of the Pol I transcriptional machinery and the 
MEK/ERK/p90RSK signalling should be addressed. 
In isolated neonatal cardiomyocytes, it has shown that during hypertrophic 
growth, levels of UBF, an rDNA transcription factor, increase (Brandenburger et al. 
2001).  Over-expression of UBF enhanced rDNA transcription in isolated neonatal 
cardiomyocytes, indicating that UBF plays a key role in the control of rRNA 
synthesis (Brandenburger et al. 2003). However, no significant changes in the levels 
of UBF can be observed in adult heart cells after the treatment of PE for 24 h 
(Fig.5.8A). Since level of UBF is not increased by PE, this observation suggests PE 
regulates the functions of UBF in the longer term treatment, or other components of 
the Pol I transcriptional machinery. 
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A) 
 
 
B) 
 
 
Figure 6.2: A scheme showing the hypothesis that how MEK/ERK/p90
RSK 
signalling regulating Pol I complex assembly in ARVC. A) Upon PE stimulation 
in cardiomyocytes, p90
RSK was activated. A significant amount of p90
RSK entered 
into the nucleus, and then activated one or more RNA polymerase I-specific 
transcription initiation factors to promote Pol I complex binding to the promoter 
region. Hence, 47S pre-rRNA transcription was enhanced. B) BI-D1870 inhibits PE-
activated p90
RSKs enter the nucleus, and impairing the activation of RNA polymerase 
I transcription initiation factors. Thus, the assembly of Pol I complex would be 
disrupted and subsequently new 47S pre -rRNA synthesis was inhibited. 
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The initiation of Pol I transcription also requires TIF-1A. An earlier study 
proposed that p90
RSKs phosphorylate TIF-1A at Ser649 in the C-terminal region 
(Zhao et al. 2003). However, there is no consensus phosphorylation site for the N- 
terminal domain of p90
RSKs in the C-terminal region of TIF-1A. The authors, 
therefore, suggested that the phosphorylation of TIF-1A was catalysed by the C-
terminal kinase domain of p90
RSKs. Nevertheless, BI-D1870 inhibits the N-terminal 
kinase domain of p90
RSKs, not the C-terminal domain (Sapkota et al. 2007). Hence, 
inhibition of rDNA transcription is not due to phosphorylation of TIF-1A at Ser649 
by p90
RSK s. The regulation of TIF-1A is more complicated than this. p90
RSKs may 
regulate Pol I activity via other components of the Pol I machinery. Additional work 
is required to identify such components.  
Nevertheless, interference with the Pol I complex cannot explain how BI-
D1870 inhibits 5S rRNA synthesis and also causes faster decay of newly- made 5S 
rRNA (Fig.5.6E&5.7B). A previous study has shown that in isolated neonatal 
cardiomyocytes, during hypertrophy growth, ERK positively regulates cell growth 
by directly binding and activating TFIIIB, thus increasing Pol III production 
(Goodfellow and White 2007). Moreover, hypertrophic stimulation increases 
expression of Brf1, an subunit of the essential Pol III-specific transcription factor 
TFIIIB (Goodfellow et al. 2006). Nevertheless, no significant changes in the levels 
of Brf1 can be observed in isolated adult heart cells with the treatment of PE for 24 h 
(Fig.5.8A). Since Brf1 expression is not affected by PE in 24 h, these data suggest 
PE requires a longer time to regulate the functions of Brf1, or that such effects of BI-
D1870 on 5S rRNA might be indirect. It is possible that inhibition of Pol I activation 
by BI-D1870 has a knock-on effect on the stability of new 5S rRNA, and 
subsequently inhibited its accumulation. Nevertheless, it cannot be ruled out 
MEK/ERK/p90
RSK signalling pathway plays a role in regulating Pol III, since 5S 
rRNA stability is affected by BI-D1870. 
This is the first study of the signalling events that control rRNA synthesis in 
adult cardiomyocytes. The information generated by this study provides new insights 
into cardiac hypertrophy, specifically the fundamental mechanisms underlying the 
control of ribosome biogenesis, including the roles of mTOR and MEK/ERK/p90
RSK 
signalling. These are all relevant to understanding the control of cardiomyocyte 
growth and the cellular mechanisms underlying this complex disease. Knowledge 150 
 
gained from this study may also valuable for developing novel medicines and 
therapeutic strategies for treating CH.  
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Sample Calculation for Real-Time PCR 
 
1.  Do average of duplicates or triplicates for each sample (Column A) 
 
Ct mean = (Ct1+Ct2)/2 
 
2.  Subtract the reference* average Ct from the target* average Ct equals Δ Ct 
(Column B): 
 
ΔCt = Cttarget –Ct reference 
 
*Here: Target = 18S pulldown (newly synthesized rRNA) 
Reference= 18S total (total rRNA) 
 
3.  A ΔΔCt value is calculated for each treatment as follow(Column C):  
 
ΔΔCt = ΔCt treated – ΔCt control 
 
4.  Calculate the change in gene expression using special primer 
efficiency*(Column D): 
 
       Relative Quantity= power (1.955,-ΔΔCt) 
 
       Here: 18S primer efficiency*is equal 1.955 
 
5.  A plot is of treatment vs. gene expression change is generated. 
 
 
  C1  C2 
Ctmean 
Column A 
Δ Ct 
Column B 
ΔΔCt 
Column C 
Quantitiy 
Column D 
100x18S 
pulldown(target)           
ActD             
control  13.72  13.69  13.705  0.2  0  1 
L-ActD  18.32  18.56  18.44  4.73  4.53  0.047985 
H-ActD  24.09  24.21  24.15  10.25  10.05  0.001186 
             
100x18S total 
(reference)           
ActD             
control  13.49  13.52  13.505       
L-ActD  13.77  13.65  13.71       
H-ActD  13.96  13.84  13.9       
             
             
             
primer efficiency of 
18S  1.955       
 180 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Actinomycin D treatment in HeLa cells with 4-TU 
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